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Abstract 
 
Antiretroviral therapy (ART) first became available in the public sector in the 
Western Cape Province in Khayelitsha in 2001. This thesis describes the effectiveness 
of ART in Khayelitsha and the Province, following adult patients for up to five years 
on ART, and examining temporal trends over seven years during which time the 
availability of ART in the Province increased dramatically. Associations are explored 
with a range of clinical outcomes, and regimen durability and tolerability are 
described, together with regimen effectiveness when ART is administered to patients 
co-infected with tuberculosis. 
 
The results chapters of the thesis are presented in the form of published or submitted 
papers.  The first paper corrects for under-ascertainment of mortality through 
linkages with the death registry. After five years on ART, four out of five patients 
were still alive.  Survival did not deteriorate in more recent years despite the large 
increase in patient numbers. Patients who remained virologically suppressed 
experienced on average continued CD4 count recovery throughout follow-up to five 
years.  The second paper describes the tolerability of each commonly used first-line 
antiretroviral drug in two townships in the Western Cape. Treatment-limiting 
toxicities were frequent and continued throughout follow-up in patients on stavudine 
(21% by 3 years on ART). Symptomatic hyperlactataemia or lactic acidosis as well as 
lipodystrophy were strongly associated with women initiating ART with a high initial 
body mass. The third paper explores the effectiveness of ART when co-administered 
with tuberculosis treatment, identifying that co-infected patients initiating nevirapine-
based ART may be at a higher risk of virological failure, but that concurrent 
tuberculosis treatment did not otherwise compromise ART outcomes.  The fourth 
paper, based on a household survey, provides an in-depth description of the 
Khayelitsha population demonstrating comparability with many of the urban settings 
in which ART is provided in the region. The final paper demonstrates that outcomes 
have not been compromised by the wider availability of ART in the Western Cape 












   
The thesis concludes that the Khayelitsha and Provincial analyses provide 
considerable reassurance that the anticipated benefits of ART have not to date been 
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Chapter 1: Introduction and literature review 
 
Section A: Introduction  
 
The contribution of Human Immunodeficiency Virus (HIV) to morbidity and 
mortality in Southern Africa is well described.  In South Africa alone, at the 
conclusion of the period covered by this thesis (2001-2007), the number of deaths 
estimated to be due to HIV infection exceeded 1,000 a day, the equivalent to the 
number of deaths from all other causes. Life expectancy at birth in South Africa fell 
from 63 years in 1990 to 51 years in 2006.1   
 
This study was conceived in the early years of the Khayelitsha antiretroviral treatment 
programme, a project started with the express aim of demonstrating the feasibility of 
antiretroviral therapy (ART) in this region, at a time when internationally momentum 
in support of ART provision in poor countries was just starting, and when nationally 
bitter political contestation surrounded antiretroviral interventions. Over time the 
project has been assimilated into much larger provincial and national programmes, 
and at the conclusion of the study, findings are reflective of these larger programmes. 
 
The Western Cape Province, and Khayelitsha more specifically, by virtue of having 
provided ART for longer, are particularly well-placed to address questions of 
effectiveness and areas of clinical uncertainty in ART provision in this setting.  At the 
start of this study in 2004, the Khayelitsha ART cohort had just published early 
findings of outcomes at two years on ART, that would later be widely cited as 
evidence of ART effectiveness in this setting.2 Projects funded by the Global Fund 
for Aids, Tuberculosis and Malaria (GFATM) and the United States bilateral 
President’s Emergency Plan for AIDS Relief (PEPFAR) were in their infancy, and 
the South African national treatment plan had just been launched.  Khayelitsha was 
therefore one of the few projects with sufficient data in terms of patient numbers, 
duration of follow-up and data quality, that could address some of the areas of 
clinical uncertainty, and this was the initial focus of analyses.  More recently, as the 
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number of publishing HIV treatment cohorts in Southern Africa has increased, the 
focus has shifted to the larger Western Cape provincial programme, to determine 
programme effectiveness at scale, to find ways of collecting monitoring data from 
these larger programmes, and to determine the longer term outcomes given 













Chapter 1: Introduction and literature review 
 
Section B: Background and literature review 
Pre-existing data on ART efficacy and effectiveness 
Azidothymidine (AZT) was originally developed in the 1960’s as a candidate drug 
that would interfere with DNA replication in replicating cancer cells,3 and was tested 
for activity against HIV in 1985. AZT inhibits viral replication by synthetically 
replacing the nucleoside thymidine triphosphate as a substrate for the reverse 
transcriptase enzyme, hence the class of drugs being termed nucleoside reverse 
transcriptase inhibitors (NRTI’s).  The first clinical trial to test AZT in humans with 
HIV was prematurely halted in 1986 due to the survival benefit observed with an 
average 4-months of follow-up.4 Only a single patient out of 145 who received AZT 
had died compared to 19 in the 137 patients who had received placebo.  The same 
and subsequent studies demonstrated however that the benefit waned with time: the 
median survival from the onset of AIDS with AZT use was 3 years.5-6 A number of 
studies also identified that the survival benefits were confined to patients starting 
treatment with lower CD4 counts (< 200 cells/µL).7-9 A meta-analysis of 15 trials 
later estimated the effect (Peto odds ratio) of therapy with AZT over placebo to be 
0.70 for progression to AIDS or death.10 
 
Additional antiretrovirals in the same class proved effective, including zalcitibane, 
didanosine (ddI), lamivudine (3TC), and stavudine (d4T). The first trials to enrol 
patients onto dual therapy began as early as 1992, and by 1996 there was a strong 
evidence-base for the superiority of combination therapy over mono-therapy.11-13 In 
the Delta trial for example, treatment-naïve adults with AIDS or a CD4 count below 
350 cells/µL who received AZT and ddI had mortality reduced by 42% compared to 
those who received AZT alone.11  A subsequent meta-analysis of 16 trials estimated 
the effect size for the progression to AIDS or death to be 0.60 comparing dual to 
monotherapy.10 
 
New classes of antiretroviral, the protease inhibitors and non-nucleoside reverse 
transcriptase inhibitors (NNRTI’s), were developed, enabling the construction of 
three-drug regimens.  The first trial to demonstrate the clinical efficacy of three-drug 
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ART reported in 1997, in which patients were randomized to receive AZT and 3TC 
with and without indinavir.14 Patients with initial CD4 counts below 200 cells/µL 
receiving the three drug treatment had progression to AIDS or death halved relative 
to those on two drugs. A subsequent meta-analysis of 9 trials estimated the effect size 
for the progressions to AIDS or death to be 0.62 comparing triple to dual therapy.10 
 
The progression of the standard of care from mono to dual to triple therapy, meant 
that the efficacy of triple therapy as compared to no therapy would never be tested in 
a direct clinical trial.  Subsequent estimates, based on complex modelling within 
antiretroviral treatment cohorts, have estimated that triple therapy reduces mortality 
or progression to AIDS by 86% compared to no treatment, and by 96% in patients 
starting treatment with CD4 counts below 200 cells/µL.15   
Effectiveness 
Following the evidence from clinical trials as to the efficacy of ART, cohort studies 
were able to demonstrate that the improvements in survival and reductions in disease 
progression were also evident in these real world settings. In British Columbia in 
Canada, patients were 1.9 times more likely to die after adjustment for other 
predictors of survival during the era when only mono-therapy was available 
compared to the era when two drugs were available.16 Patients who received two 
drugs were in turn 3.2 times more likely to die compared to patients started on ART 
in the triple-therapy era.17  This temporal trend was similarly observed in the Swiss 
HIV Cohort, with a 73% reduction in progression to AIDS or death in patients 
enrolled during 1995-96 compared to 1988-90, the former period being one with 
widespread use of dual and triple therapy.18 These improvements in mortality 
continued as triple therapy was further refined in general clinical practice.19 
 
Cohorts following patients with known dates of seroconversion have dramatically 
demonstrated the temporal trends in outcomes based on the year of seroconversion, 
as a result of the availability of combination antiretroviral therapy.  The Concerted 
Action on SeroConversion to AIDS and Death (CASCADE) collaboration reported 
in 2003 that the hazard ratio for death for seroconverters in 2001 was 0.16 compared 
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patients with HIV compared to the general population has fallen from 40.8 per 1000 
person years pre-1996 to 6.1 in 2004-2006.21 Surveillance data confirm these findings. 
In the United States, reported deaths with HIV as the underlying cause of death have 
fallen from 50,000 per year in 1995 to 16,000 in 2005.22 
Prognosis and associations with mortality 
Measured from the time of starting antiretroviral therapy, in patients without prior 
exposure to treatment, prognosis in terms of mortality or disease progression has 
remained constant since the advent of three drug antiretroviral therapy.23 Within 
cohorts however, prognosis varies based on patient characteristics when starting 
ART.24-25  In one cohort collaboration in Europe and North America, it was 
estimated that in almost 50% of patients starting ART before 2007, the risk of death 
at five years was less than 5%.25   
 
In the above settings, the characteristics most strongly associated with prognosis after 
adjustment for all other baseline characteristics, were age (those over 50 were three 
times as likely to die compared to those aged 17-29 at the start of ART), mode of 
transmission (those who acquired HIV through injecting drug use were at higher risk 
of death), clinical stage, CD4 count and viral load.25  The association with baseline 
CD4 count has weakened as duration of follow-up has increased, but even with 
follow-up extending to five years, there is a three-fold higher mortality in those 
starting ART with CD4 counts below 25 cells/µL compared to those starting with 
CD4 counts above 350 cells/µL.25 In the same collaborative cohort, analysed a few 
years previously with follow-up to three years, the adjusted hazard ratio comparing 
those starting ART with a CD4 count below 50 cells/µL to those starting ART with a 
CD4 count above 350 cells/µL was closer to five.24 Baseline CD4 counts have been 
shown in the same cohort to be related to the risk of new AIDS events up to six 
years after starting ART.26   The association with baseline viral load is attenuated after 
adjustment for other variables, but viral load has still been an important component 
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Most analyses from cohorts in Europe and North America present survival stratified 
by baseline characteristics, and absolute survival or mortality estimates for entire 
cohorts are seldom presented due to the inherent differences in the characteristics of 
patients in each cohort and temporal changes in these, limiting comparability.  For 
illustrative purposes, the online risk calculator based on the above prognostic 
models,27 estimates cumulative mortality at years 1 to 5 for one subset of patients 
(treatment-naïve adults aged 30-39, sexually infected with HIV, with an initial CD4 
count between 50 and 99 cells/µL, CDC stage C disease, and an initial viral load 
above 100,000 copies/ml), to be 3.0, 5.3, 7.2, 9.1 and 10.8% respectively.    
Biological differences in HIV-1natural history and response to therapy across settings 
Various data suggest that there is little reason to anticipate on biological grounds, that 
the response to HIV therapy should differ in Southern Africa compared to in those 
countries in which it was first available. 
 
Although there is substantial strain diversity between settings for HIV-1, with 
subtype C  predominating in Southern Africa, and subtype B in Europe and North 
America,28 the current consensus is that the time to AIDS and time to death does not 
differ markedly between patients infected with these subtypes across regions.29-30  
 
There has however been some concern that the pathways to developing resistance on 
treatment might be different in Southern Africa (where subtype C virus 
predominates) compared to patients infected with subtype B virus. For example, it 
has been suggested that in patients infected with subtype C viruses, resistance to 
NNRTI’s might develop more rapidly,31 as well as the K65R mutation in patients 
treated with tenofovir (TDF).32  Nevertheless, it is generally anticipated that overall, 
the response to first-line therapy should not differ based on geographical viral genetic 
diversity.31 33 
 
An increasing number of pharmacogenetic associations are being described for 
antiretroviral drugs.34 These are beginning to impact on clinical practice, but to date, 
more in understanding toxicity than efficacy.  For example, two studies have shown 
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allele HLA-B*5701, which is 100% specific for hypersensitivity reactions to abacavir 
(ABC).35-36 Such screening is now recommended in the International AIDS Society 
(IAS) USA guidelines.37 Although hypersensitivity to nevirapine (NVP) is of more 
relevance than that to ABC in Southern Africa due to its more widespread use, the 
genetic basis for NVP hypersensitivity is more complex and diverse that that for 
ABC.34  The association between reduced efavirenz (EFV) clearance and the G156T 
substitution in the cytochrome p450 2B6 enzyme is more clearly described,38 and has 
been found to be more frequent in African populations both in North America and 
South Africa.39-40  
 
Even though there are additionally differences in the spectrum of HIV-associated 
diseases between settings, the feasibility of antiretroviral therapy in Southern Africa 
and other poor countries was challenged on the grounds of affordability, health 
system capacity, and patient adherence.41  A discussion on co-morbidities is however 
included in the next section. 
The emergence of ART as a feasible intervention in poor countries 
The literature reviewed below follows the introduction of ART in poor countries.  
The data are introduced with a clear sense of chronology up until the point that this 
thesis was proposed, in order to enable the contributions from this thesis to be 
located relative to the time when they were conceptualized and produced.   
 
By the late 1990’s, the effectiveness of three-drug ART was well-established as 
described above. The lowest annual cost in 2000 of an effective first-line 
antiretroviral drug regimen was however $10,439 (USD) per patient per year from 
originator manufacturers.  Although in Brazil the same regimen was available for 
$2767 per patient per year produced by the state, this was not readily accessible to 
patients outside of Brazil.  By mid-2008, the same regimen (d4T, 3TC, and NVP) was 
available for $331 (originator) and $87 (generic), representing price reductions of 97% 
and 99% respectively.42  
 
In 2002, assuming already at that stage that therapy could be provided at $350 per 
year, it was argued that per disability-adjusted life year averted, ART was 28 times less 
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cost-effective than prevention.43 There was widespread anxiety about the impact of 
poorly regulated use of antiretroviral therapy in Africa leading to resistance,44-46 and 
early reports of successes were received with caution due to the possibility that they 
were anomalies, the result of extraordinary resources due to partnerships with 
implementing organizations.41 
 
The early projects to provide ART in poorer countries were premised on assuming 
that with volume increases, political pressure, and reform of trade regulations, the 
cost of therapy could be substantially reduced,47-48 that it was possible to simplify the 
model of care to enable less well-resourced health systems to deliver the intervention 
while retaining effectiveness,44 49 and that it was possible to achieve adherence levels 
that would render the intervention effective and safe at a population level, whether by 
observing therapy directly,50 or through patient education and empowerment.51  It 
was also anticipated that the availability of treatment would catalyse the response to 
the epidemic, improving the effectiveness of all interventions.49 51 
 
Against this backdrop, of assumed biological efficacy, the early projects providing 
ART in the region sought to demonstrate that the new models of ART care 
provision, different in many ways from those in Europe, North America and Brazil, 
could ensure adequate outcomes at individual and programme level, especially when 
combined with the use of more affordable generic drugs. 
 
The first programme descriptions on 60 patients treated with ART in Haiti, were 
based on a project in which treatment was provided on clinical criteria, and 
monitoring was also restricted to clinical parameters, and were published in 2001.49  
This project popularized the use of “accompagnateurs” a cadre of community health 
workers responsible for assisting with treatment, an extension of the directly-
observed component of the DOTS model for tuberculosis treatment.50   
 
The first two publications of results from routine ART programmes in Africa were 
published in mid-2002. As early as 1998, UNAIDS created the Drug Access Initiative 
(DAI) in order to facilitate access to antiretrovirals at lower prices in selected 
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still responsible for their own health care costs, found that for 204 patients starting 
ART, survival at one year was 82% and 67% for patients starting ART with CD4 
counts above and below 50 cells/µL respectively.52  The Senegalese government had 
also in 1998 begun a government sponsored ART programme.  In 58 patients 
enrolled by mid-2002 with a median CD4 cell count of 110 cells/µL, 85% remained 
alive and free of new AIDS events at one year.53 Follow-up extended to 18 months.  
In the latter study, all patients received an un-boosted protease inhibitor (PI) as part 
of their regimen. NNRTI’s were available in the former study, but the proportion 
using them was not reported. In analyses of those who received ART (as opposed to 
intention-to-treat analyses), virological suppression was 42% (Uganda) and 61% 
(Senegal) at one year in these two studies.  
 
An evaluation in a DAI project in Côte d’Ivoire of 276 adults who received triple 
therapy and returned for follow-up care, estimated in 2003 that survival at one year 
was 84% and for the 35 patients with virological assessment around one year, 50% 
had viral loads below 200 copies/mL.54  A smaller cohort study reported on 
outcomes for 90 patients who started three-drug ART in Côte d’Ivoire from 1996-
2002, full details of which could not be accessed.55  
 
A cross-sectional chart-review of 217 adult patients started on three-drug ART in 
private practice in Kenya from 1996-2000 reported in 2003 that 51% remained alive 
and in care, 8% were alive but not in care, 15% were lost to follow-up, 11% had died, 
and 13% had transferred or moved their care.56  Of the 55 patients receiving a viral 
load test between 7 & 12 months on ART, 47% had values below 400 copies/mL. A 
review of 139 patients in Tunisia started on ART reported cross-sectionally that 6.4% 
had died and 63.5% had achieved virological suppression over a median 23 months 
of follow-up.57 
 
A review of adherence and virological outcomes in African patients receiving ART 
through clinical trials in Cape Town from 1996-2001 demonstrated high levels of 
adherence as measured by pill-count (median 93.5%) and virological suppression 
(66% below 400 copies/mL at 48 weeks), and predictors of detectable viral loads that 
were similar to those described in other settings.58  A public sector treatment 
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programme initiated by the same research group in Gugulethu in Cape Town 
reported virological outcomes at 16 weeks for the first 16 patients starting ART, all of 
whom had undetectable viral loads.59 Médecins Sans Frontières also reported in 2003 
that of 743 patients started on ART in seven countries in Africa and South East Asia, 
89.5% remained alive at 6 months, and 89.8% of 118 tested at six months had 
undetectable viral loads (all from Khayelitsha, South Africa).60  
 
The early results from Khayelitsha published in 2004, were the first detailed public 
sector cohort results for ART from Southern Africa. The study extended follow-up 
to two years, and reported on a project that was predominantly based on the use of 
generic drugs which had been imported from Brazil (see below).2  All metrics in this 
study improved on the previously published African studies, with survival at two 
years of 86.3% in a population with very advanced disease at the start of ART 
(median CD4 count 43 cells/µL), and 89%, 84% and 70% achieving viral load 
suppression at 6 months, 1 and 2 years respectively. This project also popularized an 
adherence model premised on careful patient preparation and education, treatment 
assistants that were voluntary and known to the patients as opposed to employed 
community health workers, support groups and the encouraging of disclosing HIV 
status.51 61-62 
 
A clinical trial in Cameroon further demonstrated the effectiveness of programmes 
based on the use of generic drugs. The fixed-dose combination Triomune®, 
comprising d4T, 3TC and NVP, was used to treat 60 patients, 80% of whom 
achieved virological suppression at 24 weeks.63 This study built on a small adherence 
study in Uganda, which reported that for 34 patients on Triomune followed to 12 
weeks, 76% had undetectable viral loads.64 
 
The above studies were the only African studies identified in reviews published in 
2005,65-66 and form the backdrop to the conceptualization of this thesis in 2004 when 
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Proliferation of evidence as to the effectiveness of ART in African 
countries 
The evidence as to the effectiveness of ART in Southern Africa emerged rapidly 
thereafter, with the dramatic expansion of ART linked to the awarding of GFATM 
grants, and the launch of the World Health Organization (WHO) 3x5 initiative and of 
PEPFAR.  It is not possible or useful to chronologically and exhaustively review each 
incremental or parallel contribution to this evidence base.  Instead, relevant studies 
are grouped thematically or geographically. 
South Africa 
In late 2003, the South African government approved a plan to routinely provide 
ART for treatment of HIV in the public sector,67 implemented starting in April 2004.  
By March 2009, almost 700,000 patients were reported to have started ART in the 
public sector in South Africa.  There is however a paucity of data on the effectiveness 
and outcomes of this national programme.  A number of individual projects and 
provinces have however published outcome data. 
 
The cohort in Gugulethu, Cape Town, referenced above,59 has described patient 
outcomes when looking at the timing of mortality,68-69 the contribution of 
cryptococcal meningitis to mortality,70 the relationship between mortality and the 
most recent CD4 count,71 the role of viral load monitoring,72 the effect on outcomes 
of increasing patient enrolment,73 and the associations with mortality.74  The project 
has developed a lay health worker model for patient support, and is one of the best 
followed cohorts in South Africa.  Although loss to follow-up is not formally 
accounted for, the longest follow-up reported to date was 4 years, at which duration 
13.2% of patients had died.71 
 
The Free State province has tracked all patients enrolled into HIV care in the public 
sector in a common monitoring system, and was able to report on the early outcomes 
for all HIV-infected patients as well as those starting ART.75 The availability of data 
for all patients enabled an analysis similar to the one described above in the Swiss 
HIV Cohort Study,15 in which the effectiveness of ART compared to no ART could 
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be estimated.  ART was associated with an 86% reduction in mortality.  Additional 
striking findings were that in the period of follow-up (2004-2006), 53% of patients 
died, 87% of whom had not started ART, and 80% of the deaths were only 
ascertained on the basis of linkage to the national death registry.  Virological 
outcomes were not reported. 
 
McCord Hospital is a state-aided hospital in Durban, at which patients pay a small 
and all-inclusive co-payment.   An analysis of outcomes for 309 patients 
demonstrated the associations between disease advancement and mortality.76 Cross-
sectionally over a mean follow-up of 257 days, 16% of patients had died and 7.4% 
had been lost to follow-up.  Virological outcomes were not reported. 
 
The Western Cape Province has described outcomes at scale across the entire 
province based on the routine monitoring system in place in the province.77 This 
analysis incorporates data from both Khayelitsha and Gugulethu.  In a combined 
cohort of 12,587 adults, 72% remained alive and in care at four years. There was a 
parallel decline in early mortality and increase in loss to follow-up over time.  
Virological suppression to below 400 copies/mL was 85% or higher throughout 
follow-up.  The Khayelitsha cohort has been able to use death registry linkages as was 
done in the Free State province, to robustly describe patient survival and temporal 
trends in outcomes for over 7,000 patients.  Both of these analyses form part of this 
thesis, describing the effectiveness of ART in this setting over longer durations and at 
scale in a provincial health service. 
 
Whereas ART has only been available in the public sector in South Africa in recent 
years, it has been available in the private sector since before the era of triple therapy.  
An analysis of one of the largest private sector cohorts demonstrated that for 6288 
patients started on ART by March 2003, 3.5% had died, and 18% had been lost to 
follow-up.78  There was a strong relationship between the proportion of pharmacy 
refills collected and survival. This relationship was subsequently described with the 
probability of sustaining viral load responses in patients starting on NNRTI 
regimens.79 In patients who collected all of their drugs, 73% had continued viral load 
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favourable viral load outcomes for patients on EFV compared to NVP.80 Workplace 
programmes in South Africa have similarly demonstrated the effectiveness of ART 
since 2002, with good viral load results, but a high proportion stopping treatment 
over and above those who died.81  
Other African settings 
Botswana was the first country in Southern Africa to launch a national treatment 
programme, with treatment beginning at Princess Marina Hospital in Gabarone in 
2001.82-83 The programme started with a regimen based on a NRTI backbone of d4T 
and ddI which would later no longer be recommended for first-line therapy, together 
with an NNRTI.  Viral load monitoring is provided in Botswana, the only other 
country in the region besides South Africa to routinely provide this. In a cohort of 
153 patients starting ART in 2001-2002 at Princess Marina Hospital, survival and 
virological suppression were as anticipated from earlier studies, and a high proportion 
(32%) had changed therapy due to toxicity on this regimen.82  Poor programme 
monitoring has resulted in few data being available on the effectiveness of the 
Botswana national programme, although a retrospective chart review of 633 adults 
started on ART by the end of 2002 and followed until April 2007 demonstrated good 
longer term (five year) outcomes whereby 21% of patients had died and 22% were 
lost to follow-up.84  Established measures of disease advancement were confirmed to 
be associated with mortality.85  Despite the lack of programme-level data on 
effectiveness, reviews of national mortality data in Botswana, where vital registration 
is considered good, demonstrated a decline in mortality in adults aged 25-54 
coinciding with the rapid expansion in the national ART programme (2003-2005).86 
 
Malawi developed a comprehensive and context-appropriate national programme for 
ART, informed in part by experiences in the national tuberculosis programme,44 87 
and donor-assisted initiatives in the Thyolo and Chiradzulu districts.88-89 Although the 
cohort monitoring system in use has been the benchmark for the WHO,90-92 adult 
outcomes of the country programme have only been reported as cross-sectional,91 93 
or at one year duration on ART.94-96  
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Whereas the Chirudzulu programme reported 76% of patients retained in care at one 
year,89 the national programme reported 81% alive and in care over a much larger 
cohort tracked through the paper-based monitoring system.94  A viral load survey of 
334 patients on ART for 6 months or more in the Chirudzulu programme showed 
84% of them to have values below 400 copies/mL.89  A separate study reporting on 
the outcomes in patients lost to follow-up (9% at one year)94 reported that half had 
died and an additional quarter could not be traced.97 Sub-analyses have demonstrated 
that patients starting ART on concurrent treatment for tuberculosis have equivalent 
or better outcomes (survival, retention and CD4 count response) than those not on 
treatment for tuberculosis,95 and inferior outcomes for patients starting ART with 
concurrent Kaposi’s sarcoma.98 A demographic surveillance system was able to 
identify a small decline in adult mortality soon after the introduction of ART in 
Malawi,99 although this estimate was based on very few averted deaths.100 
 
In Zambia, 21,755 adults were enrolled onto ART in the space of 18 months 
beginning in April 2004.101 This project reported outcomes at one year, 
demonstrating successful rapid scaling up of care, the same risk factors for mortality 
as above, and confirming that most of the mortality occurred early (71% in the first 
three months). Patients accessed care earlier than the South Africa cohorts described 
above (median CD4 count 143 cells/µL at enrolment), and in keeping with other 
Southern African cohorts, more women than men accessed ART (61%). This 
programme has also demonstrated success in shifting clinical care from doctors to 
clinical officers and nurses.102   
 
In West Africa, the Senegalese government programme described above reported 
updated results at 3 and 5 years on ART for those enrolled by April 2002.103-104 105  
Reporting on 404 patients, a quarter had died at five years, not accounting for loss to 
follow-up which was not estimated beyond two years.104  The Triomune trial in 
Cameroon demonstrated sustained efficacy at 24 months duration, although viral load 
suppression to below 50 copies/mL (versus below 400 copies/mL) was considerably 
lower at 24 months compared to 12 months (64% vs. 79%, as-treated analysis). 
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In Côte d’Ivoire, the ANRS 1203 cohort in Abidjan (later known as Cotrame and 
then CEPREF) which was one of the early cohorts to report on outcomes as 
described above,55 provided updated estimates of the effect of ART on mortality,106 
severe opportunistic infections,107 tuberculosis,108, and morbidity events.109  During 
the rapid scale up of treatment post 2004 in this and related cohorts, 18 month 
mortality was 15% with an additional 21% of patients lost to follow-up for 3 months 
or more.106 
 
In Uganda in East Africa, a cross-sectional virological survey (median duration on 
ART of 38 weeks, 137 patients) found 66% of patients to be virologically suppressed, 
with unplanned treatment interruptions independently associated with non-
suppression.110 In a rural clinic in Mbarara, Uganda, mortality estimates were 
corrected with data from patients who were lost to follow-up and subsequently 
traced, yielding a cumulative mortality estimate at 3 years of 12.2%.111  An 
observational study and later a clinical trial run by the The AIDS Support 
Organisation (TASO) in Uganda have both demonstrated very effective home-based 
ART interventions.112-113 Excellent adherence in patients receiving home-based ART 
has separately been demonstrated in Uganda.114 In a research cohort of 559 ART-
naïve adult patients nested into the programme run by the Infectious Diseases 
Institute at Makerere University, 17% of patients died overall, with mortality 
declining with duration on ART from 17.9 deaths per 100 patient years in the first 
year to 1.2 deaths per 100 patient years between two and three years on ART. The 
majority (86% of first year deaths) were considered HIV-related. Four deaths (7%) in 
the first year were attributed to immune reconstitution inflammatory syndrome 
(IRIS), and all to unmasking as opposed to paradoxical IRIS.  Cumulative mortality 
for the whole cohort was not presented, but stratified by CD4 count, appeared 
similar to other cohorts in the region. Patients with CD4 counts below 25 cells/µL at 
ART initiation were at particularly high risk of death, with over 25% having died by 3 
years. 
 
In Western Kenya, the Academic Model for the Prevention and Treatment of 
HIV/AIDS (AMPATH) project has seen a rapid scaling up of ART provision.  The 
project reported in 2006 on a cohort of over 2000 adults started on ART.115 Overall 
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5.4% of patients had died (cross-sectionally, i.e. all deaths at the time or reporting 
divided by all patients who ever started ART in the study period, irrespective of 
duration of follow-up), and cumulative loss to follow-up (3 months without a visit) 
was 30% at two years on ART.  The project was later able to demonstrate in over 
23,000 patients how rapid scaling up had resulted in patients accessing ART with less 
advanced disease.116 
Collaborations 
There have been important contributions from collaborations based on cohorts in 
resource-limited or African settings.  These analyses are included in relevant sections 
below, but are briefly summarised in this section. 
 
The Antiretroviral Therapy in Lower Income Countries (ART-LINC) collaboration117 
was instrumental, through comparative analysis with a longstanding collaboration 
from wealthier countries, in demonstrating differences in early mortality on ART 
between settings.118 The collaboration included many African and in particular 
Southern African cohorts, in addition to cohorts in Brazil, Thailand and India. 
Subsequent analyses have demonstrated that the relative decline with duration on 
ART in tuberculosis case-finding is comparable across settings in spite of higher case-
finding in lower-income countries,119 and that women in Southern Africa are not 
disadvantaged in their access to ART compared to estimates of need.120 The scale-up 
of ART in the region was reflected in the collaborative database,121 as was the 
increase of loss to follow-up with increasing scale-up, together with the associations 
of fee-for-service and low baseline CD4 counts with loss to follow-up.122 The 
collaboration has described the evolution of CD4 count on ART,123 and has 
demonstrated the poor performance of CD4 count measures at predicting virological 
failure.124  In participating cohorts with viral load monitoring available, switching to 
second-line regimens occurred earlier and at higher CD4 counts than in cohorts 
without viral load monitoring.125  
 
The majority of the Southern African cohorts which participated in the ART-LINC 
collaboration now contribute data to the International Epidemiologic Databases to 
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date from this collaboration include the description of treatment-limiting toxicities in 
South Africa that forms part of this thesis,126 the comparison of outcomes in the 
public health approach to ART as applied in South Africa to outcomes in the Swiss 
HIV Cohort Study,127 and the comparison of mortality on ART to background 
mortality in selected sub-Saharan African countries.128 
Clinical and programme design considerations 
The above sections have detailed the emergence of data on the effectiveness of ART 
as it has emerged in South Africa and the region, as well as other African countries. 
 
Reviewed below are clinical or programme design issues related to the provision of 
ART in these settings, and draws together studies from different countries and 
settings. As the papers included in this thesis have been prepared and published over 
a period of rapid advancement in our understanding of treatment in this region, some 
of the thesis findings form part of this review. 
Loss to follow-up 
As mentioned at the end of the previous section, cohort attrition due to loss to 
follow-up has emerged as a major challenge to assessing cohort performance in 
Africa.   
 
Traditionally in high income countries, loss to follow-up has been treated as a 
censoring event in survival analyses. Studies have however demonstrated that patients 
lost to follow-up in these settings do have inferior survival and laboratory 
outcomes.129 
 
It was not surprising that as ART programmes have expanded where health systems 
are weak and patients experience substantial barriers to accessing care, an increasing 
number would be lost to follow-up.  This has been demonstrated succinctly in the 
Western Cape looking at early loss to follow-up which has increased while early 
mortality has declined.77 A review of treatment programmes with published outcomes 
up to two years on ART presented a view that published outcomes were 
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unrealistically optimistic due to loss to follow-up, estimating that 40% of patients 
were lost to care (including deaths) by two years.130   
 
In response it was pointed out that varying definitions were used for defining loss to 
follow-up. Typically, the convention has been to define loss to follow-up as patients 
not being seen for two consecutive clinical visits. In high income settings, stable 
patients are usually seen 6-monthly, hence the use of 12 or 13 months to define loss 
to follow-up. This was the definition initially proposed in a collaborative analysis 
from resource-limited settings.118  Other studies have used 3 months without a visit,77 
demonstrating the wide variability in this definition. 
 
Follow-up studies have powerfully demonstrated that a high proportion of patients 
lost to follow-up in these settings have in fact died, ranging in African studies from 
12% to 87%.97 131-134  In settings where services are based in the community through 
primary care clinics, retention in care is generally better than for large hospital-based 
programmes.135-136 
 
Statistical approaches are developing to correct mortality estimates in the context of 
loss to follow-up. Some are based on multiple-imputation,128 and others, sometimes 
termed “double-sampling”, are based on the outcomes from exercises to trace 
patients lost to follow-up.111 137  While it is widely anticipated that reported mortality 
is an underestimate of true mortality, a double-sampling based correction has 
demonstrated this to be the case in a Ugandan cohort.111 
Early mortality and comparative studies 
Many early reports from ART programmes in Africa drew attention to the high early 
mortality (in the first 3 or 6 months on ART),2 52 but still considered the outcomes to 
be comparable to those for very ill patients in high income countries.  A comparative 
study, which included two cohorts from the Western Cape, was able to adjust for 
degree of illness, and reported that after adjustment, mortality was higher in resource-
limited settings in the early months on treatment (adjusted hazard ratio [AHR] 4.3 in 
the first month, and 1.5 for months 7-12).118 The confidence intervals beyond 6 
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the Swiss HIV Cohort Study reported AHR’s for mortality of 5.9 and 1.8 for months 
1-3 and 4-24 on ART respectively.127  Standardised mortality ratios (SMR’s) 
comparing mortality on ART to background mortality in the general population in 
resource-limited settings have also demonstrated the excess mortality soon after 
starting ART compared to longer durations on treatment: for patients initiating 
therapy with less advanced disease and a CD4 count above 200 cells/µL, the SMR fell 
from 30.2 to 1.1 comparing months 1-3 on ART to months 13-24.128 
 
Explanations offered for this higher early mortality include the high prevalence of 
tuberculosis and immune reconstitution inflammatory syndromes (eg. to tuberculosis 
and cryptococcal pathogens), limited acute care capacity, and the late presentation of 
patients with respect to disease advancement.69 127 Mortality declines have occurred in 
parallel to progressively earlier ART initiation, but it has not been known if these are 
fully predicted by measured improvements in baseline CD4 count and clinical stage.77 
Regimens 
Most African ART programmes are based on a first-line regimen consisting of two 
NRTI’s and an NNRTI.  The NRTI’s most commonly used are d4T and 3TC, in 
combination with NVP or EFV. One of the reasons for the widespread use of this 
NRTI combination with NVP is their availability as a single tablet fixed-dose 
combination.63 
 
The d4T/3TC combination has been shown to be as effective as other NRTI 
combinations such as TDF/3TC.138  In high-income countries however, the most 
commonly used NRTI combination is TDF/FTC, which outperformed AZT/3TC 
when combined with EFV on virological, immunologic and safety measures.139 The 
use of this combination has been boosted by the availability of a once-daily single 
tablet fixed-dose combination of TDF/FTC/EFV, which is increasingly the initial 
antiretroviral regimen of choice in high-income countries.  The main obstacles to the 
wider use of this regimen in African programmes are the cost (generic products are 
only beginning to emerge),140 contra-indications to EFV use (pregnancy or pregnancy 
risk), and concerns about the need for renal function monitoring in patients on TDF.  
TDF has however been shown to have a similar renal safety profile to d4T,141 and 
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long term small declines in glomerular filtration rate over time have not been 
considered clinically relevant.142 Studies in African settings have shown that ART 
generally improves renal function in patients who begin therapy with renal function 
impairment,143 and where comparison with TDF containing regimens was possible, 
observed deteriorations in creatinine clearance were not associated with the 
regimen.144 
 
Greater concerns have been expressed however about the toxicity profile of d4T 
rather than virological inferiority.126 145-153  In particular, life-threatening lactic acidosis, 
already known to occur more frequently in patients on d4T compared to other 
NRTIs,154 has been demonstrated to occur much more frequently in Southern 
Africa,126 145 147 152 and in particular in women with high body weight or mass indices 
at the start of ART.126  International guidelines were changed to avoid higher doses of 
d4T based on evidence of lower toxicity risks with retained efficacy.155 The impact of 
this guideline change on toxicity is not yet known.  Symptomatic hyperlactataemia 
and lactic acidosis are rare before six months on ART, and one strategy proposed has 
been to initiate ART with d4T, and routinely substitute d4T with AZT after six 
months of therapy.156  It is argued that this strategy could potentially minimize the 
toxicity risks of both drugs, since AZT-related anaemia is less common in patients 
initiating AZT-based ART with higher CD4 counts, and substantial recovery in 
immune function is anticipated by six months on ART.157  It would however require 
closer clinical or laboratory safety monitoring after six months of ART when for 
many stable patients clinical visits are already three or more months apart. 
 
The preferential use of NNRTI’s compared to boosted protease inhibitors (BPI) for 
first-line regimens in the region is based on cost, stability and efficacy.  EFV has been 
shown to be superior to lopinavir/ritonavir158 or amprenavir/rionavir159 in terms of 
time to virological failure. There was a greater increase in CD4 count in the BPI 
group in the former study, the clinical importance of which was unknown. Regarding 
the choice of NNRTI,  NVP use has predominated in the region for many of the 
same reasons as the use of d4T – it is frequently co-formulated in a cheap generic 
fixed-dose combination.42 In South Africa however, EFV is more often used than 
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the regimens are not provided as fixed-dose combinations, eliminating one of the 
major advantages of NVP-based regimens. As concerns efficacy, clinical trial data 
initially failed to demonstrate inferiority of NVP compared to EFV,160 although for 
the South African participants in the 2NN trial, virological responses were inferior 
for those receiving NVP.  A number of cohort studies have subsequently 
demonstrated inferior virological outcomes for patients on NVP compared to EFV 
in both high income161-165 and low and middle-income settings.79 105 166-168 This 
difference may be accentuated when patients are concurrently on tuberculosis 
treatment when starting NVP-based ART,166 169 which is frequently the case in 
countries where access to EFV is limited.  Concerns have also been expressed that 
overweight patients on NNRTI’s may be particularly susceptible to sub-therapeutic 
drug levels.166 170-171 
 
Although a much wider range of antiretroviral agents are available, including abacavir, 
these are not discussed further as they have not featured prominently in 
considerations for optimal regimens in resource-limited settings.  There was a time 
when regimens containing three NRTI’s were considered a good option as this 
spared an additional class of agents for subsequent regimens, but this has faded with 
the evidence of inferior outcomes with this strategy.172-175 Regimen options for 
second and third-line regimens in the region are also not discussed further. 
Other associations with virological response 
Measures of disease severity at the start of ART have been identified for many years 
to be associated with higher risks of virological failure, including a high initial viral 
load,162 164 176-177 low baseline CD4 count,164 176 and a previous AIDS diagnosis.164 
These have been confirmed in Southern Africa for viral load and CD4 count.79 166 178 
Younger age166 177 179 and current CD4 count177 have further been associated with 
virological failure, whereas gender has not generally been found to be associated with 
failure. 
 
Factors influencing adherence have been found to be associated with virological 
failure in South Africa, including the language of the service provider, and higher 
dosing frequencies.58 Adherence measures where available, have been confirmed to 
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be associated with virological failure in Southern African (pharmacy refill)79 180 and 
Brazil (self-report).181 
 
Clinicians have long been concerned that abruptly stopping NNRTI-based therapy 
places patients at risk of a period of NNRTI monotherapy due to the relatively long 
half-life of NVP and EFV.  Cohort studies have supported this concern, 182-183 and 
unplanned treatment interruptions have been found to be associated with viraemia in 
patients on ART in other African settings.110 A similar mechanism is operative when 
pregnant women receive NVP at the onset of labour as part of prevention of mother-
to-child transmission (PMTCT) interventions, where the long half-life of NVP is 
linked to NNRTI resistance.184 
 
Studies looking at the clinical impact of this resistance post PMTCT first 
demonstrated that virological outcomes at 6 months were inferior in women exposed 
to single dose NVP (SD-NVP).185  It was subsequently demonstrated that women in 
whom there had been a delay of 6-18 months between SD-NVP and starting ART 
responded as well to NNRTI-based ART as unexposed women.178 186-187 Additional 
antiretrovirals antenatally,188 as well providing additional antiretroviral coverage post-
natally to cover the relatively longer half-life of NVP, have both been demonstrated to 
reduce NVP resistance, but have not been tested with respect to subsequent clinical 
response to ART.189 
Immunological responses 
Estimates as to the ability of HIV-infected individuals to quantitatively restore 
immune function through CD4 count recovery have been constantly upgraded.  As 
early as 2003, cohorts in Europe and North America reported on CD4 count 
recovery in patients with sustained virological suppression, reporting at the time that 
for all groups of patients, recovery was still continuing at 3 and 4 years 
respectively.190-191 Nevertheless it has long been established that there is a small 
subgroup of patients who have limited immunological recovery in spite of virological 
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Within the natural variation of response, a third of virologically suppressed patients in 
the Swiss HIV cohort had not attained a CD4 count above 500 cells/µL by 5 years 
on ART.  Lower CD4 counts in the first six months on ART, older age, and starting 
with a lower CD4 count were all associated with failure to attain this response.194 
 
Updates to these estimates have been slightly divergent with respect to continued 
CD4 count recovery. One analysis identified a plateau in absolute CD4 count in 
virologically suppressed patients, at all strata of baseline CD4 count, at 5 and 6 years 
duration on ART,195 whereas another found that on average, patients from all strata 
were still accumulating CD4 cells beyond 5 years on ART.196 
 
African studies have not generally been able to examine CD4 count responses on the 
basis of virological suppression, due to viral load measures not being available. One 
collaborative study without the benefit of viral load measures (which included data 
from Khayelitsha), found evidence of plateaus being reached, more marked for 
patients starting ART with very low CD4 counts.123 
 
Due to the much lower starting CD4 cell counts,118 even with equivalent recovery, 
patients in this setting spend a much higher proportion of time with lower CD4 
counts, placing them at greater risk of morbidity and mortality.197   
Monitoring the response to therapy and switching therapy 
The approach to monitoring therapy has evolved with the development of drugs and 
technology, and in well-resourced settings, the International AIDS Society 
recommendation is for stable patients to have frequent viral load tests (every 3 to 4 
months), in concert with CD4 count tests until the CD4 count is consistently above 
350 cells/µL, after which the CD4 counts could be done less frequently.37 Viral load 
monitoring more frequently than 6-monthly is supported by a clinical trial with 
respect to viral load outcome, and possibly survival,198 whereas a cohort study 
reported a low risk of treatment failure in stable patients in whom it may be safe to 
space the tests further apart.199 
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In the above guidelines, patients with confirmed viral loads above 50 copies/mL 
meet the definition of treatment failure.37  If the level of viraemia is above 500 
copies/mL, resistance testing is considered “essential”.200 
 
This contrasts markedly with many African country programmes, where the resources 
for regular viral load monitoring are not available, and WHO, recommendations for 
resource-limited settings do not recommend routine viral load monitoring.201 
Nevertheless, many clinicians in these settings still consider virological monitoring to 
be the goal, evidenced by the plethora of studies demonstrating that immunological 
failure criteria, however constructed, are a poor proxy for virological failure.202-206  
 
Recent evidence demonstrating that earlier initiation of ART than previously 
recommended,207 208 as well as avoidance of treatment interruptions, are associated 
with improved clinical outcomes,209-211 are lending support to the view that viraemia, 
independent of immunological status, is harmful to patients.212  
 
The alternate position, is that identifying virological failure early may not necessarily 
result in improved programme-level outcomes given the limited number of drugs and 
regimens available.  It is based on evidence that low grade viraemia (around 4 log10 
copies/mL) can support immunological stability or further recovery,213-220 and the 
argument that second-line regimens may still be highly effective in spite of resistance 
to the first-line regimen.221  
 
This view has been leant support by a modelling study which did not find benefits to 
viral load monitoring with the current regimens in use in most African settings,222 
whereas another study has found that for patients on NNRTI’s as opposed to BPI’s, 
CD4 count decline is more likely with low-grade viraemia.223  The only clinical trial to 
formally seek to address the optimal timing of treatment switching was unable to 
complete enrolment, due to the very widely held view amongst clinicians and patients 
in favour of early switching.224  
 
The resistance consequences of delayed switching in the context of a public health 












Chapter 1: Introduction and literature review 
 
Malawi programme, switching is guided by CD4 count criteria. At the time of switch, 
the majority of patients had treatment-limiting resistance to 3TC (81%) and NNRTI’s 
(93%) as anticipated.  In addition, 56% of patients had thymidine analogue mutations 
(TAMS), of whom 44% had three or more TAMS.  Unexpectedly 23% of patients 
had mutations conferring resistance to TDF. In the South African national ART 
programme by contrast, where switching is based on confirmed viraemia above a 
threshold of 1000 or 5000 copies/mL, whereas there was also a high frequency of 
mutations conferring resistance to 3TC and NNRTI’s (78% and 86% respectively), 
there was a much lower proportion with TAMS (23%), and those with TAMS had 
fewer mutations (20% had two or more TAMS).226 Nine percent of patients in this 
study had the K65R mutation limiting future treatment with TDF, ddI or ABC. The 
switching strategy in the South African programme when applied diligently, is 
therefore more likely to preserve efficacy of recycled or substituted thymidine 
analogues in the second-line regimen than strategies based on CD4 count criteria 
alone (97% without 3 or more TAMS compared to 75%). 
 
Arguments in favour of viral load testing in resource-limited settings are also based 
on the value of viral load testing as an early warning sign of adherence difficulties,72 
227 and on the assumption that increased demand will lead to technological 
improvements and more widespread availability and affordability of viral load testing. 
Stratification of patients based on viral load might enable more efficient use of 
resources for patient follow-up and monitoring. 
Co-morbidities 
One of the contextual factors differentiating HIV treatment in Southern Africa from 
the epidemic in wealthier countries, is the unique spectrum of HIV-associated 
illnesses diagnosed during treatment, in particular the much higher incidence of 
tuberculosis disease in resource limited settings (Figure 1).  Although tuberculosis is 
the leading opportunistic infection in the first three months on ART in both settings, 
the absolute incidence in this period is about 10 times higher in resource limited 
settings.  The other notable diagnosis with high mortality in resource limited settings 
that features less prominently in wealthier countries is cryptococcal meningitis. 
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Source: Egger 2007  228 
Figure 1. Incidence of HIV-associated conditions in the first 3 months on ART 
Overall tuberculosis case-finding exceeds 300/100,000 patients in Southern Africa, 
compared to less than 50/100,000 in most of Europe and North America.  The 
annual risk of tuberculosis in HIV-infected individuals with advanced immuno-
suppression approaches 30% in some settings.229 The estimate of the incidence rate 
ratio for being diagnosed with tuberculosis in Southern Africa comparing patients 
with HIV to those without was previously reported as 6,230 but more recently has 
been estimated to be much higher (20). 231 
 
In Khayelitsha and many parts of the region, tuberculosis is one of the major entry 
points into HIV care and ART, evidenced by 40% of patients starting ART in 2007 
already being on treatment for tuberculosis.166 The high level of co-infection around 
the time of patients first being found to be eligible for ART leads to a number of 
areas of clinical uncertainty, including: the timing of initiating ART in patients 
recently started on treatment for tuberculosis; the optimal antiretroviral regimens to 
be used; how best to improve the diagnosis of tuberculosis when a high proportion 
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sputum smear microscopy; and, whether or not there are adjunctive interventions to 
ART which might further reduce the risk of tuberculosis. 
 
Antiretroviral therapy has been found to reduce the risk of tuberculosis.  Compared 
to HIV-infected patients not on ART, the risk reduction has variously been reported 
as 82% and 39%, with a variety of methodological approaches employed in the 
analyses.75 232  Duration of ART has been found to reduce the relative risk of 
tuberculosis disease similarly across settings in spite of the very different baseline 
incidences.119 There has been concern that even after some years of ART, there is a 
substantial proportion of patients who remain at a high risk of new or repeated 
tuberculosis disease.233-234 There is observational evidence that isoniazid preventive 
therapy in addition to ART is effective at further averting tuberculosis episodes.235-236 
 
Although tuberculosis immune reconstitution disease has been found to be relatively 
common, especially in patients with advanced HIV disease, it has not to date been 
considered a major driver of early mortality on ART.237-238  Patients with diagnosed 
tuberculosis who start ART have variously been reported to have similar or improved 
outcomes to those without tuberculosis in adjusted166 and unadjusted95 analyses, and 
higher mortality in unadjusted analyses.239  Autopsy studies and mortality reviews 
however still identify tuberculosis as a major contributor to HIV-associated mortality 
in Southern Africa, and to early mortality on ART.240 69 241 Unrecognised resistance to 
tuberculosis drugs has been identified as an important reason for clinical deterioration 
in hospitalised patients with HIV-associated tuberculosis.242 
 
Cyrptococcal immune reconstitution disease and incident events have also been 
implicated as an important cause of morbidity and mortality on ART in Southern 
Africa.69-70 243-244 Recent evidence suggests that patients at risk of this can be readily 
identified through serological antigen screening prior to ART initiation.245  
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Aim and Objectives 
 
The first part of the above review outlines the evidence that existed as to the 
effectiveness of ART in the region at the time that this thesis was conceptualised.  It 
is against this backdrop that the aims and objectives of this project were developed.  
The above review has also reflected on the evolution of this evidence base, as well as 
some of the more detailed clinical questions, based on studies that have overlapped 
with those included in the thesis. 
 
The aim of this thesis at the time of conceptualisation was to describe the clinical 
outcomes, determinants of outcomes and scalability of the Khayelitsha antiretroviral 
treatment programme 
 
Specific objectives were: 
 
1. to describe the survival and related proximate outcomes of ART in 
Khayelitsha, and determinants thereof 
2. to describe the tolerability and durability of drug regimens used in Khayelitsha 
and the Western Cape Province 
3. to describe the impact of concomitant tuberculosis on ART treatment 
outcomes 
4. to explore the effect of ART availability in Khayelitsha on the risk behaviour 
of those not on ART 
5. to describe the Khayelitsha population in detail in order to be able to relate 
the Khayelitsha experience to other treatment contexts in the region 
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Section C: The Khayelitsha and Western Cape Programmes 
Background to Khayelitsha 
The Khayelitsha HIV treatment programme and later ART programme were set up 
as strategic projects by the international non-governmental organisation Médecins 
Sans Frontières (MSF).  Soon after combination ART as described above had 
revolutionised HIV treatment in wealthy countries, activists had noted the potential 
for patients in those countries hardest hit by the HIV pandemic to benefit, and the 
global inequities inherent in their not being able to access ART. The MSF initiative 
was located in Khayelitsha by chance – the head of the mission had, on arriving in 
South Africa in 1998, sought South African National Department of Health approval 
for a project which he initially envisioned would be in Gauteng.  Such approval was 
never forthcoming at a time when already there was political confusion in South 
Africa as to the role of antiretrovirals in addressing HIV.  In the Western Cape 
however, there was at the time a government initiative in Khayelitsha to reduce 
mother-to-child transmission of HIV through the provision of AZT to pregnant 
mothers. MSF were initially invited to provide technical support to this initiative and 
established a base in Khayelitsha in 1999. 
 
Khayelitsha is a relatively young township, formally established in 1985 towards the 
end of apartheid.  There are very widely divergent estimates of how many people live 
in Khayelitsha, but a verification exercise in 2005 estimated the population then to be 
400,000.246  For the past decade the health care infrastructure has been relatively 
static, comprising three provincial government run community health centres, and 8 
local government clinics. The community health centres provide acute and chronic 
care, and generally have a doctor available.  Two of the three have emergency units, 
and one is open 24 hours a day for emergencies.  There is no hospital within 
Khayelitsha, and patients requiring hospitalisation are transported by ambulance to 
either G F Jooste or Karl Bremer Hospitals (15-20 km). The local government clinics 
predominantly provide child health and tuberculosis care. The clinical staff are nurses 
with occasional support to the tuberculosis programme from sessional doctors. 
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HIV in Khayelitsha 
The Western Cape began tracking district level antenatal HIV seroprevalence in 2001 
(Figure 2).  It appears as if the Khayelitsha epidemic may have lagged slightly behind 
the national epidemic at this point, and may have peaked slightly higher than the 
national average for pregnant women, notwithstanding the difficulties in interpreting 
the national antenatal HIV seroprevalence data.247 
 
The comparisons within the provincial data are more robust however, due to a 
consistent probabilistic sampling approach throughout.248  Khayelitsha has always 






















South Africa 7.8 10.4 14.2 17.0 22.8 22.4 24.5 24.8 26.5 27.9 29.5 30.2 29.1 28.0
Western Cape 1.2 1.7 3.1 6.3 5.2 7.1 8.7 8.6 12.4 13.1 15.4 15.7 15.1 16.2
Khayelitsha 22.0 24.9 27.2 33.0 32.6 32.7 31.1
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
 
Figure 2. National, provincial and sub-district HIV antenatal seroprevalence 1994-2007 
The establishment of dedicated HIV treatment services in Khayelitsha 
Dedicated HIV clinics were set up by MSF in 2000 in the three community health 
centres in Khayelitsha. MSF initially employed one doctor, one nurse and two 
counsellors per clinic, and provided drugs commonly used for HIV care.  The clinics 
were located in space provided by either the provincial or local government, and in 
instances where patients required drugs that were not HIV-specific, these were 
obtained from the community health centre pharmacies.  From inception patients 
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From April 2000 to May 2001, the focus in the new clinics was to establish continuity 
of care, and treatment of opportunistic infections. Some medicines such as acyclovir 
for treating acute herpes simplex virus infections, had not previously been generally 
available prior to MSF’s involvement.  During this time the initial protocol for ART 
was developed, drawing extensively on local expertise in the research and private 
sectors where ART had already been available for some time, and on other initiatives 
within MSF, such as in Thailand where a similar protocol had been developed.  ART 
was introduced as a research project with the following stated objectives: 
 
The prime objective of this project is to offer comprehensive care for HIV to 
a cohort of people with HIV/AIDS and show that the use of combination 
antiretroviral therapy in a primary health care setting in a resource-
limited environment is feasible, affordable and reproducible. 
 
As such, this project seeks to develop a model of care for people with 
HIV/AIDS that can be widely adopted, including by government.  For the 
project to be a suitable model for the government, it must achieve several key 
goals in the context of limited resources (including limited laboratory 
capacity): 
 Reductions in AIDS-related morbidity and mortality, and improvements 
in quality of life; 
 Practical feasibility of using such interventions at the primary health care 
level; 
 Social acceptability of introducing complicated combination therapy in a 
community characterized by a lack of stable institutions; 
 Economic feasibility, through an analysis of the clinical cost-savings 
associated with the use of antiretrovirals. 
 
As a second objective, the pilot project aims to demonstrate that it is 
possible for developing countries to provide affordable care for people 
with HIV/AIDS immediately through the use of low-cost 
antiretrovirals, whether generic or patent-protected. 
 










Chapter 1: Introduction and literature review 
 
 
Direct importation of generic drugs would provide a powerful example to 
governments in developing countries of how they can affordably and 
sustainably confront the problem of treating people with HIV/AIDS. 
  
This protocol sought to treat 180 patients. The first patients were started on ART in 
May 2001. The initial first-line regimen comprised AZT/3TC in a fixed dose 
formulation, and NVP or EFV if NVP was contraindicated.  AZT, 3TC and NVP 
were imported from the Brazilian state manufacturer FarManguinhos from the 
beginning of 2002, continuing into 2004 until all drugs were available from the 
provincial drug depot.  The clinical aspects of the early protocol were very similar to 
the current provincial protocol, with the addition of an extra viral load test at 3 
months on treatment, and baseline viral load tests for everyone. 
 
Early on in the project there was a strong emphasis on social eligibility criteria 
including the signing of a “contract” with the service providers, receiving a home 
visit, disclosing HIV status to a confidant who could provide support, and joining a 
support group.  Alongside these criteria was a formal selection process in which all of 
these social eligibility criteria would be evaluated.51  
Evolution of the HIV services in Khayelitsha 
By late 2002 the project had already increased the target number of patients to 400.  
The Western Cape Province was also actively raising funds for treatment, including 
receiving support from the GFATM, agreeing with MSF to fund additional treatment 
beyond the 400 patients initially agreed to. This resulted in a rapidly growing and 
changing project.   
 
In terms of staffing, a second nurse was added to each clinic soon after ART was first 
provided, followed thereafter by an additional doctor and nurse at each clinic, and 
additional counsellors.  The Provincial government began in 2004 to create posts for 
medical officers and nurses, and also to rotate community service doctors through 
the HIV clinics.  Government indirectly also took over the funding of counsellors 
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doctor-based care than had initially been envisaged by MSF due to the provisioning 
of medical officer posts ahead of nursing posts.  By 2006 MSF’s contribution to 
staffing the original three clinics consisted of two doctors filling in as required when 
there were staffing shortages. At the same time however, MSF was supporting the 
local government clinics to introduce ART.  There have been a few clinicians who 
have remained in the HIV services in Khayelitsha throughout this period, but for the 
most part, there has been a reasonably high turnover of staff, especially when 
compared to other HIV services in the province. 
 
There were subtle trends in clinical practice throughout this period.  There was a shift 
towards more widespread use of EFV over NVP in 2002 and early 2003, after which 
a concerted effort was made to use NVP in preference to EFV in order to reduce 
costs, and enable the potential use of a NVP-containing fixed-dose combination 
which was anticipated in the public sector, even though it was never made available 
on the national tender.  D4T replaced AZT in the starting regimen in late 2003 in 
anticipation of the national programme which provided for d4T use.  Around this 
time (late 2003, early 2004), NVP was also used by some clinicians concomitantly 
with tuberculosis treatment based on the available evidence at the time, a practice 
continuing until late 2005.  The baseline viral load was dropped for treatment-naïve 
adults in 2005, as well as the 3 month viral load, in order to align with practices in 
other clinics.   
Antiretroviral therapy in the Western Cape 
By the time the national ART programme was formally started in April 2004, there 
were already well over 2000 patients on ART in the Western Cape public sector, with 
the majority from districts other than Khayelitsha.  Due to donor and research 
funding, many other ART projects had started, beginning in 2002. By April 2006, 
over 12,000 treatment-naïve adults had started ART in the provincial and city 
government health services, and at the time it was estimated that around half of those 
newly in need of treatment each year were managing to access treatment.  This 
trajectory was followed until the end of data collection for this thesis, with 
corroborating data demonstrating that morbidity and mortality were constant over a 
number of years in the province. Increases in enrolment were therefore keeping pace 
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with increases in advanced HIV, but were not managing to further close the gap 
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Section D: Data management and ethics 
Data management and processing 
Although the methods sections of each included paper give a brief account of data 
management, this section is intended to give a more detailed account of the data 
sources used in these analyses. 
Khayelitsha data management 
Key to the collection of data in Khayelitsha has been the use of structured clinical 
records, introduced in 2000 by MSF. These records, in which each visit was 
represented by a column on an A3 sheet, enabled excellent integration of clinical 
information over time, and formed the basis of the structured clinical record later 
used in the Province, and included by WHO as a country example in their guidelines 
on monitoring ART programmes.249  Each column also serves as a source for data 
extraction and capture. Although it is required that data capturers interpret free-text 
with this system, it was felt to be the best compromise between ensuring continuity 
and integration of clinical care, and accurate data capture. The clinical records were 
adapted in 2006 throughout the province to allow more space in each column, 
thereby ensuring that for the majority of consultations, additional recording of clinical 
notes would not be necessary. 
 
An MS Excel™ template was initially used to capture each visit from these structured 
records, which was soon converted to a MS Access™ database application.  From 
mid-2002 until the end of 2004, this application (eKapa) underwent many iterations 
of enhancement and development and was used until the end of 2007 as the patient 
information system for the three original HIV clinics in Khayelitsha.  A locally 
networked instance of the entire database was running at each clinic, with the data 
residing on one computer on the network. Each week the backend databases at these 
three clinics were synchronised with a copy held on removable storage. 
 
The University of Cape Town (UCT) employed a full-time data quality assurance 
nurse from 2003 until 2006, who was responsible for verifying the quality, accuracy 
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and completeness of data held in the eKapa database, by systematically comparing a 
printed copy of the electronically held data with each source patient folder. This 
process was maintained for data until the end of 2005, at which point it was no longer 
possible to systematically verify each patient record.  Database routines were then 
developed to highlight missing or inconsistent data, which were flagged for correction 
by various members of the data teams from epidemiologists working at UCT, to data 
quality control staff, to the MSF or government employed data capturers at the 
clinics.   
 
Laboratory data were available in electronic form from late 2002, and from then until 
the end of 2007, electronic laboratory data, when available, were used to fill in gaps in 
the 6-monthly monitoring of viral load and CD4 count. 
 
Two standard exports were built into the database application, one producing a 
summary table in the format of one line per patient, and one in the format of one line 
per visit. These exports did not include patient identifiers, and were used as the basis 
for the analyses of Khayelitsha ART programme data. 
Western Cape data management 
In late 2003, as ART availability was extending to many primary care and hospital 
sites in the province, a provincial committee agreed on standard structured clinical 
records, registers, and monthly and quarterly reports, which could be used in all 
facilities, irrespective of the availability of electronic systems.  This end-to-end paper-
based system resulted in comprehensive provincial data being collected on the limited 
monthly and quarterly data elements which had been defined. Based on this data, the 
first detailed report was produced covering until the end of March 2006, two years 
after the official launch of the national antiretroviral treatment programme.  A year 
later, an updated report was produced.  The first report formed the basis of one of 
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There are a number of unique features to this data collection system which enabled 
its success, including: 
 data are reported 3 months in arrears, giving time for registers to be updated, 
and outcomes such as loss to follow-up and laboratory results, to be fully 
ascertained. 
 A limited number of data elements are reported, each as an aggregate number, 
ensuring that they can be easily extracted from a register 
 Indicators are all proportions based on the above aggregate numbers, and are 
very limited in number, facilitating greater completion and coverage of those 
that are collected 
 
The system has been cited by WHO as a country example of  appropriate cohort 
monitoring of ART.249 Monthly data elements are the total number of new patients 
and total patients in care, reported separately for adults and children.  This is 
sufficient for month-to-month resource planning.  Quarterly indicators include, for 
each 6-monthly duration of follow-up and for each successive calendar quarter, 
mortality, loss to follow-up, viral load suppression (as a proportion < 400 
copies/mL), CD4 count response (proportion with a CD4 count >=200 cells/µL in 
adults), and proportion on first and second-line regimens. 
 
Those sites such as Khayelitsha which collected their data electronically, exported it 
in the required aggregate format for incorporation into the provincial dataset. 
Household survey sampling and data management 
The final data source used in this thesis was a household survey conducted in 
Khayelitsha in 2003/4. This survey was managed by the Infectious Disease 
Epidemiology Unit of the University of Cape Town.  The 1996 national census was 
used (the 2001 census was not available at the time), to select 80 enumerator areas 
(areas comprising approximately 200 households) based on probability proportional 
to size.  Aerial photographs as well as GIS data files (ArcView v3.2™) were obtained 
from the City of Cape Town. For formal areas, within each selected enumerator area, 
10 erfs were randomly selected by the GIS software as a sample of all erfs in the 
given area.  For informal areas, 10 spatially random points were selected by the GIS 
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software. Each point was then manually positioned on the accompanying aerial 
photograph on the nearest dwelling. 
 
Maps of each selected enumerator area were printed from the GIS aerial photograph 
and street layers, with the selected erfs or households clearly indicated. 
 
Fieldwork teams visited each enumerated household up to three times in order to 
interview the designated male and female adult household members.  In each 
household, all adults aged 14-49 were enumerated. If more than one man or women 
in this age range lived in the household, one was randomly selected based on a 
procedure that utilised the given age in the enumeration table, to ensure it was 
repeatable. 
 
Questionnaires were cross-checked on site by a field-work supervisor, and were 
double-captured into a custom MS Access™ database.  The duplicate databases were 
compared for discrepancies, which were resolved based on the source questionnaires, 
prior to one of the databases being ported to Stata™ for statistical analysis. 
The candidate’s role in data collection and management 
The candidate built and maintained the MS Access database that was used as the 
electronic patient information system in Khayelitsha from mid-2002 until the end of 
2007, provided clinical care in the programme on a part-time basis from 2003-2005, 
and co-supervised the data quality assurance. The candidate co-ordinated the 
establishment of a Provincial structured clinical record as well as the facility-based 
registers and cohort monitoring system.  The candidate conducted the sampling for 
the household survey, developed the survey database and co-supervised the survey 
data entry and validation. 
Ethical approval 
The Khayelitsha programme initially received ethical approval from the South 
African Medical Association.  This was however superseded after the launch of the 














Research Ethics Committee (REC REF 395/2005). This approval covered all 
Khayelitsha analyses included in this thesis. The approval did not require individual 
informed consent, as it was based on the premise that all clinical care was standard of 
care, that the research component consisted solely of ensuring accuracy and 
completeness of routine data, and that data would be anonymised prior to analysis.  
All three of these requirements have been continuously met. 
 
Separate approval was sought for the data linkage to the national death registry. This 
required the transferring of identified data to a trusted party for data matching. The 
Khayelitsha project received ethical approval for the linkage exercise, as did the 
recipient who did the linkage and returned the matched data, Mr David Bourne (REC 
REF 971/2008). 
 
The household survey was also approved by the University of Cape Town Research 
Ethics Committee (REC REF 021/2003). The analysis of provincial data was based 


























Chapter 2: Results in the form of published papers 
Seven year experience of a primary care antiretroviral treatment 
programme in Khayelitsha, South Africa  
 
Paper overview 
This paper presents a comprehensive set of clinical outcomes, covering temporal 
trends over seven years, and five years duration on ART.   
 
The paper covers the commonly reported domains of cohort effectiveness: mortality, 
loss to follow-up, virological and immunological outcomes. It also covers the 
durability of the first-line regimen, but does not cover the tolerability of the regimen 
(see below).  Associations with each of the main outcomes (mortality, virological 
failure and CD4 count response) are modelled. 
 
Contribution to the thesis and novelty 
This paper addresses the first and main objective of the thesis, as well as the question 
of durability in the second objective. There is currently no other study from the 
region that is able to report treatment outcomes over this duration or calendar period, 
and correct for the under-ascertainment of mortality.  Other contributions of the 
paper that are unique to the setting are the descriptions of the immunological 
response conditioned on virological failure, as well as the time to meeting guideline 
definitions of virological failure. 
 
Contributions of candidate 
The candidate was co-responsible for the data management of the cohort since 2002, 
and conducted all the analyses in the manuscript.  The candidate wrote and managed 
all drafts of the manuscript, incorporating suggestions from co-authors. 
 
Publication status 
Submitted 26 June 2009 for review to AIDS, accepted 01 October 2009. 
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A further analysis was conducted subsequent to the acceptance of this paper for 
publication, to address the concern that patients with civil identification numbers may 
be different to those without. If this were the case, the weighting of patients lost to 
follow-up with a civil identification number to represent all patients lost to follow-up 
could introduce bias.  The baseline CD4 counts were compared in patients with and 
without civil identification numbers who met the analytical loss to follow-up 
definition. This was restricted to those lost in the first year of ART, where the 
probability of mortality was highest, and differences in disease severity would be most 
likely to introduce bias.  Although the median baseline CD4 count was slightly higher 
in those lost to follow-up with civil identification numbers who started ART in 2006 
and 2007 (Table 1), the absolute difference was unlikely to result in large mortality 
differences (2006), or the numbers were too small to make valid inferences about the 
differences (2007). 
 
Table 1. Comparison of baseline CD4 count in patients lost to follow-up in the first 
year of ART with and without civil identification numbers 
Year of ART n Mean Median n Mean Median p‐value*
2004 29 79           76 4 71               78 0.825
2005 38 91           98 42 100            98 0.538
2006 93 99           74 87 106            95 0.063
2007 14 91           61.5 22 140            119 0.270

















Seven-year experience of a primary care antiretroviral
treatment programme in Khayelitsha, South Africa
Andrew Boullea, Gilles Van Cutsema,b, Katherine Hilderbranda,b,
Carol Craggc, Musaed Abrahamsb, Shaheed Matheec, Nathan Forda,b,
Louise Knightb, Meg Oslera, Jonny Myersa, Eric Goemaereb,
David Coetzeea and Gary Maartensd
Objectives: We report on outcomes after 7 years of a community-based antiretroviral
therapy (ART) programme in Khayelitsha, South Africa, with death registry linkages to
correct for mortality under-ascertainment.
Design: This is an observational cohort study.
Methods: Since inception, patient-level clinical data have been prospectively captured
on-site into an electronic patient information system. Patients with available civil
identification numbers who were lost to follow-up were matched with the national
death registry to ascertain their vital status. Correctedmortality estimates weighted these
patients to represent all patients lost to follow-up. CD4 cell count outcomes were
reported conditioned on continuous virological suppression.
Results: Seven thousand, three hundred and twenty-three treatment-naive adults (68%
women) started ART between 2001 and 2007, with annual enrolment increasing from
80 in 2001 to 2087 in 2006. Of 9.8% of patients lost to follow-up for at least 6 months,
32.8% had died. Corrected mortality was 20.9% at 5 years (95% confidence interval
17.9–24.3). Mortality fell over time as patients accessed care earlier (median CD4 cell
count at enrolment increased from 43cells/ml in 2001 to 131 cells/ml in 2006). Patients
who remained virologically suppressed continued to gain CD4 cells at 5 years (median
22cells/ml per 6 months). By 5 years, 14.0% of patients had failed virologically and
12.2% had been switched to second-line therapy.
Conclusion: At a time of considerable debate about future global funding of ART
programmes in resource-poor settings, this study has demonstrated substantial and
durable clinical benefits for those able to access ART throughout this period, in spite of
increasing loss to follow-up.  2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
AIDS 2010, 24:563–572
Keywords: antiretroviral therapy, cohort study, death registries, HIV, loss to
follow-up, resource-limited settings, South Africa
Introduction
Less than 10 years ago, opinions were divided as to
the feasibility of providing antiretroviral therapy
(ART) in those countries, mostly in Africa, in which
the majority of people living with HIV reside [1,2].
Since then, a number of African ART programmes
have demonstrated excellent adherence and clinical
outcomes for the first wave of patients accessing care
[3–8].
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The focus of attention is now shifting from feasibility to
sustainability. Little is known about either the longer term
outcomes on ART in these settings or whether the early
outcomes have been sustained for patients accessing care
more recently. In particular, the true outcomes of patients
who are lost to follow-up are hardly known outside of
study settings [7,9].
One of the first programmes that demonstrated the
feasibility of ART in Southern Africawas the Khayelitsha
ART programme [3], established in 2001 by Médecins
Sans Frontières and the provincial government of
the Western Cape, South Africa. Early outcomes from
the Khayelitsha programme helped to establish the
importance of a patient-centred adherence model and
strong community activism for ART care [10]. This
study describes outcomes for adults in Khayelitsha
up to 5 years on ART and temporal trends in these
outcomes over 7 years, utilizing linkages with the South
African vital registration system to correct mortality
estimates for increasing loss to follow-up (LTF) in
recent years.
Setting
The Khayelitsha HIV treatment programme was estab-
lished in 2000 at three public sector primary care clinics in
Khayelitsha township, home to an estimated 500 000
people. Antenatal HIV prevalence was 22.0% in 2001 and
32.7% in 2007 [11]. ART was first provided through a
pilot demonstration project in May 2001, with modest
capacity to provide therapy for 180 adults [12]. By the end
of 2007, the service had cumulatively enrolled over 7000
treatment-naive adults onto ART and was operating as a
routine government service.
Adult patients are eligible for ART if their CD4 cell
count drops below 200 cells/ml or if they have a WHO
stage IV condition other than extrapulmonary tubercu-
losis. The initial regimen was zidovudine (ZDV) and
lamivudine (3TC) together with nevirapine (NVP) or
efavirenz (EFV). Stavudine (d4T) replaced ZDV in the
standard first-line regimen in late 2003 in order to align
with the South African national guidelines, which were
implemented in April 2004 [13]. Viral load (NucliSens
EasyQ HIV-1 assay; bioMérieux, Boxtel, The Nether-
lands) and CD4 cell count (single-platform panleucogat-
ing method) [14] testing are provided 6-monthly
after starting ART. Serum alanine aminotransferase and
haemoglobin aremonitored for patients onNVPandZDV,
respectively. Guidelines make provision for a second-line
regimen (ZDV, didanosine and lopinavir/ritonavir) to be
started after virological failure is confirmed (two conse-
cutive viral load results 5000 copies/ml, in spite of
enhanced adherence promotion after the first elevated
result).
The major sources of referral to the service are from acute
care and tuberculosis services in the subdistrict. Nurse-
based care has been central to this treatment programme
since inception with more than two-thirds of consul-
tations with nurses, and this model of care has continued
to evolve over time. The frequency and intensity of
clinical contact has decreased, with stable patients seen by
a nurse 2 or 3-monthly, and many of the consultations for
long-term stable patients being integrated into group
sessions (‘clubs’). The adherence model remains patient-
centred but no longer includes routine home visits or a
signed patient contract. Pharmacist assistants now
dispense most drugs, and doctors see patients predomi-
nantly on the basis of internal referral of patients by
nurses.
Prevention of mother-to-child transmission (PMTCT)
services have been available since 1999, initially based on
short-course ZDV [15], and since late 2003, on both
short-course ZDV and peripartum NVP in women not
eligible for triple therapy [16]. Data on the type of
PMTCT received were not available for this analysis.
Methods
Data management and processing
Clinicians have used structured clinical records through-
out the period of analysis, which are captured on-site into
an electronic patient information system by dedicated
data capturers. All clinical care, record keeping and data
capture are part of routine patient management as per
provincial guidelines. Rule-based consistency checks
identify specific patients and data elements for review by
quality assurance staff.
This analysis includes all data on treatment-naive patients
(including those exposed only to PMTCT interventions)
of age 14 years and older, until the end of 2007. Mortality
and LTF estimates include patients enrolled until the
middle of 2007 in order to give all patients the
opportunity of meeting the LTF definition of 6 months
without a clinic visit.When adjusting analyses for the year
of enrolment, the first 2 years were combined into a single
period due to the small numbers enrolled in these years
and similarity in patient profile.
Civil identification numbers, where available, were cross-
checked in the national death registry to confirm or
ascertain dates of death for those with registered deaths. It
was not possible to differentiate deaths due to HIV from
deaths due to other causes. All data were anonymized
prior to being made available for analysis.
Follow-up laboratory results were considered as repre-
senting the nearest 6-monthly follow-up duration.
Baseline CD4 cell counts included measures from
564 AIDS 2010, Vol 24 No 4
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12 months prior to 1-week posttreatment initiation. If
more thanonemeasurewas available, themeasure closest to
baseline or 6-monthly duration was used. When compar-
ing viral loads on first and second-line regimens, first-line
viral loads were restricted to tests done prior to the
switching. Second-line viral loads were restricted to
measures that followed the initiation of second-line by at
least 3 months in order to exclude repeated baseline viral
loads at the initiation of second-line. Laboratory outcomes
are presented only for those patients on treatment inwhom
test results were available, and no assumption is made on
laboratory outcomes in those who missed a scheduled test
or who were lost to care at the time.
Analysis
Kaplan–Meier estimates of time to death and LTF (date
last seen) are described. A weighted Kaplan–Meier
approach was used to correct the mortality estimate for
those who were LTF but had died, by weighting those
patients who were LTF but for whom a definitive
outcome could be established from the death registry, to
represent all patients lost to follow-up [17]. Weights were
calculated separately by year and duration of follow-up.
Bootstrap confidence intervals (CIs) for the weighted
Kaplan–Meier failure estimates were calculated by
sampling from the dataset with replacement 1000 times.
Patients who were known to have transferred to other
services were right censored at the date of transfer. Cox
proportional hazard models based on the same weighted
data were used to explore associations with early
(<3 months) and late mortality.
Virological responses were described as the proportion
below 400 copies/ml at each year of follow-up for all
patients, and separately for patients on first and second-
line regimens. Virological responses on first and second-
line therapy were compared across all durations in a
logistic regression model clustered on individuals with
robust standard errors. CD4 cell responses were described
as median absolute value, change from baseline count and
change from previous count at each duration of follow-
up. This was repeated on a subset of patients who had
been continuously virologically suppressed until the CD4
cell count measure. Proportions were compared using the
chi-squared test and medians using the rank sum test.
Time to confirmed virological failure and time to the
initiation of second-line therapy were described as
standard Kaplan–Meier estimates, and associations with
virological failure were explored with a standard Cox
model. A population-averaged linear regression model
with an exchangeable correlation matrix was used to
explore associations with CD4 cell count responses in
each 6-month interval, limited to patients with continu-
ous virological suppression.
All analyses were conducted using Stata statistical
software, version 10.0 (Stata-Corp Inc., College Station,
Texas, USA). The analysis of routine cohort data and the
linkage to the national death registry were both approved
by the University of Cape Town Research Ethics
Committee.
Results
Annual enrolment increased from 80 treatment-naive
adult patients in 2001 to 2087 in 2006 (Table 1), with a
total of 7323 enrolled during the period under analysis.
Women constituted 68.2% of the cohort and were
younger at enrolment than men (median 31 vs. 36 years,
P< 0.001). Overall, 3.7% of women initiated ARTwhile
pregnant and 11.1% had previously received PMTCT
interventions. Median baseline CD4 cell count increased
from 43 [interquartile range (IQR) 13–95] cells/ml in
2001/2002 to 131 (IQR 64–191) cells/ml in 2007. The
proportion with clinically advanced disease (AIDS as
defined byWHO clinical stage IV) [18,19] decreased over
the same period from 54.5 to 28.9%. The proportion
initiating ARTwhile already on treatment for tuberculosis
increased from 22.7 to 42.4%.
Civil identification numbers were available for 57.0% of
all patients and 70.6% of patients enrolled in 2007
(Webtable 1). Cross-sectionally, 9.8% of patients enrolled
by the middle of 2007 (628/6402) had been LTF. Just
under half of those LTF had a civil identification number
(46.7%), of whom 32.8% had a registered death before the
end of 2007. Patients lost in their first year of treatment
(59.2%) were more likely to have died compared with
those lost thereafter (42.4 vs. 18.1%, P< 0.001).
In patients whose deaths were reported to the services and
for whom a civil identification number was available,
90.5% (172/190) were matched in the death registry,
whereas 99.9% (2941/2944) of patients known to be alive
and with valid civil identification numbers were not
found in the registry, reflecting the sensitivity and
specificity of the data linkage.
The cumulative estimate of mortality based on clinic-held
data was 15.5% (95% CI 13.1–18.3) at 5 years (Fig. 1a),
whereas the equivalent estimate of LTF was 23.4% (95%
CI 20.5–26.6). Combining LTF and mortality, 35.3%
(95%CI 32.1–38.6) of patients were lost to care at 5 years.
LTF has occurred earlier with each successive year of
enrolment (Fig. 1b). The weighted estimates of mortality,
including patients LTF who could be matched in the
death registry, were 9.9% (95%CI 8.9–10.9), 12.6% (95%
CI 11.5–13.8) and 20.9% (95% CI 17.9–24.3) at 1, 2 and
5 years, respectively (Fig. 1c). Incorporating the linkage
data, overall mortality has decreased over time (Fig. 1d).
Low baseline CD4 cell count, an AIDS diagnosis and a
low body weight were all strongly associated with
Seven years of ART in Khayelitsha, South Africa Boulle et al. 565
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mortality in the first 3 months on ART (Table 2) and
remained associated, although attenuated, beyond 3
months. Older age (>50 years) was associated with
higher mortality after 3 months on ART. Year of ART
initiation was not associated with mortality after
adjustment for baseline characteristics.
For all patients combined, 87.6, 88.1 and 83.8% of those
who remained in care and received viral load tests were
virologically suppressed (<400 copies/ml) at 1, 3 and
5 years, respectively (Table 3). Patients on second-line
ARTwere less likely to be virologically suppressed com-
pared with patients remaining on first line at equivalent
durations on ART [odds ratio (OR) 0.51, 95% CI 0.26–
1.01], although 22 out of 29 (75.9%) patients on second-
line ART at 5 years were virologically suppressed.
Patients who remained virologically suppressed through-
out follow-up had gained a median of 474 (IQR 341–
660)CD4cells/ml by 5 years and continued to gain a
median of 22 cells/ml per 6-month period between 4 and 5
years on ART (Table 3). Additional factors independently
associated with CD4 cell count gain (Table 4) were female
sex, younger age and measures of disease advancement at
ART initiation (AIDS, tuberculosis and low CD4 cell
count). At 5 years on ART, 3.7, 11.9 and 25.7% of
virologically suppressed patients had CD4 count values less
than 200, 200–349 and 350–499 cells/ml, respectively.
By 5 years, 14.0% (95%CI 11.9–16.4) of patients had met
the guideline definition of confirmed virological failure
(Fig. 2) and 12.2% (95% CI 10.1–14.8) had started
second-line therapy. Seventy-four percent of those
starting second-line therapy formally met the guideline
definition and started second line a median 5.3 (IQR
2.2–11.2) months after the date of the second raised viral
load. The remaining patients were started on second-line
therapy with one of the raised values being between 400
and 5000 copies/ml or without a confirmatory viral
load test.
Seven years of ART in Khayelitsha, South Africa Boulle et al. 567
Fig. 1. Cumulative estimates of mortality, loss to follow-up and loss to care. Kaplan–Meier estimates of reported mortality and
loss to follow-up (a), loss to follow-up by year of initiation (b), corrected mortality (c) and corrected mortality by year of initiation
(d). ART, antiretroviral therapy; CI, confidence interval. Loss to care includes both those who have died and those lost to follow-
up. Vital status was ascertained for patients lost to follow-up from the national death registry if a civil identification number was
available. These patients were weighted in this analysis to represent all patients lost to follow-up. Vertical bars represent 95% CIs.
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ART interruptions, PMTCT exposure, low initial CD4
cell count and the use of NVP (especially concomitantly
with treatment for tuberculosis) were all independently
associated with virological failure (Table 5).
Discussion
Our analysis demonstrates that ART benefits, in a poorly
resourced primary care setting, are durable, with almost
568 AIDS 2010, Vol 24 No 4
Table 2. Characteristics at the start of antiretroviral treatment associated with mortality in multivariate weighted Cox proportional hazard
models.
First 3 months on ARTa Beyond 3 months on ARTb
AHR 95% CI P AHR 95% CI P
Age 50 years 1.2 0.7–2.3 0.523 2.3 1.4–3.6 <0.001
Male sex 1.2 0.9–1.6 0.160 1.3 1.0–1.7 0.071
CD4 cell count category (cells/ml) <0.001 0.003
0–50 3.9 2.3–6.6 1.8 1.2–2.6
50–149 1.9 1.2–3.3 1.2 0.8–1.7
150–249 (ref.) 1.0 – 1.0 –
AIDS diagnosis when starting ART 1.8 1.3–2.4 <0.001 1.4 1.0–1.9 0.038
Baseline weight (per 10 kg) 0.6 0.5–0.6 <0.001 0.8 0.7–0.9 <0.001
Was on TB treatment when starting ART 1.1 0.8–1.4 0.509 0.7 0.5–1.0 0.071
Year of starting ART 0.275 0.941
2001/2002 1.3 0.7–2.5 1.2 0.3–5.1
2003 1.2 0.6–2.1 1.2 0.3–5.5
2004 0.7 0.4–1.3 1.4 0.3–6.2
2005 1.0 0.6–1.7 1.2 0.3–5.0
2006 1.0 0.6–1.7 1.1 0.3–4.7
2007 (ref.) 1.0 – 1.0 –
AHR, adjusted hazard ratio; ART, antiretroviral therapy; CI, confidence interval; TB, tuberculosis.
a5346 observations, weighted n¼5631.
b4833 observations, weighted n¼4931.
Table 3. Viral load and CD4 cell count responses for up to 5 years on antiretroviral therapy.
1 year 2 years 3 years 4 years 5 years
Viral load
Combined
Total in care 4512 2561 1235 458 191
Tested (%) 3932 (87.1) 2198 (85.8) 983 (79.6) 351 (76.6) 148 (77.5)
Suppressed (%)
[<400 copies/ml]
3446 (87.6) 1905 (86.7) 866 (88.1) 311 (88.6) 124 (83.8)
First line
Total in care (%) 4505 (99.8) 2506 (97.9) 1147 (92.9) 405 (88.4) 155 (81.2)
Tested (%) 3890 (86.3) 2127 (84.9) 914 (79.7) 310 (76.5) 119 (76.8)
Suppressed (%)
[<400 copies/ml]
3407 (87.6) 1851 (87.0) 812 (88.8) 282 (91.0) 102 (85.7)
Second line
Total in care (%) 7 (0.2) 55 (2.1) 88 (7.1) 53 (11.6) 36 (18.8)
Tested (%) 5 (71.4) 47 (85.5) 63 (71.6) 41 (77.4) 29 (80.6)
Suppressed (%)
[<400 copies/ml]
4 (80.0) 31 (66.0) 50 (79.4) 29 (70.7) 22 (75.9)
CD4 cell count
All patients
Total in care 4512 2561 1235 458 191
Tests available 3823 2108 931 341 127
CD4 cell count, median,
cells/ml (IQR)
297 (209–397) 383 (276–515) 425.5 (309.5–581) 486 (346.5–669) 512 (353–689)
Change from baseline,
median (IQR)
192 (116–282) 282 (180–406) 341 (224–488) 413 (263–580) 442 (266–615)
Change over 6 months,
median (IQR)
51 (7 to 111) 43 (18 to 111) 24.5 (55 to 99.5) 20.5 (54.5 to 124.5) 6 (85 to 116)
Patients with continuous viral load suppression documented
Tests available 3380 1847 820 307 109
CD4 cell count, median,
cells/ml (IQR)
304 (218–404) 398 (299–531) 459.5 (341.5–601) 511 (391–714) 542 (393–725)
Change from baseline,
median (IQR)
198 (124–288) 300 (203–420) 371 (251–509) 441 (317–629) 474 (340.5–659.5)
Change over 6 months,
median (IQR)














80% of patients remaining alive at 5 years, of whom more
than 80% of those tested were virologically suppressed.
Improvements in CD4 cell count and clinical stage at
ART initiation were translated in absolute terms into
improved survival since 2004. After adjustment for these
measures, we found that the rapid scale-up in patient
numbers has not resulted in increased mortality. Although
the link between improved access to care and reduced
early mortality has been previously reported in the
broader provincial programme of which the Khayelitsha
cohort is a part [7], the current analysis was able to correct
for possible underascertainment of mortality.
The relatively high proportion of patients who have
remained virologically suppressed for up to 5 years on
treatment is reassuring. Nevertheless, almost one in five
patients reaching 5 years are on a second-line regimen in
spiteof thedelays inswitchingtosecondline, suggestingthat
a substantial number of patients are going to need to access
second-line therapy as programmes mature. Predictors of
both virological failure and CD4 cell count gain
conditioned on continuous virological suppression are
rarely reported from scale-up settings. The association
between virological failure and PMTCTexposure, in spite
of the likelymisclassification of some non-NVPexposures,
adds to concerns that NVP-based PMTCT may compro-
mise future ART effectiveness [20,21]. The 1.6-fold
increased risk of virological failure following each treat-
ment interruption is also of concern, especially given the
highproportionof patientswhodevelop serious toxicityon
the current first-line regimens in use, which often
necessitates treatment interruption [22], and that themajo-
rityof interruptions in patients lost to follow-upwill not be
staggered to cover the longer half-life of non-nucleoside
reverse transcriptase inhibitors (NNRTIs) [23,24].
Patients in this cohort who remained virologically
suppressed continued to restore CD4 cells throughout
follow-up, with the rate of increase slowing as CD4 cell
counts reached the normal range. This finding is similar
to the equivalent subgroups of patients in recent analyses
of European and North American cohorts [25,26] but
differs from a collaborative analysis from resource-limited
Seven years of ART in Khayelitsha, South Africa Boulle et al. 569
Table 4. Multivariate associations with 6-monthly CD4 cell count changes.
CD4 cell count changesa over 6 months
Coefficientb 95% CI P
Male sex 14.3 17.1 to 11.5 <0.001
AIDS diagnosis at the start of ART 3.0 0.4–5.7 0.026
Had TB at the start of ART 4.7 1.8–7.6 0.002
Age at the start of ART (years) 0.107
16–24 (ref) 0.0 –
25–49 4.5 9.1 to 0.1
50 7.4 15.4 to 0.6
CD4 cell count at the start of ART (cells/ml) <0.001
0–50 13.2 9.7–16.7
50–149 2.2 1.1 to 5.5
150–249 (ref.) 0.0 –





ART, antiretroviral therapy; CI, confidence interval; TB, tuberculosis.
aCD4 cell count changes are change for each 6-monthly interval in patients who continuously had viral loads below 400copies/ml up until the time
of the second CD4 cell count measurement. Population-averaged linear regression model with an exchangeable correlation matrix, clustered on
individual patient. Thirteen thousand and forty-five observations are reported in 4314 patients.
bAdjusted for other variables.
Fig. 2. Time to virological failure and starting second-line
therapy. Virological failure defined as two consecutive viral
loads above 5000copies/ml, at the time of the second elevated
value. ART, antiretroviral therapy; CI, confidence interval.
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settings, which was not conditioned on viral load
suppression [27]. The negative associations between
CD4 cell count response and older age and male sex have
also previously been described [27]. In total, after 5 years,
41.3% of virologically suppressed patients had a CD4 cell
count below 500 cells/ml compared with 35.8% in a
comparable study in Switzerland [28]. This difference is
most likely the result of the lower baseline CD4 cell
counts of patients in Khayelitsha and highlights how
advanced disease at enrolment results in more time spent
in CD4 cell count strata that carry substantial morbidity
and mortality [29].
It is well established that immunological measures are
poorly predictive of virological failure [30–33]. In spite of
the controversies around the utility of viral load
monitoring in this setting [34,35], there is extensive
pressure for the more widespread availability of viral load
monitoring [36]. The current study is one of the very few
in southern Africa to report on the systematic use of viral
load testing to identify treatment failure. Applied in a
context of rapid scale-up, the South African guidelines
still result in an average delay of many months between
the first evidence of failure and subsequent switching.
This is the result of the time taken to confirm the failure,
the pressures on service providers due to increasing
patient numbers and a reluctance on the part of clinicians
to commit patients to second-line therapy before
adherence issues have been exhaustively addressed.
It is unknown whether the delays in switching therapy in
viraemic patients as described in our study compromise
the effectiveness of subsequent regimens or whether there
would be additional consequences of leaving patients on
their first-line regimen until they fail immunologically.
Two recent African studies [37,38] reported genotypic
resistance data at the time of failure of first-line ART.
As expected, both studies reported widespread resistance
to 3TC and NNRTIs. The Malawian study, in which
viral load monitoring is not available, reported a high
prevalence of thymidine analogue mutations and the
K65R mutation, but the South African study, in which
viral load monitoring is available, reported a much
lower prevalence of these mutations, suggesting that
virological monitoring will better preserve future
treatment options. With increasing numbers of patients
on second-line regimens, however, some of whom are
already failing second line, pressure for a third-line
regimen in resource-limited settings is emerging and
there is more concern from clinicians about switching too
late than too early.
Many of those who have failed virologically and switched
to second-line therapy may have had suboptimal
adherence to their first-line regimens and may be less
adherent than those who have remained on first line.
This, in addition to the higher pill burden and more
complex dosing intervals of the available second-line
regimen, could explain the lower proportion of patients
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Table 5. Multivariate associations with confirmed virological failure.
Virological failurea
AHR 95% CI P
Male sex 1.0 0.8–1.3 0.977
Exposed to PMTCT prior to ART 1.5 1.1–2.0 0.024
Interruptions to ART (per interruption 7 days) 1.6 1.1–2.2 0.012
Age at the start of ART (years) <0.001
16–24 2.0 1.5–2.7
25–49 (ref.) 1.0 –
50 0.9 0.5–1.7
CD4 cell count at the start of ART (cells/ml) 0.009
0–50 1.7 1.2–2.3
50–149 1.4 1.0–1.9
150–249 (ref.) 1.0 –
NNRTI used and TB status at the start of ART 0.002
EFV, no TB (ref.) 1.0 –
EFV, TB 1.3 0.9–1.9
NVP, no TB 1.5 1.1–2.1
NVP, TB 2.5 1.6–4.1




2005 (ref) 1.0 –
2006 1.1 0.8–1.6
2007 0.7 0.2–1.8
AHR, adjusted hazard ratio; ART, antiretroviral therapy; CI, confidence interval; EFV, efavirenz; NNRTI, non-nucleoside reverse transcriptase
inhibitor; NVP, nevirapine; PMTCT, prevention of mother-to-child transmission of HIV; TB, tuberculosis.
aVirological failure defined as two consecutive viral loads of at least 5000 copies/ml; n¼5743, Cox proportional hazards model.
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on second-line therapy whowere virologically suppressed
at each duration of follow-up.
Our finding that LTF is increasing with calendar time is in
line with previous studies from resource-limited settings
[7,39], which we ascribe to rapidly increasing patient
numbers and resultant pressure under which services are
operating, and the declining ability of services to actively
trace patients who miss appointments.
A number of tracing studies [40–42] done in southern
Africa have demonstrated that upwards of a quarter of
patients LTF have died. Our analysis confirms high
mortality in those lost to follow-up (33%). We also found
that the probability of death amongst those LTF is related
to the duration on ART prior to being lost. In order
to understand the long-term effectiveness of ART in
southern Africa, it will be necessary to establish well
supported sentinel cohorts in which ascertainment of
both laboratory and vital status outcomes is prioritized.
Initial positive reports of patient outcomes on ART in
resource-poor settings were interpreted by many as
demonstration projects, made possible by the investment
of additional resources that might not be sustained over
time and when scaled up. Khayelitsha is, however, one of
the most difficult areas in the Western Cape Province in
which to provide health services due to chronic under-
resourcing and an enormous burden of infectious and
noncommunicable disease. The Khayelitsha ART service
has been predominantly staffed and run by government
health services for the past few years and has faced the
same stresses, understaffing and crises faced by the health
services in the area in general. When compared with
routine reporting across the entire province [7], or other
cohort studies in the province [43], Khayelitsha is an
averagely performing subdistrict. It is, thus, likely that
our findings are generalizable to other low and middle-
income countries, but aspects may not apply to
programmes without virological monitoring. In the first
group of patients accessing ART in Botswana followed up
to 5 years [8], cumulative mortality and LTF at 5 years
were 21.8 and 21.0% compared with 15.5 and 23.4% in
our study prior to incorporating death registry data.
Available viral load suppression measures in the Botswana
study were comparable or higher than in our study at each
duration on ART. In a Senegalese cohort, cumulative
mortality at 5 years was 24.6% in a cohort with very low
reported LTF [44].
This study has a number of limitations. First, although the
level of ascertainment of deaths through data-linkage
with national vital statistics may be an improvement on
what is feasible in many parts of southern Africa, the
sensitivity of the record-linkage was only 90%, indicating
residual underascertainment of a small proportion of
deaths. Although we do not consider that there is any
systematic bias introduced by patients who do and do not
have recorded civil identification numbers, the lower
availability of this linkage field for patients starting ART
in the first few years of the cohort could have introduced a
bias. Second, laboratory outcomes are limited to measures
that were available, and patients without tests available or
who were alive but no longer in care might have altered
these findings had it been possible to test them. The lack
of detailed exposure data impeded some of the
explorations such as the association between PMTCT
interventions and subsequent virological failure on
HAART, in which the inclusion of NVP in the PMTCT
intervention was not known. Finally, the absence of
resistance data in patients who were failing virologically
limited our ability to explore the effect of delays in
switching therapy on future treatment options.
At a time when there is uncertainty about continued and
increased direct bilateral and multilateral funding of ART-
specific interventions in countries with limited resources,
these findings provide considerable reassurance that the
benefits of ART in these settings are sustained. Many of
the early innovations to support patient adherence have
endured the rapid scale-up in patient enrolment and are
today standard of care in Khayelitsha and beyond. The
scale-up has itself led to further health service develop-
ments such as task shifting to nurse-managed clinical care.
This study has demonstrated substantial and durable
clinical benefits for those able to access the intervention
throughout a 7-year period.
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Webtable 1. Linkages to the death register in patients lost to follow-up.
2004 2005 2006 2007 Total
Patients starting ART by mid-2007
n 1735 1641 2087 939 6402
Patients with valid recorded civil identification numbers
n (% of total) 689 (39.7%) 966 (58.9%) 1332 (63.8%) 663 (70.6%) 3650 (57.0%)
Patients lost to follow-up
Lost in first year on ART - n (% of total lost) 33 (19.3%) 92 (48.9%) 204 (90.7%) 43 (100%) 372 (59.2%)
Lost between 1 and 5 years on ART - n (% of total lost) 138 (80.7%) 96 (51.1%) 21 (9.3%) 0 (0.0%) 256 (40.8%)
Total lost - n (% of total started) 171 (9.9%) 188 (11.5%) 225 (10.8%) 43 (4.6%) 628 (9.8%)
Patients lost to follow-up with civil ID numbers
Lost in first year on ART - n (% of lost) 4 (12.1%) 48 (52.2%) 97 (47.5%) 28 (65.1%) 177 (47.6%)
Lost between 1 and 5 years on ART - n (% of lost) 51 (37.0%) 55 (57.3%) 9 (42.9%) 0 116 (45.3%)
Total - n (% of lost) 55 (32.2%) 103 (54.8%) 106 (47.1%) 28 (65.1%) 293 (46.7%)
Weights used in the corrected mortality estimates
For patients lost in first year on ART 8.3 1.9 2.1 1.5
For patients lost from 1 to 3 years 2.9 1.7 2.3
For patients lost from 3 to 5 years 1.9
Deaths in patients lost to follow-up with ID numbers
Lost in first year on ART - n (% of lost) 3 (75.0%) 19 (39.6%) 38 (39.2%) 15 (53.6%) 75 (42.4%)
Lost between 1 and 5 years on ART -n (% of lost) 6 (11.8%) 13 (23.6%) 1 (11.1%) 0 21 (18.1%)
Total - n (% of lost) 9 (16.4%) 32 (31.1%) 39 (36.8%) 15 (53.6%) 96 (32.8%)
ART, antiretroviral therapy; ID, identification.
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Introduction: The patterns and reasons for antiretroviral
therapy (ART) drug substitutions are poorly described
in resource-limited settings. 
Methods: Time to and reason for drug substitution
were recorded in treatment-naive adults receiving ART
in two primary care treatment programmes in Cape
Town. The cumulative proportion of patients having
therapy changed because of toxicity was described for
each drug, and associations with these changes were
explored in multivariate models. 
Results: Analysis included 2,679 individuals followed
for a median of 11 months. Median CD4+ T-cell count
at baseline was 85 cells/μl. Mean weight was 59 kg,
mean age was 32 years and 71% were women. All
started non-nucleoside reverse transcriptase inhibitor-
based ART (60% on efavrienz) and 75% started on
stavudine (d4T). After 3 years, 75% remained in care
on-site, of whom 72% remained on their initial
regimen. Substitutions due to toxicity of nevirapine
(8% by 3 years), efavirenz (2%) and zidovudine (8%)
occurred early. Substitutions on d4T occurred in 21%
of patients by 3 years, due to symptomatic hyper-
lactataemia (5%), lipodystrophy (9%) or peripheral
neuropathy (6%), and continued to accumulate over
time. Those at greatest risk of hyperlactataemia or
lipodystrophy were women on ART ≥6 months,
weighing ≥75 kg at baseline. 
Discussion: A high proportion of adult patients are able
to tolerate their initial ART regimen for up to 3 years.
In most instances treatment-limiting toxicities occur
early, but continue to accumulate over time in patients
on d4T. Whilst awaiting other treatment options, the
risks of known toxicities could be minimized through
early identification of patients at the highest risk.
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With the dramatic scaling up of antiretroviral therapy
(ART) in South Africa and other resource-limited
settings, there has been a move towards highly standard-
ized treatment approaches [1,2]. As in many countries,
the South African national ART programme is based
on the World Health Organization (WHO) guidelines,
with provision for two treatment regimens: an initial
non-nucleoside reverse transcriptase enzyme inhibitor
(NNRTI)-based regimen followed by a protease inhibitor
(PI)-based regimen [2]. Only seven antiretrovirals are
routinely available for treatment in South Africa; the
limited treatment options here and in other resource-
poor settings makes the changing of regimens, because
of virological failure, contraindications or drug toxicity,
a particularly important issue in the scale up of
national HIV treatment programmes.
One of the most frequently used nucleoside reverse
transcriptase inhibitors (NRTIs) in the first-line
regimen in South Africa is stavudine (d4T), which is
increasingly recognized as contributing to a number of
Introduction
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toxicities such as peripheral neuropathy, lipodystrophic
body changes and hyperlactataemia. These may signif-
icantly effect the well-being and adherence of individ-
uals on first-line therapy, as well as the ability of
programmes to simplify clinical interventions [3–7].
There are, however, few reliable estimates of the
incidence of toxicities of commonly used antiretrovirals
in resource-poor settings. Existing insights come
primarily from clinical trials and research populations
in Europe and North America, where the thresholds for
modifying therapy are likely to be much lower than in
contexts with more limited choices of antiretrovirals. In
large scale-up settings accurately determining the inci-
dence of toxicities is a major challenge because of
service and information system constraints. In these
settings the reporting of those toxicities that result in a
drug change is an approach that is frequently recom-
mended [8]. The aim of this study was to describe the
contribution of individual drugs to toxicity- or
contraindication-based modification of ART in a large
public sector treatment cohort in South Africa. 
Methods
Data were drawn from ART services in two districts in
Cape Town, Nyanga and Khayelitsha. The estimated
combined population in these districts is 700,000; both
communities are densely populated and predominantly
poor, with unemployment over 40%, and a high
burden of HIV (2005 antenatal HIV seroprevalence
approximately 30%) [9–11]. Tuberculosis case finding
is extremely high in both districts (>1,000/100,000).
ART has been offered since 2001 in Khayelitsha and
2002 in Nyanga. There are three clinics in Khayelitsha
and one in Nyanga providing ART. By August 2006
ART was being provided free of charge to 5,390 people
attending the four antiretroviral clinics in these
districts. Specimens for laboratory testing are processed
on-site or are transported the same day to a single
regional laboratory, and point-of-care lactate testing
(Accutrend™, Roche Diagnostics, Randburg, South
Africa) has been available at the clinics since early
2005. Each site maintains electronic information
systems to capture routine clinical information from
patient records. The University of Cape Town Research
Ethics Committee has provided approval for the data
collection and analysis in both districts.
Treatment regimens and clinical protocols
At all sites, treatment was provided according to the
South African National ART guidelines [2,12]. In the
first 2 years of the Khayelitsha programme
(2001–2003), however, zidovudine (AZT) replaced
d4T in the initial NRTI backbone. Patients were
reviewed at least monthly until their third month on
ART, after which they had a scheduled clinical visit at
least every 3 or 4 months. Care was provided by either
doctors or professional nurses with HIV clinical
training, with all sites having a doctor permanently
available. CD4+ T-cell counts and viral loads were done
at baseline and then 4 or 6 monthly thereafter. Safety
blood tests were provided according to standard proto-
cols – monthly haemoglobin tests in patients on AZT
and monthly alanine transferase (ALT) tests in patients
on nevirapine (NVP) for the first 3 months, at
6 months, and then 6 monthly.
Single drug changes were defined as substitutions.
These included changes due to a drug-related adverse
event or toxicity (for example, AZT-induced anaemia
or NVP hypersensitivity) as well as changes due to
potential drug interactions or contraindications (for
example, avoiding EFV in pregnancy or NVP with
concomitant anti-tuberculosis therapy). Although
previous studies have described that relatively few of
the deaths in these programmes can be ascribed to anti-
retroviral toxicities [13,14], if a patient death was
related to toxicity of a drug which was not discontinued
prior to death, a drug discontinuation due to toxicity
was recorded. Changes of two or more drugs due to
virological failure were described as a switch in
therapy. Rates of virological failure in this cohort have
been described previously [15,16].
Protocols in use by clinicians recommended that
adverse drug reactions were graded using the AIDS
Clinical Trial Group (ACTG) toxicity scale [17], with
indications for toxicity-related substitutions being
grade 3 or 4 toxicities. The working definition of
symptomatic hyperlactataemia applied in this setting
was an uncuffed venous lactate in excess of
2.5 mmol/l in a symptomatic patient with no signs of
acidosis. For this analysis, patients with symptomatic
hyperlactataemia or lactic acidosis were combined
into a single group (SHLA).
Analysis
All patients initiating ART from programme
commencement until August 2005 (Nyanga) or
December 2004 (Khayelitsha) were considered for
analysis, and patients were followed until August
2005 and June 2005, respectively. Those who were
treatment-experienced at presentation and children
<14 years old were excluded. Patient time on each
starting antiretroviral drug was included from treat-
ment commencement until the substitution of that
drug, with patients being right-censored at either their
last visit prior to the cut-off date, or at the date of
discontinuing therapy for other reasons such as death
and loss to follow up. The reasons for drug substitutions
were coded according to the reasons recorded by
clinicians in the clinical records.
A Boulle et al.
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Analysis was carried out using Stata™ (Version 9,
College Station, TX, USA).
Patient demographics were described using medians
and interquartile ranges (IQRs) for continuous variables
and counts and percentages for categorical data. Time
to treatment substitution or discontinuation were
described using Kaplan–Meier analyses. Where >1
causes of failure were analysed together for patients on
stavudine, the cumulative incidence for each cause of
failure was estimated using a competing risks frame-
work [18]. Rates of substitutions and toxicities are
presented per 1,000 patient–years (py). Associations
with substitutions were modelled using Cox proportional
hazards regression, with the covariates retained in each
model being those associated with the outcome in
multivariate analysis, or those thought a priori to be
associated with the outcome. We analysed CD4+ T-cell
counts as a binary variable comparing ≥50 to
<50 cells/μl. WHO stage at baseline was analysed as an
ordinal variable. Age was included as a continuous
variable in all multivariate analyses, with results
presented per 10-year increment.
Results
The analysis included 950 individuals from Nyanga
and 1,729 individuals from Khayelitsha (n=2,679;
Table 1) with a median follow-up time on ART of
11.1 months (IQR: 6.9–18.6) comprising 3,105 py in
total. Most individuals commencing treatment were
women (n=1,896, 71%), with a median age of 32 years
and a median weight of 58.7 kg. The median CD4+
T-cell count at baseline was 85 cells/μl and the median
baseline log10 viral load was 5.5. At programme entry,
almost 90% (n=2,394) of the cohort presented with
WHO clinical stage 3 or 4 disease. The most frequent
starting regimen comprised d4T, lamivudine (3TC) and
efavirenz (EFV) (n=1,179, 44%), followed by d4T,
3TC and NVP (n=825, 31%) (Table 1). At 3 years,
cumulatively 75% (95% confidence interval [CI]:
72–77%) of the cohort were still in the programme in
these districts whilst 5% had been transferred to other
districts, 15% were known to have died, and the
remaining 5% had been lost to follow up. 
Of 151 patients remaining in care and who had been
on treatment for ≥3 years, 108 (72%) remained on
their initial ART regimen in cross-sectional analysis
(Figure 1). Eight percent (n=12) of individuals had had
a single substitution due to toxicity and a further 11%
(n=17) due to a contraindication. An additional 9%
Antiviral Therapy 12:5 755








Age on starting ART, years 32 (28–38)
Baseline CD4+ T-cell count, cells/μl 83 (34–140)
Baseline viral load, log10 copies 5.5 (4.6–5.5)
WHO clinical stage on starting ART
Stage 1 107 (4)
Stage 2 177 (7)
Stage 3 1,356 (51)
Stage 4 1,038 (39)






Follow-up time on ART, months 11.1 (6.9–18.6)
Continuous variables are given as median (interquartile range). Ordinal and
discrete variables are given as n (%). 3TC, lamivudine; ART, antiretroviral
therapy; AZT, zidovudine; d4T, stavudine; EFV, efavirenz; NVP, nevirapine; WHO,
World Health Organization.
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Figure 1. Regimen modifications in patients who remain on
their original ART regimen at 1, 2 and 3 years of therapy
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(n=14) had had >1 drug substitution, including those
who had started second-line therapy. 
The estimated cumulative substitutions due to toxicity
by individual drug are described in Figure 2. There
were no instances of regimen modification solely due
to toxicity ascribed to 3TC. Thereafter, the least
likely drug to be substituted was EFV (25 substitu-
tions, 1.9% at 3 years), with substitutions occurring
early in therapy. A larger proportion of individuals
were substituted off NVP (n=63, 7.6% at 3 years).
Again, the majority of these changes occurred within
the first few months of therapy and were related to
hypersensitivity (including rash and transaminitis). In
multivariate analysis, an initial weight below 60 kg
was associated with a higher risk of substitution for
both NNRTIs (hazard ratio [HR] 2.6 for NVP and
3.1 for EFV; Table 2). Greater age was further associ-
ated with NVP substitutions and higher clinical stage
was associated EFV substitutions.
A similar proportion of individuals required AZT to
be substituted (n=47, 7.8% at 3 years), largely because of
developing anaemia or neutropenia in the first months of
treatment. In multivariate analysis, a baseline CD4+ T-cell
count <50 cells/μl was associated with AZT substitution
(HR: 2.0; Table 2), whilst age and WHO stage were also
found to be associated with this substitution.
A Boulle et al.
© 2007 International Medical Press756
Zidovudine Nevirapine Efavirenz
Association HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Baseline weight <60 kg 2.6 1.5–4.6 0.001 3.1 1.1–9.4 0.039
Age per 10 year increase 1.3 0.9–1.9 0.113 1.4 1.1–1.9 0.008
WHO stage per increment 1.9 1.0–3.4 0.045 2.6 1.1–6.2 0.025
Nadir CD4+ T-cell 2.0 1.1–3.7 0.028
count <50 cells/μl
CI, confidence interval; HR, hazard ratio; WHO, World Health Organization.
Table 2. Multivariate models of associations with toxicity-related regimen modifications in patients on zidovudine, nevirapine
or efavirenz






















































Figure 2. Estimates of cumulative regimen substitutions due to toxicity by individual drug over a 3-year period
The graph shows Kaplan–Meier failure estimates by drug. There were no lamivudine substitutions related to toxicity. AZT, zidovudine; CI, confidence interval; d4T,
stavudine; EFV, efavirenz; NVP, nevirapine.
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The largest number of drug substitutions due to toxi-
city was in patients on d4T. By 3 years, cumulatively
20.8% of those who originally commenced therapy
with d4T had it substituted because of toxicity
(125 substitutions; Figure 2), usually with AZT. The
timing of d4T substitution depended on the toxicity
involved (Figure 3). SHLA were largely confined to a
period between 6 and 18 months on therapy and
cumulatively 4.7% had changed from d4T for this
reason after 3 years on ART. Lipodystrophic body
changes resulted in 9.0% of patients stopping d4T by
3 years on ART. These changes were also infrequent
until after 6 months on ART. By contrast, substitutions
due to peripheral neuropathy were seen from soon
after commencement on ART, with 6.2% having had
their regimen modified for this reason by 2 years.
The rates for substitutions of d4T were explored
for individual toxicities for all patients as well as in
subgroups characterized by gender, duration on ART
and baseline weight (Table 3). The rate of substitution
due to SHLA in women who had been on therapy for
>6 months was 7× greater than in men with equiva-
lent exposure (49 vs 7 substitutions/1000 py; rate
ratio: 7.5; 95% CI: 1.8–31.2). The rate in women
was markedly influenced by weight at baseline; those
who weighed ≥75 kg at treatment commencement
had a substantially higher rate of substitution beyond
6 months on ART of 184/1000 py than women
whose initial weight was <75 kg (21/1000 py; rate
ratio 8.8; 95% CI: 4.3–17.7). Although less marked,
a similar pattern was noted in the rate of substitution
due to lipodystrophy: those at the highest risk were
women who weighed more than 75 kg at baseline
and who had been on therapy for >6 months. The
rate of substitution due to peripheral neuropathy
increased slightly after 6 months on therapy, but did
not differ markedly by weight or gender.
In multivariate models of associations with substitu-
tions to d4T by indication (Table 4), female gender
was strongly associated with substitutions due to
both lipodystrophy and SHLA (HRs 10.0 and 10.7
respectively). However initial weight was more
strongly associated with substitution due to SHLA
than that due to lipodystrophy. Gaining ≥5 kg of
weight in the first 3 months on ART was further found
to be associated with a 3× increase in the hazard of
subsequent substitution of d4T due to SHLA. Age and
WHO stage were weakly associated with an increased
risk of peripheral neuropathy. In addition, patients in
the Nyanga district were more likely to have d4T
substituted because of lipodystrophy and less likely to
have substitution due to SHLA, whereas there were no
differences across clinical sites involving other reasons
for d4T substitution.
Antiviral Therapy 12:5 757
Antiretroviral substitutions due to contraindications or toxicity

















































Figure 3. Substitutions of stavudine due to toxicity by indication over a 3-year period
The graph shows the estimated cumulative incidence of each toxicity. PN, peripheral neuropathy; SHLA, symptomatic hyperlactataemia or lactic acidosis.
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This analysis presents novel data on the occurrence of
and reasons for antiretroviral drug substitution in two
of the longest running public sector ART programmes
in Southern Africa. Although overall a high proportion
of patients remained on their initial therapy for up to
3 years, there were substantial differences in the
tolerability of commonly used first-line antiretroviral
drugs, and clearly identifiable risk factors for some of
the major toxicities.
The study has a number of strengths. The cohort is
representative of many of the settings in the region
where treatment access is being rapidly expanded. As
these were some of the first cohorts to routinely offer
ART in the region, the duration of follow up together
with the variability in first-line regimens has allowed
an exploration of toxicity for up to 3 years for most
of the commonly used drugs. Furthermore, the focus
on treatment-limiting toxicities enabled near-complete
ascertainment of outcomes. A potential weakness of
the study, however, is that although all clinicians were
working to common protocols, differences in clinical
practice between sites or between clinicians could
have resulted in different thresholds for substituting
individual drugs.
More than 70% of patients remained on the initial
NNRTI-based antiretroviral treatment regimen after
3 years. This compares favourably with the two studies
from the UK in which the reported median duration of
the first-line ART regimen was 17 months, and 38% of
patients had experienced all three classes of antiretro-
virals within 2–5 years of commencing therapy [19,20].
Previous estimates of time to treatment substitutions
from Europe and North America included a quarter of
patients having changed the initial regimen by 1 year
[21], a median of 8 months to regimen modification
[22], and a quarter having modified their regimen by
6 months on therapy [23]. With the highly regimented
approach to therapy promoted in guidelines for
resource-limited settings [1], and the limited number of
treatment options available, these data suggest that
decisions to substitute therapy are taken with caution
in these settings. 
Despite this caution, a substantial number of
patients, up to 28%, did have a drug substitution at
least once in the first 3 years of ART. The experience of
this cohort suggests that contraindications are more
common than treatment-limiting toxicities, most
commonly due to a new diagnosis with tuberculosis in
patients on NVP, or either pregnancy or a desire to fall
pregnant in patients on EFV. This highlights a major
A Boulle et al.
© 2007 International Medical Press758
Toxicity by subgroup at risk Rate, per 1,000 py Events, n (95% CI) RR (95% CI)
Symtomatic hyperlactataemia or lactic acidosis
All durations on ART 19 36 (14–26) –
All patients <6 months on ART – 0 –
All patients ≥6 months on ART 36 36 (26–50) –
Men ≥6 months on ART 7 2 (2–26) –
Women ≥6 months on ART 49 34 (35–69) 7.5 (1.8–31.2)
Women <75 kg, ≥6 months on ART 21 12 (12–37) –
Women ≥75 kg, ≥6 months on ART 184 22 (121–279) 8.8 (4.3–17.7)
Lipodystrophy
All durations on ART 14 26 (9–20) –
All patients <6 months on ART – 0 –
All patients ≥6 months on ART 26 26 (18–38) –
Men ≥6 months on ART 3 1 (0–23) –
Women ≥6 months on ART 36 25 (24–53) 11.0 (1.5–81.3)
Women <75 kg, ≥6 months on ART 24 14 (14–41) –
Women ≥75 kg, ≥6 months on ART 92 11 (51–170) 3.8 (1.7–8.3)
Peripheral neuropathy
All durations on ART 28 53 (21–36) –
All patients <6 months on ART 17 16 (11–29) –
All patients, ≥6 months on ART 37 37 (27–51) 2.1 (1.2–3.8)
ART, antiretroviral therapy; CI, confidence interval; RR, rate ratio compared with previous line.
Table 3. Rates of treatment substitution due to specific toxicities for adults on stavudine categorized by gender, weight and
duration on therapy
This PDF is for personal use only. To obtain commercial reprints,
please contact the editorial office on +44 20 7398 0700
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challenge as a result of tuberculosis in these settings,
compounded in countries where NVP-containing,
fixed-dose combinations are the mainstay of first-line
therapy. The difficulties in ensuring family planning
and managing fertility intentions in patients on EFV
are also illustrated by these findings.
Toxicities of NNRTIs occurred in the first few
months on ART. Although there are existing guidelines
for dose reduction of NNRTIs in very small adults, the
higher risk of hypersensitivity reactions in patients
below 60 kg for both NVP and EFV warrants further
exploration, confirming previous findings in the case
of NVP [24].
AZT substitution also occurred within the first few
months of therapy, with no additional substitutions
due to toxicity beyond a year on ART. Patients with
more advanced disease, as indicated by either the base-
line CD4+ T-cell count or clinical stage, were more
likely to develop treatment-limiting haematological
toxicity. It is tempting to infer that AZT would be
better tolerated if started after individuals have recovered
immune function on other first-line drugs. However,
there is a concern that after the first few months on
ART, monitoring is less intensive in scale-up settings,
and even if there were fewer cases of severe anaemia,
there might be a higher probability of this being missed
in patients many months into therapy. 
Almost all substitutions due to toxicity after longer
durations on ART were observed in patients on d4T.
We found that 21% of individuals commencing stavu-
dine had stopped this drug before 3 years because of
toxicity. The replacement drug was usually AZT,
which in turn could be recycled in the second-line
regimen should this be required. The toxicities and
intolerances experienced were those expected from
d4T use: peripheral neuropathy, hyperlactataemia and
lipodystrophic body changes [3–6]. With the first-line
regimens in use in this cohort, clinicians cited these
toxicities as a reason for changing therapy only in
patients changed from d4T. Previous studies from various
settings have also found that severe hyperlactataemia
was almost always associated with exposure to d4T
[7,25], and have also found risk factors similar to
those described here. The markedly increased rate of
substitution due to hyperlactataemia for women ≥75
kg on ART for ≥6 months has resulted in changes in
local policy to select AZT instead of d4T for these
patients. Evidence that the dose escalation of d4T in
patients ≥60 kg is not required for virological effi-
cacy could result in the phasing out of the 40 mg
formulation and consequently lower rates of toxicity
[26]. The higher rate of substitution of d4T due to
lipodystrophy in the Nyanga district, and the corre-
spondingly lower rate of substitution due to SHLA,
suggests that early substitution for any metabolic
toxicities could prevent subsequent, more severe
toxicities developing [27].
The different reasons for stopping stavudine
because of toxicity could be related to the same
underlying disease process. The associations with each
toxicity-mediated substitution could therefore potentially
be biased by censored observations (related to stopping
stavudine for other toxicities). We explored estimating
the associations jointly across all three toxicity-related
reasons for stopping stavudine [28] and the results
from this exercise were consistent with those
presented here.
In summary, we found that a high proportion of
treatment-naive adult patients are able to tolerate their
initial ART regimen for up to 3 years in this large South
African public-sector cohort. However, treatment-
limiting toxicities are present and continue to accumulate
with time in the case of d4T. Because of limited ART
options, this and other substitutions might compromise
future therapy. Access to alternative NRTIs would
provide additional options to clinicians and patients,
Antiviral Therapy 12:5 759
Antiretroviral substitutions due to contraindications or toxicity
Lipodystrophy Hyperlactataemia/lactic acidosis Peripheral neuropathy
Association HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Female gender 10.0 1.3–74.5 0.025 10.7 1.5–79.0 0.02 – – –
Weight
<60 kg 1.0 – – 1.0 – – – – –
60–74.9 kg 0.6 0.2–1.9 0.017 5.7 1.5–21.0 <0.001 – – –
≥75 kg 4.1 1.6–10.5 – 36.1 10.6–122.8 – – – –
Nyanga district 3.5 0.9–12.8 0.062 0.4 0.2–0.9 0.026 – – –
Weight gain first 3 months ≥5 kg – – – 3.1 1.5–6.2 0.002 – – –
Age per 10-year increase – – – – – – 1.4 1.0–1.9 0.034
WHO stage per increment – – – – – – 1.6 1.0–2.5 0.040
CI, confidence interval; HR, hazard ratio; WHO, World Health Organization.
Table 4. Multivariate models of associations with toxicity-related regimen modifications in patients on stavudine, by specific toxicity
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but regrettably these agents (for example tenofovir and
abacavir) are currently either too costly or are not
widely available in resource-limited settings. Until
alternative agents are available, clinicians should be
encouraged to be aware of d4T-related toxicity and
substitute AZT earlier rather than later. Avoiding d4T
in women ≥75 kg and using lower dose d4T might also
contribute to reductions in severe toxicity. 
Acknowledgements
In Khayelitsha, clinical services and research activities
were funded by Médecins Sans Frontières and the
Provincial Government of the Western Cape. In
Nyanga services were funded by the non-governmental
organization Crusaid, and the Provincial Government
of the Western Cape. Services in both districts receive
funding from the Global Fund for AIDS, Tuberculosis
and Malaria (GFATM). 
All sites participate in the International
Epidemiological Databases to Evaluate AIDS in
Southern Africa (IeDEASA) collaboration which is
funded by the National Institutes for Health (NIH;
U01 AI069924-01), which provided additional support
for this analysis.
Catherine Orrell and Robin Wood receive partial
support from the NIH through a CIPRA-SA grant.
Catherine Orrell receives partial support from the
President’s Emergency Plan for AIDS Relief (PEPfAR).
Reference 
1. World Health Organization (2006) Antiretroviral therapy
for HIV infection in adults and adolescents in resource-
limited settings: towards universal access. Geneva: World
Health Organization.
2. National Department of Health (2004) Antiretroviral
Treatment Guidelines, 1st edn. Pretoria: National
Department of Health.
3. Nolan D, Mallal S. Thymidine analogue-sparing highly active
antiretroviral therapy (HAART). J HIV Ther 2003; 8:2–6.
4. Lonergan JT, McComsey GA, Fisher RL, et al. Lack of
recurrence of hyperlactatemia in HIV-infected patients
switched from stavudine to abacavir or zidovudine. 
J Acquir Immune Defic Syndr 2004; 36:935–942.
5. Dragovic G, Jevtovic D. Nucleoside reverse transcriptase
inhibitor usage and the incidence of peripheral neuropathy
in HIV/AIDS patients. Antivir Chem Chemother 2003;
14:281–284.
6. McComsey GA, Paulsen DM, Lonergan JT, et al.
Improvements in lipoatrophy, mitochondrial DNA levels
and fat apoptosis after replacing stavudine with abacavir or
zidovudine. AIDS 2005; 19:15–23.
7. Geddes R, Knight S, Moosa MY, Reddi A, Uebel K,
Sunpath H. A high incidence of nucleoside reverse tran-
scriptase inhibitor (NRTI)-induced lactic acidosis in
HIV-infected patients in a South African context. S Afr
Med J 2006; 96:722–724.
8. Carr A. Improvement of the study, analysis, and reporting
of adverse events associated with antiretroviral therapy.
Lancet 2002; 360:81–85.
9. Bekker LG, Myer L, Orrell C, Lawn S, Wood R. Rapid
scale-up of a community-based HIV treatment service:
programme performance over 3 consecutive years in
Guguletu, South Africa. S Afr Med J 2006; 96:315–320.
10. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after
two years of providing antiretroviral treatment in
Khayelitsha, South Africa. AIDS 2004; 18:887–895.
11. National Department of Health (2006) Antenatal HIV and
Syphilis Prevalence Survey 2005. Pretoria: National
Department of Health.
12. Provincial Government of the Western Cape. Antiretroviral
Treatment Protocol. Version 2; 2004. Cape Town:
Provincial Government of the Western Cape.
13. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early
mortality among adults accessing a community-based anti-
retroviral service in South Africa: implications for
programme design. AIDS 2005; 19:2141–2148.
14. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood
R. Determinants of mortality and nondeath losses from an
antiretroviral treatment service in South Africa: implications
for program evaluation. Clin Infect Dis 2006; 43:770–776.
15. Orrell C, Harling G, Lawn S, et al. Conservation of first-
line antiretroviral treatment regimen where therapeutic
options are limited. Antivir Ther 2007; 12:83–88.
16. Coetzee D, Boulle A, Hildebrand K, Asselman V, Van CG,
Goemaere E. Promoting adherence to antiretroviral therapy:
the experience from a primary care setting in Khayelitsha,
South Africa. AIDS 2004; 18 Suppl 3:S27–S31.
17. Centers for Disease Control and Prevention. 1993 revised
classification system for HIV infection and expanded
surveillance are for AIDS among adolescents and adults.
MMWR Recomm Rep 1992; 41(RR-17):1–19.
18. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler
D, Auerbach AD. A note on competing risks in survival
data analysis. Br J Cancer 2004; 91:1229–1235.
19. Mandalia S, Parmar D, Fisher M, et al. Naively changing
HAART. HIV Med 2002; 3:254–262.
20. Sabin CA, Hill T, Lampe F, et al. Treatment exhaustion of
highly active antiretroviral therapy (HAART) among
individuals infected with HIV in the United Kingdom:
multicentre cohort study. Br Med J 2005; 330:695.
21. d’Arminio MA, Lepri AC, Rezza G, et al. Insights into the
reasons for discontinuation of the first highly active anti-
retroviral therapy (HAART) regimen in a cohort of
antiretroviral naive patients. I.CO.N.A. Study Group.
Italian Cohort of Antiretroviral-Naive Patients. AIDS
2000; 14:499–507.
22. Kirstein LM, Greenblatt RM, Anastos K, et al. Prevalence
and correlates of highly active antiretroviral therapy
switching in the Women’s Interagency HIV Study. J Acquir
Immune Defic Syndr 2002; 29:495–503.
23. Mocroft A, Youle M, Moore A, et al. Reasons for
modification and discontinuation of antiretrovirals: results
from a single treatment centre. AIDS 2001; 15:185–194.
24. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe
hepatotoxicity associated with nevirapine use in HIV-
infected subjects. J Infect Dis 2005; 191:825–829.
25. Calza L, Manfredi R, Chiodo F. Hyperlactataemia and
lactic acidosis in HIV-infected patients receiving antiretroviral
therapy. Clin Nutr 2005; 24:5–15.
26. Meta–analysis of efficacy and safety for clinical studies of
d4T 40mg versus 30mg BID in 1008 patients. XVI
International AIDS Conference. 13–18 August 2006,
Toronto, Canada. Abstract ThPE0120.
27. Cossarizza A, Moyle G. Antiretroviral nucleoside and
nucleotide analogues and mitochondria. AIDS 2004;
18:137–151.
28. Lunn M, McNeil D. Applying Cox regression to competing
risks. Biometrics 1995; 51:524–532.
A Boulle et al.
© 2007 International Medical Press760
Accepted for publication 28 March 2007
 
Page 64












Outcomes of Nevirapine- and Efavirenz-Based Antiretroviral 




This analysis explores the impact of tuberculosis co-infection on ART outcomes, as 
tuberculosis is one of the most important contextual co-morbidities in the region. 
The analysis is directed towards an important area of clinical uncertainty, which is the 
choice of NNRTI in patients on ART while also on treatment for tuberculosis. 
 
Contribution to the thesis and novelty 
The analysis addresses the third objective, which is to describe the impact of 
concomitant tuberculosis on ART treatment outcomes. Although the paper and data 
are oriented to address the question of the choice of NNRTI, all the outcomes 
described in the first paper in this thesis are also described in this paper in patients 
with and without concomitant tuberculosis.  The analysis was able to demonstrate 
that co-infection with tuberculosis does not compromise ART outcomes, except for 
virological response in co-infected patients initiating NVP-based ART.  At the time 
of publication it was the largest study to compare outcomes in these groups of 
patients, and the first to suggest inferior outcomes for co-infected patients initiating 
NVP-based ART compared to patients who were not on tuberculosis treatment. 
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ANTIRETROVIRAL THERAPY(ART) programs are rapidlybeing scaled up in resource-limited countries, where tu-
berculosis is the most common oppor-
tunistic infection.1 Combination ART
is frequently initiated when patients are
being treated for tuberculosis.2,3 Al-
though ART reduces tuberculosis in-
cidence, tuberculosis continues to oc-
cur at considerably higher rates than in
individuals who are not infected with
human immunodeficiency virus
(HIV).1-4 Coadministration of ART and
antitubercular therapy may be compli-
cated by shared toxicity, notably hepa-
totoxicity,5 or by adverse drug interac-
tions. Rifampicin is a potent inducer
of cytochrome P450 enzymes, which
metabolize many drugs including
nonnucleoside reverse transcriptase in-
hibitor (NNRTI) antiretroviral agents.
The NNRTIs are recommended as
components of initial combination ART
regimens in the public health ap-
proach advocated by the World Health
Organization (WHO).6
Of the 2 available NNRTIs, efavirenz
ispreferredforcoadministrationwithrif-
ampicin6,7 because the reduction in the
concentration of efavirenz is more mod-
est, efavirenz has a lower risk of hepato-
Author Affiliations: School of Public Health and Fam-
ily Medicine (Drs Boulle and Coetzee and Ms Hilder-
brand), Division of Clinical Pharmacology, Depart-
ment of Medicine (Drs Cohen and Maartens),
University of Cape Town, Médecins Sans Frontières
(Drs Van Cutsem and Goemaere and Ms Hilder-
brand), and Site B Community Health Centre,
Department of Health, Provincial Government of the
Western Cape (Drs Mathee and Abrahams), Cape
Town, South Africa.
Corresponding Author: Andrew Boulle, MBChB, MSc,
School of Public Health and Family Medicine, University
of Cape Town, Cape Town, South Africa (andrew
.boulle@uct.ac.za).
Context Rifampicin-based antitubercular therapy reduces the plasma concentra-
tions of nevirapine and efavirenz. The virological consequences of these interactions
are not well described.
Objective To assess the effectiveness and tolerability of concomitant efavirenz- or nevira-
pine-based combination antiretroviral therapy and rifampicin-based antitubercular therapy.
Design, Setting, and Participants Cohort analysis of prospectively collected rou-
tine clinical data in a community–based South African antiretroviral treatment pro-
gram. Antiretroviral treatment-naive adults enrolled between May 2001 and June 2006
were included in the analysis, and were followed up until the end of 2006.
Interventions Patients starting antiretroviral therapy with or without concurrent an-
titubercular therapy received either efavirenz or nevirapine at standard doses. Pa-
tients developing tuberculosis while taking antiretroviral therapy that included nevira-
pine were either changed to efavirenz or continued taking nevirapine.
Main Outcome Measures Viral load of 400 copies/mL or more after 6, 12, and
18 months of antiretroviral therapy; time to the first viral load of 400 copies/mL or
more; time to confirmed virological failure (2 consecutive values 5000 copies/mL);
time to death; and time to treatment-limiting toxicity were assessed.
Results The analysis included 2035 individuals who started antiretroviral therapy with
efavirenz (1074 with concurrent tuberculosis) and 1935 with nevirapine (209 with con-
current tuberculosis). There were no differences in time to death or substitution of either
antiretroviral drug for toxicity with and without concurrent tuberculosis. Patients starting
nevirapine with concurrent tuberculosis were at a higher risk of elevated viral load most
notably at 6 months (16.3%; 95% confidence interval [CI], 10.6%-23.5%) than those
without tuberculosis (8.3%; 95% CI, 6.7%-10.0%; adjusted odds ratio [OR], 2.1; 95%
CI,1.2-3.4; and in thecombinedestimate, adjustedOR,1.7;95%CI,1.2-2.6). In the time-
to-event analysis of confirmed virological failure (2 consecutive values of 5000 copies/
mL), patients starting nevirapine with concurrent tuberculosis developed virological fail-
ure sooner (adjusted hazard ratio [HR] 2.2; 95% CI, 1.3-3.7). There were no differences
betweenpatients startingefavirenzwithandwithoutconcurrent tuberculosis (adjustedOR,
1.1; 95% CI, 0.8-1.5 [combined estimate] and adjusted HR, 1.1; 95% CI, 0.6-2.0, respec-
tively). There was no difference in time to virological rebound in patients free of tubercu-
losis and those developing tuberculosis during follow-up while taking nevirapine (adjusted
HR, 1.0; 95% CI, 0.5-2.0) or efavirenz (adjusted HR, 0.8; 95% CI, 0.4-1.7).
Conclusion In this cohort study, virological outcomes were inferior when nevirapine-
based antiretroviral therapy was commenced while taking antitubercular treatment (vs
without concurrent tuberculosis) but comparable when starting efavirenz-based an-
tiretroviral therapy (vs without concurrent tuberculosis) or when tuberculosis devel-
oped while taking established nevirapine- or efavirenz-based therapies.
JAMA. 2008;300(5):530-539 www.jama.com
530 JAMA, August 6, 2008—Vol 300, No. 5 (Reprinted) ©2008 American Medical Association. All rights reserved.
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toxicity, and there are several studies
showing good ART outcomes with efa-
virenz.8,9 Some experts recommend in-
creasingthedoseofefavirenzwhencoad-
ministeredwithrifampicin,6butevidence,




weighing more than 60 kg).7





en of childbearing potential because it is
notaknownteratogen.Inmanycountries,
it is the only available NNRTI. Pharma-
cokineticstudiesshowamoresignificant
reduction in plasma nevirapine concen-
trations (20%-55% reduction in serum
concentrations or the area under the
curve) compared with efavirenz when
coadministered at standard doses with
rifampicin.9,11-16 Nevirapine has a higher
risk of hepatotoxicity than efavirenz, al-
thoughonlyasmallproportionofpatients
develop clinical hepatitis.17-19 There are
3 small published studies (32 patients
fromSpain20and70patients21and111pa-
tients from Thailand22) that suggest that




to ethnic differences in drug effects and
the low body weight of the patients, and
theSpanishstudywasretrospectivewith-
out a comparison group.
Thus a need for more studies exists,
particularly from Africa where approxi-
mately 85% of HIV-associated cases of
tuberculosis occur.4 Our primary objec-
tive was therefore to assess the virologi-
cal outcomes of concomitant efavirenz-
or nevirapine-based combination ART
and rifampicin-based antitubercular
therapy in a cohort of South African pa-
tients from a public sector ART pro-
gram established in 2001.23
METHODS
Setting
This study was conducted at 3 commu-
nity health centers in the Cape Town
township of Khayelitsha, where ART has
been available since May 2001, with the
number of patients starting ART increas-
ing dramatically in recent years. ART-
naive individuals enrolled between May
2001 and June 2006 were included in the
analysis and were followed up until the
end of 2006. The community of 400 000
inhabitants has an extremely high bur-
den of both HIV and tuberculosis, with
antenatal HIV seroprevalence of more
than 30%,23,24 and tuberculosis case-
finding exceeding 1500 per 100 000 an-
nually.2 This government program has
been supported by Médecins Sans Fron-
tières since inception.
The cohort received approval in 2005
from the University of Cape Town eth-
ics committee for analyses (including
those with a view to scientific publica-
tion) based on anonymized routine
clinical data without requiring in-
formed consent. All data in this analy-
sis were anonymized and had been col-
lected as part of the routine standard
of care intervention.
Antiretroviral Therapy Program
Patients were referred to the dedicated
HIV services within these community
health centers from local clinics and hos-
pitals, as well as from the tuberculosis
services and the prevention of mother-
to-child transmission program. Once re-
ferred, patients accessed treatment based
on clinical eligibility, treatment readi-
ness, and clinical severity. Race is not
routinely measured as part of clinical or
administrative data, but the study site is
located in a township in which resi-
dents are of black African or mixed an-
cestry, which describes the patients rep-
resented in analyses herein. Women who
had been exposed through a regimen in-
tended to prevent mother-to-child trans-
mission to short-course zidovudine or
peripartum nevirapine25 were offered the
same first-line ART as other women with
and without concurrent tuberculosis.
Antiretroviral drugs were provided
weekly or fortnightly for the first 2
months of ART, then monthly until the
first suppressed viral load, and thereaf-
tereithermonthlyorbimonthly.Patients
were seen by a nurse or physician at each
follow-up visit and either received the
drugs during the consultation or from a
dedicated dispensing room immedi-
atelyafter theconsultation.Patientswere
all provided with weekly pillboxes.
There is a structured adherence pro-
motion program at the antiretroviral clin-
ics, which has previously been de-
scribed.26 Adherence is assessed during
consultations by pill counts and self-
report, especially shortly after initiation
of ART and if patients default or expe-
rience virological failure. Quantitatively,
adherence is indirectly reflected by vi-
ral load outcomes and retention in care.
The first-line ART regimen has al-
ways consisted of an NNRTI (either efa-
virenz or nevirapine) together with 2
nucleoside reverse transcriptase inhibi-
tors. Guidelines in use strongly recom-
mended prescribing efavirenz with rif-
ampicin-based antitubercular therapy
until 2004 when provincial guidelines
changed to allow clinicians to select
either nevirapine or efavirenz.27 There-
after, clinical practice in the choice of
NNRTI with antitubercular therapy var-
ied, with some clinicians continuing to
prescribe efavirenz while others pre-
scribed nevirapine.
Standard doses of both efavirenz (600
mg daily) and nevirapine (lead-in dose
of 200 mg daily for 2 weeks followed by
200 mg every 12 hours) were used with
concurrent tuberculosis treatment in
keeping with provincial, national, and in-
ternational guidelines.6,27,28 The clinical
protocols provide for monitoring of vi-
ral load and CD4 cell count every 6
months. Baseline viral loads are no longer
universally drawn in treatment-naive
adults. Patients are deemed eligible for
ART when their CD4 cell count ap-
proaches or falls below 200 cells/μL or
when they have a WHO clinical stage IV
illness other than extrapulmonary tu-
berculosis. The local definition of viro-
logical failure is 2 consecutive viral load
measurements of 5000 copies/mL or
higher. Viral load tests were performed
by the National Health Laboratory Ser-
vice, initially using the NucliSens HIV-1
QT assay and later the NucliSens EasyQ
HIV-1 assay (bioMérieux, Boxtel, the
Netherlands).
ANTIRETROVIRAL AND ANTITUBERCULAR THERAPY
©2008 American Medical Association. All rights reserved. (Reprinted) JAMA, August 6, 2008—Vol 300, No. 5 531
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Tuberculosis medication was pro-
vided daily (5 days a week) at 8 dedi-
cated tuberculosis clinics in the com-
munity and was directly observed
either by clinic staff or by trained
community-based tuberculosis treat-
ment supporters. Fixed-dose combi-
nations are used to promote adher-
ence (for new tuberculosis cases,
these comprise rifampicin, pyrazin-
amide, isoniazid, and ethambutol for
2 months, followed by rifampicin and
isoniazid for 4 months). Tuberculosis
was diagnosed according to standard
guidelines, with either positive
microscopy for acid-fast bacilli, a
positive culture of Mycobacterium
tuberculosis, or after the application of
an algorithm for identifying smear-
negative tuberculosis.29
Data Management and Analysis
Routine clinical data have been prospec-
tively entered into an electronic patient
information system, which is regularly
validated for accuracy and complete-
Figure 1. Inclusion of Patients in the Analysis
1975 Started nevirapine-based ART 2142 Started efavirenz-based ART
4117 Patients enrolled
583 Completed 18-mo follow-up
520 Had viral load test
96 Completed 18-mo follow-up
80 Had viral load test
253 Completed 18-mo follow-up
230 Had viral load test
238 Completed 18-mo follow-up
218 Had viral load test
852 Completed 12-mo follow-up
784 Had viral load test
120 Completed 12-mo follow-up
115 Had viral load test
471 Completed 12-mo follow-up
434 Had viral load test
475 Completed 12-mo follow-up
426 Had viral load test
1240 Completed 6-mo follow-up
1126 Had viral load test
153 Completed 6-mo follow-up
141 Had viral load test
682 Completed 6-mo follow-up
609 Had viral load test
812 Completed 6-mo follow-up











5 Lost to follow-up
42 Stopped or changed
drug






5 New TB episodes
0 Lost to follow-up







0 Lost to follow-up
22 Stopped or changed
drug






1 Lost to follow-up
38 Stopped or changed
drug






1 Lost to follow-up
64 Stopped or changed
drug






2 Lost to follow-up
7 Stopped or changed
drug






6 Lost to follow-up
28 Stopped or changed
drug






2 Lost to follow-up
36 Stopped or changed
drug






23 Lost to follow-up
123 Stopped or changed
drug






2 Lost to follow-up
35 Stopped or changed
drug






14 Lost to follow-up
59 Stopped or changed
drug






21 Lost to follow-up
55 Stopped or changed
drug
20 New TB episodes
87 Insufficient follow-up
dataa
ART indicates antiretroviral therapy; TB, tuberculosis.
aAdditional censoring at each duration of follow-up was due to the patients not being in care for long enough at the close of the study.
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ness. In this analysis, all treatment-
naive individuals 14 years or older, with
a CD4 cell count lower than 250 cells/
μL, who started receiving NNRTI-based
ART by June 30, 2006, were included.
Patients were excluded if they had con-
current tuberculosis at the time that they
started ART, but subsequently discon-
tinued tuberculosis therapy within 14
days of starting ART. The remaining pa-
tients were classified into 4 groups based
on whether ART initiation overlapped
with concurrent treatment for tubercu-
losis and based on which NNRTI was
part of their starting ART regimen
(FIGURE 1). Patients were followed up
until the earliest of the following pos-
sibilities: loss to the program (death, lost
to follow-up, transferred out); inter-
ruption of ART therapy for any rea-
son; substitution of the initial NNRTI
due to toxicity or contraindications (eg,
efavirenz changed to nevirapine in preg-
nancy); starting tuberculosis treat-
ment due to a subsequent diagnosis; or
the last visit prior to December 31,
2006. Patients were classified as lost to
follow-up after 6 months without a visit
to the service. Viral loads were classi-
fied as 6-, 12-, or 18-month values based
on the duration closest to the actual
dates of the test, provided the test was
performed within 3 months of the des-
ignated duration.
The analysis was conducted between
October 2007 and February 2008. Base-
line characteristics were described as me-
dians with interquartile ranges for con-
tinuous variables and as proportions with















Age, median (IQR), y 32 (28-37) 32 (28-38) .47 31 (27-37) 34 (29-40) .001
CD4 cell count, median (IQR), cells/μL 80 (42-137) 61 (27-117) .002 116 (58-167) 93 (37-155) .001
Viral load, median (IQR), log10 copies/mL 5.3 (4.6-5.7) 5.3 (4.8-5.7) .28 5.0 (4.4-5.5) 5.1 (4.6-5.5) .04
Weight, median (IQR), kg 56 (51-65) 56 (49-63) .45 60 (53-69) 59 (52-68) .009
ALT, median (IQR), UL 24 (18-33.5) 27 (19-40) .07 23 (18-33) 32 (21-53) .001
Duration of TB treatment, median (IQR), d 87 (60-135) 73 (44-115) .001
Women, % (95% CI) 73.7 (67.2-79.5) 62.1 (59.1-65.0) .001 80.0 (78.0-81.9) 57.1 (53.9-60.3) .001
AIDS diagnosis, % (95% CI) 55.0 (48.0-61.9) 58.1 (55.1-61.1) .002 27.3 (25.2-29.5) 37.9 (34.8-41.0) .001
Zidovudine in starting regimen, % (95% CI) 4.3 (1.5-7.1) 14.4 (12.3-16.5) .001 12.4 (10.8-14.0) 31.3 (28.4-34.3) .001
Extrapulmonary TB, % (95% CI) 37.3 (30.7-44.3) 37.2 (34.3-40.2) .98
Abbreviation: ALT, alanine aminotransferase; CI, confidence interval; IQR, interquartile range; TB, tuberculosis.
aThe number of patients with ALT values was 128; weight, 203; and viral load, 181.
bThe number of patients with ALT values was 688; weight, 1054; and viral load, 806.
cRank-sum test for continuous variables, and 2 test for binary variables.
dThe number of patients with ALT values was 1107; weight, 1668; and viral load, 1314.
eThe number of patients with ALT values was 489; weight, 943; and viral load, 757.
Figure 2. Failure to Suppress Viral Load in Patients With Concurrent Tuberculosis at the Start of Antiretroviral Therapy vs Those Without
Concurrent Tuberculosis
2.01.00.5
Adjusted Odds Ratio (95% CI)
Viral Load ≥400 Copies/mL 




































CI indicates confidence interval; TB, tuberculosis.
aAdjusted for age, sex, and baseline CD4 cell count. The adjusted odds ratios and 95% CIs were rounded to 1 decimal.
bCombined odds ratios were calculated with generalized estimating equation and an exchangeable correlation matrix.
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exact binomial confidence intervals (CIs)
for categorical variables, compared be-
tween groups, respectively, through rank
sum and 2 statistics.
The proportions of patients with vi-
ral loads of 400 copies/mL or more were
calculated at each duration in each of
the 4 groups (Figure 1). The odds of a
value at or higher than this threshold
in patients who were receiving concur-
rent tuberculosis treatment when start-
ing ART were compared with those who
were not, in separate multivariate lo-
gistic regression models at each dura-
tion for each NNRTI. Pooled odds ra-
tios (ORs) across all durations were
additionally determined for each
NNRTI and for all 4 groups together
with generalized estimating equation re-
peated-measures analyses accounting
for intraindividual correlation through
an exchangeable correlation matrix.
For all multivariate models, variables
were included based on a priori consid-
erations, if they were themselves associ-
atedwith theoutcomeor if theychanged
the other associations in the model.
Kaplan-Meier failure estimates were
determined comparing the 2 tuberculo-
sis exposure groups receiving each
NNRTI for time to death, time to NNRTI
substitution due to toxicity, time to the
first viral load at the threshold of 400 cop-
ies/mL or more (restricted to values be-
yond 30 days of follow-up), time to loss
to follow-up, and time to virological fail-
ure as defined above. In the analysis of
time to death, patients were not cen-
sored with subsequent tuberculosis epi-
sodes or with changes or interruptions
to the NNRTI. In the analysis of time to
treatment-limiting toxicity, patients start-
ing ART with TB were censored at the
end of the initial tuberculosis episode.
Log-rank statistics and adjusted hazard
ratios (HRs) from Cox proportional haz-
ard models were determined for each
comparison. The proportional hazards
assumptions were validated for the Cox
models based on Schoenfeld residuals.
The CD4 cell count changes relative to
baseline were compared at 18 months in
separate multivariate linear regression
models for each NNRTI.
A second analysis was performed in
patients who did not have tuberculo-
sis at the start of ART, in which the time
to virological rebound was deter-
mined from the time of the first viral
load lower than 400 copies/mL. Con-
current tuberculosis treatment as a
result of incident tuberculosis during
follow-up was included as a time-
varying exposure in both Kaplan-
Meier estimates and multivariate Cox
proportional hazard models. Patients
developing tuberculosis remained in
this exposure group even if they were
followed up beyond the end of the tu-
berculosis treatment episode. Fol-
low-up was censored in the same way
as in the first analysis, except in the case
of incident tuberculosis whereby pa-
tients were censored if a second epi-
sode of tuberculosis occurred during
follow-up.
Using the 6-month follow-up dura-
tion, the 141 and 1126 patients as-
sessed who started nevirapine-based
ART with or without concurrent anti-
tubercular therapy would ensure 88%
power to detect a 10% decline in viral
load suppression in the group receiv-
ing concurrent tuberculosis treat-
ment, assuming a 90% suppression in
the reference group (=.05)
The analysis was conducted using
Stata statistical software, 10.0 (Stata-
Corp Inc, College Station, Texas). In
each analysis, only observations with
complete data on the outcomes and co-
variates were used, while the complete-
ness of both the main outcome and co-
variate data are reported (Figure 1 and
TABLE 1, respectively). All statistical
tests were 2-sided.
RESULTS
The proportion of patients starting ART
while receiving concurrent tuberculo-
sis therapy increased from 21% (17 of
80) in 2001 to 40% (439 of 1099) in
2006. Since 2004, the majority of pa-
tients initiated nevirapine-based ART,
although in patients with concurrent tu-
berculosis, efavirenz use has still pre-
dominated.
Of 4117 individuals who met the ini-
tial inclusion criteria, 2687 were not re-
Table 2. Multivariate Model of Associations With Failure to Suppress Viral Loada
OR (95% CI) P Value
Women 1.0 (0.7-1.2) .73
30 y 1.4 (1.1-1.8) .003
Baseline CD4 cell count,
per 25 cells/μL increase
0.9 (0.9-1.0) .004
NNRTI and TB at start of ART
Efavirenz, no TB 1 [Reference]
Efavirenz and prevalent TBb 1.1 (0.8-1.6) .001
Nevirapine, no TB 1.6 (1.1-2.2)
Nevirapine and prevalent TBb 3.2 (2.0-5.2)
Duration on ART, mo
6 1 [Reference]
12 1.5 (1.2-1.7) .001
18 1.8 (1.4-2.1)
Weight at baseline, kg
60 1 [Reference]
60-79.9 1.2 (0.9-1.5) .06
80 1.6 (1.1-2.4)
Year of ART initiation
2001-2002 1 [Reference]
2003 0.7 (0.4-1.2)
2004 0.7 (0.5-1.1) .08
2005 0.6 (0.4-0.8)
2006 0.7 (0.4-1.2)
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; NNRTI, nonnucleoside reverse transcriptase inhibi-
tor; OR, odds ratio; TB, tuberculosis.
aModel included 5283 observations involving 2670 patients.
bPatients had received concurrent treatment for tuberculosis for at least 14 days at the time of starting ART.
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ceiving tuberculosis treatment at the start
of therapy (Figure 1). Of the remaining
1430 who started ART while receiving
concurrent tuberculosis therapy, 249
started taking nevirapine-based ART and
1181 started taking efavirenz-based ART.
Of these, 209 and 1074 patients, respec-
tively, had overlapping treatment for at
least 14 days. Overall, in all groups at all
durations of follow-up, between 83% and
96% of patients who were eligible for vi-
rological assessment and inclusion in the
analysis were assessed.
Patients with concurrent tuberculo-
sis were compared between NNRTI
groups at the start of ART (Table 1) and
were similar with respect to age, base-
line viral load where available, weight
(median of 56 kg in both groups with
concurrent tuberculosis), alanine ami-
notransferase where available, and the
proportion with extrapulmonary tuber-
culosis. Patients with tuberculosis initi-
ating nevirapine had a slightly higher
CD4 cell count (80 vs 61 cells/μL,
P=.002) and had been receiving tuber-
culosis therapy for slightly longer than
those initiating efavirenz (87 vs 73 days,
P .001). They were also more likely to
be women (73.7% vs 62.1%, P .001
[because efavirenz is teratogenic, it is of-
ten avoided in women of childbearing
potential]), less likely to have started tak-
ing zidovudine (4.3% vs 14.4%,
P .001), and were less likely to have a
stage IV–defining illness (55.0% vs
58.1%, P=.002). Findings in the same di-
rections were observed comparing base-
line characteristics between NNRTI
groups without concurrent tuberculo-
sis (Table 1), except that patients initi-
ating efavirenz were older and had higher
baseline aminotransferase values when
available.
Overall, the proportion of patients
with elevated viral loads was lowest at 6
monthswhile takingARTinall 4groups
(FIGURE2).Therewasnodiscernabledif-
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Time to first viral load ≥ 400 copies/mLA
Adjusted HR, 1.4 (95% CI, 1.0-1.9)












1074 747 195395 123
961 617 188391 147
Taking ART, mo
TB at start of ART
Yes
No
Adjusted HR, 0.9 (95% CI, 0.7-1.1)
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Time to second viral load ≥ 5000 copies/mLB
Adjusted HR, 2.2 (95% CI, 1.3-3.7)












1074 818 232462 149
961 684 446465 193
Taking ART, mo
Adjusted HR, 1.1 (95% CI, 0.6-2.0)
Log-rank P = .28
ART indicates antiretroviral therapy; CI, confidence interval; HR, hazard ratio; TB, tuberculosis. Error bars indicate 95% CIs. Adjusted for age, sex, and baseline CD4 cell count.
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ference in this measure based on base-
line tuberculosis therapy status in pa-
tients initiating efavirenz (combined
adjustedOR,1.1;95%CI,0.8-1.5).How-
ever, a higher proportion of patients ini-
tiating nevirapine with initial concur-
rent tuberculosishadelevatedviral loads
during follow-up than those without
concurrent tuberculosis. This was most
notable at 6 months (16.3%; 95% CI,
10.6%-23.5% vs 8.3%; 95% CI, 6.7%-
10.0%; adjusted OR, 2.1; 95% CI, 1.2-
3.4), and in the combined estimate (ad-
justed OR, 1.7; 95% CI, 1.2-2.6).
A model combining all the groups to-
gether demonstrated clearly the infe-
rior virological outcomes (failure to sup-
press viral load) in the group starting to
take both nevirapine and tuberculosis
treatment relative to the efavirenz groups
(eg, adjusted OR, 3.2; 95% CI, 2.0-5.2
for the group initiating nevirapine and
tuberculosis treatment vs the group ini-
tiating efavirenz without concurrent tu-
berculosis at the start of ART, TABLE 2).
The outcomes associated with receiving
nevirapine were inferior even without
concurrent tuberculosis (adjusted OR,
1.6; 95% CI, 1.1-2.2 for the group initi-
ating nevirapine without concurrent tu-
berculosis vs the group initiating efavi-
renz without concurrent tuberculosis).
Age younger than 30 years, a low base-
line CD4 cell count, and increasing base-
line weight were independently associ-
ated with failure to suppress viral load
in this model. The use of zidovudine over
stavudine in the starting regimen was not
associated with the outcome; therefore,
this was not included in the final model.
We found little evidence for interac-
tions between the NNRTI used or con-


























Adjusted HR, 0.9 (95% CI, 0.5-1.8)a













Adjusted HR, 0.8 (95% CI, 0.5-1.1)a


































Time to treatment changeB
Adjusted HR, 1.5 (95% CI, 0.8-2.8)b
Log-rank P = .03
0
No. at risk







Adjusted HR, 0.9 (95% CI, 0.4-2.0)b
Log-rank P = .77
Nevirapine-based ART Efavirenz-based ART
TB at start of ART
Yes
No
ART indicates antiretroviral therapy; CI, confidence interval; HR, hazard ratio; TB, tuberculosis. Error bars indicate 95% CIs.
aAdjusted for age, sex, baseline CD4 cell count, and year of ART initiation.
bAdjusted for age, sex, and baseline CD4 cell count.
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current tuberculosis and any of the other
exposure variables in the model (all P val-
ues .05 [likelihood ratio test]). In al-
ternate models that included available
baseline viral load data, this was inde-
pendently associated with failure to sup-
press subsequent viral loads (adjusted
OR, 1.3 for each log10 increase in the
baseline value, 95% CI, 1.1-1.6) and did
not confound the associations between
this outcome—choice of NNRTI—and
concomitant tuberculosis.
The time-to-event analysis of fail-
ure to suppress viral load (FIGURE 3A)
provided adjusted HR estimates con-
sistent with the pooled adjusted OR es-
timate above (for nevirapine, adjusted
HR, 1.4; 95% CI, 1.0-1.9; for efavi-
renz, adjusted HR, 0.9; 95% CI, 0.7-
1.1). The difference in the case of re-
ceiving nevirapine with and without
concurrent tuberculosis treatment was
more marked when assessing time to
confirmed virological failure (ad-
justed HR, 2.2; 95% CI, 1.3-3.7;
Figure 3B). Concurrent tuberculosis
treatment was not associated with time
to confirmed virological failure in pa-
tients starting efavirenz-based ART (ad-
justed HR, 1.1; 95% CI, 0.6-2.0).
Other Outcome Measures
In comparing other outcomes, there was
no difference after adjustment be-
tween the groups receiving tuberculo-
sis treatment vs those without concur-
rent tuberculosis for each NNRTI in
regard to mortality (adjusted HR for
nevirapine, 0.9; 95% CI, 0.5-1.8; ad-
justed HR for efavirenz, 0.8; 95% CI,
0.5-1.1; FIGURE 4A), or in regard to time
to toxicity-mediated NNRTI substitu-
tion (adjusted HR for nevirapine, 1.5;
95% CI, 0.8-2.8; adjusted HR for efa-
virenz, 0.9; 95% CI, 0.4-2.0; Figure 4B).
In patients without concurrent tuber-
culosis, those patients receiving nevira-
pine were more likely to have their
therapy substituted due to toxicity com-
pared with those receiving efavirenz
(cumulative proportion receiving
nevirapine having treatment substitu-
tion by 6 months, 4.9%; 95% CI, 3.9%-
6.1% vs 1.4%; 95% CI, 0.8%-2.4% in the
case of efavirenz).
For both nevirapine and efavirenz,
concurrent tuberculosis treatment at the
start of ART was associated with an ad-
ditional gain of 29 cells/μL in CD4 cell
count at 18 months compared with base-
line, adjusted for age, sex, and baseline
CD4 cell count (95% CI, 1-56 for nevira-
pine; 95% CI, 6-51 for efavirenz), in com-
parison with patients taking nevirapine
and efavirenz without tuberculosis.
In the 4 groups combined, viral load
suppression to less than 400 copies/mL
was 92.4% (95% CI, 91.3%-93.4%) at 6
months, 89.3% (95% CI, 87.8%-90.7%)
at12months,and86.8%(95%CI,84.6%-
88.8%) at 18 months of ART. Cumula-
tive loss to follow-up was 5.6% (95% CI,
4.4%-7.5%)at24monthsofARTandwas
comparable between the 4 groups.
Incident Tuberculosis in Patients
Already Receiving NNRTI-Based ART
The final analysis compared the time to
virological rebound between patients re-
maining free of tuberculosis during fol-
low-up and those who were initially free
of tuberculosis but subsequently started
tuberculosis treatment due to a new tu-
berculosis episode (FIGURE 5). There was
no difference in time to rebound be-
tween the groups among those who did
and did not experience incident tuber-
culosis receiving either NNRTI (ad-
justed HR, 1.0; 95% CI, 0.5-2.0 for





tubercular therapy at ART initiation re-
sulted in higher probabilities of an el-
evated viral load or virological failure in
the first 2 years of therapy in patients tak-
ing nevirapine-based ART but not in
patients who started efavirenz-based
ART. In spite of these differences, viro-
Figure 5. Cumulative Estimates of Time to Elevated Viral Load Since First Suppressing Viral Load ( 400 copies/mL) in Patients Without
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Adjusted HR, 1.0 (95% CI, 0.5-2.0)
Log-rank P = .98
0 6 1812 24
56 49 2038 15
634 428 167262 133
Duration Since Viral Suppression, mo
Incident tuberculosis
No tuberculosis during follow-up
Adjusted HR, 0.8 (95% CI, 0.4-1.7)
Log-rank P = .70
ART indicates antiretroviral therapy; CI, confidence interval; HR, hazard ratio. Error bars indicate 95% CIs. Adjusted for age, sex, and baseline CD4 cell count.
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logical outcomes were good, with 80%
of patients in the initial nevirapine-
rifampicin group being virologically sup-
pressed at 18 months’ duration of ART.
For both NNRTIs, incident tuberculo-
sis during follow-up did not result in an
increased risk of virological rebound.
Underlying Mechanisms
The differential findings between the
group starting nevirapine with preva-
lent tuberculosis and those develop-
ing tuberculosis once already estab-
lished on ART could be the result of the
limited power of the latter analysis to
detect a difference due to the inclu-
sion of fewer patients with incident tu-
berculosis. An alternative explana-
tion, however, is a drug interaction
mediated by rifampicin during the
lead-in dosing phase of nevirapine. A
2-week lead-in period of once daily in-
stead of twice daily dosing is recom-
mended to allow for the autoinduc-
tion of the cytochrome P450 enzyme
system by nevirapine. In patients tak-
ing rifampicin, the system is however
already induced. A recent Malawian
study30 found that 59% of patients coin-
fected with HIV and tuberculosis had
subtherapeutic nevirapine concentra-
tions during the lead-in dosing phase.
A Thai study that compared patients ini-
tiating efavirenz-based or nevirapine-
based ART with concurrent tubercu-
losis reported an OR between these
groups for achieving a viral load lower
than 50 copies/mL at 48 weeks of 0.590
(95% CI, 0.302-1.153)22 but was based
on smaller numbers of patients.
Strengths and Limitations
of This Study
The published literature on the viro-
logical efficacy of standard doses of
NNRTI-based ART coadministered with
rifampicin is sparse, but the data are
generally encouraging. The existing
studies have, however, been limited by
small sample sizes8,20,21,30,31 or by the fail-
ure to include a control group.30,31
Key strengths of our study include
the large sample size of patients start-
ing ART, a good follow-up rate, and the
assessment of virological responses by
failure to suppress, rebound, and con-
firmed failure. Adherence in this co-
hort, as best as can be measured, was
generally good as reflected by virologi-
cal suppression and comparably low
rates of loss to follow-up between
groups. Thus, it seems unlikely that dif-
ferences in adherence account for the
differences that we found in virologi-
cal outcomes.
The study has a number of limita-
tions. First, although we demon-
strated inferior virological outcomes in
patients starting ART with prevalent tu-
berculosis and nevirapine, we were un-
able to demonstrate differences in sur-
vival or CD4 cell count change.
Interpretation is therefore based on the
premise that virological failure would
eventually result in clinical failure. Sec-
ond, although we believe that the de-
cision to use nevirapine with rifampi-
cin in this study has been a systematic
one rather than by clinical indication,
as an observational study, there re-
mains the possibility of residual con-
founding by indication. In comparing
the clinical characteristics of patients
with tuberculosis when starting ART,
it would appear that if anything, the
sicker coinfected patients with a higher
risk of virological failure were more
likely to start efavirenz-based ART as
evidenced by a lower median baseline
CD4 cell count, a higher probability of
having AIDS, and a shorter duration of
tuberculosis treatment. Third, the de-
tection limit of the viral load assay in
our study was 400 copies/mL, whereas
virological suppression to values 10-
fold lower than this are required for
long-term suppression.32 Finally, it was
not possible with the available data to
compare tuberculosis outcomes be-
tween the groups studied.
Additional Findings
The association with increased weight
and failure to suppress viral load in the
combined model underlines the im-
portance of weight in assessing the ad-
equacy of NNRTI dosing. In addition
to concerns about subtherapeutic dos-
ing, at the other end of the spectrum,
a low baseline weight has been associ-
ated with NNRTI toxicity.19 More de-
tailed analyses of associations be-
tween weight and virological outcomes
and toxicity in patients on NNRTIs are
required in this setting.
For both NNRTIs, CD4 cell count in-
creases were higher in patients who
commenced ART with prevalent tuber-
culosis compared with patients with-
out tuberculosis. The likely explana-
tion for this is the additive effect of the
CD4 cell count increase observed when
tuberculosis is treated in the absence of
ART.33 This confounds any attempt to
determine the effect of the observed dif-
ferences in virological outcomes on
CD4 cell count changes.
The association between nevirapine
use and failure to suppress viral load
in patients without concurrent tuber-
culosis is consistent with data from both
randomized controlled trials18 and a
number of observational studies.34-36
The more rapid development of treat-
ment-limiting toxicity in patients re-
ceiving nevirapine compared with those
receiving efavirenz, irrespective of tu-
berculosis treatment, has previously
been described together with a charac-
terization of the toxicities involved.19
CONCLUSION
Nonnucleoside reverse transcriptase in-
hibitor–based ART is tolerable and ef-
fective when coadministered with rif-
ampicin-containing antitubercular
therapy. Probabilities of elevated viral
loads during follow-up and confirmed
virological failure are higher in pa-
tients with prevalent tuberculosis start-
ing nevirapine-based ART. Given the
continued reliance on nevirapine-
containing ART regimens in Africa, to-
gether with the important role tuber-
culosis services play as an entry point
for ART, further prospective studies ex-
ploring this outcome are warranted.
One of the most striking aspects of our
study was the demonstration that 40%
of patients starting ART in recent years
have concurrent tuberculosis, under-
scoring the public health importance of
improving affordable treatment op-
tions for patients infected with HIV and
tuberculosis in this setting.
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The objective of this cross-sectional household survey was to assess factors influencing HIV risk perception,
behaviour and intervention uptake in a community characterised by high HIV prevalence and availability of
antiretroviral therapy (ART). The survey was conducted in Khayelitsha, South Africa and involved two-stage
sampling with self-weighting clusters and random selection of households within clusters. One man and woman
between 14 and 49 years old was interviewed in each household; 696 men and 879 women were interviewed for
a response rate of 84% and 92% respectively. Ninety-three percent and 94% were sexually active with median
age of sexual debut 15.3 and 16.5 years. Eighty-three percent and 82% reported a partner at the time of
interview and 29% and 8% had additional partner(s). Forty-one percent and 33% reported condom use during
the last sexual encounter. Thirty-seven percent of men not using condoms did not as they believed their partner
to be faithful, whilst 27% of women did not as their partner refused. Twenty-eight percent and 53% had been
tested for HIV. Having undergone HIV testing was not associated with condom usage, whilst current
relationship status was the strongest association with condom usage for both men and women. In spite of a
relatively high uptake of condoms and testing as well as ART availability, the HIV epidemic has continued
unabated in Khayelitsha. Even greater coverage of preventive interventions is required, together with a national
social and political environment that builds on the availability of both preventive and treatment services.
Keywords: HIV; sexual behaviour; South Africa; survey, prevention; treatment; anti retroviral therapy;
condoms; voluntary counselling and testing
Introduction
The moral, social and economic imperative of
providing antiretroviral treatment (ART) for people
living with AIDS in resource-poor settings is today
no longer questioned. However, the duality between
prevention and treatment continues. In rich coun-
tries, prevention and treatment programmes are
independently funded. Treating a patient with ad-
vanced AIDS is not put in balance with resource
allocation for prevention, as is often the discourse in
poorer countries (Marseille, Hofmann, & Kahn,
2002) where a false dichotomy between treatment
and prevention is created. Such dichotomies can
be detrimental to policy development for both
prevention and care, whilst increasingly it is argued
that these should be mutually reinforcing (Berkman,
2001; Coetzee et al., 2004; De Cock & Grubb, 2006;
Salomon et al., 2005). Proponents of ART have
argued that turning AIDS from a death sentence
into a treatable chronic disease will alleviate the
surrounding stigma and that breaking the silence
results in a more open approach to prevention
(Médecins sans Frontières & University of Cape
Town, 2003).
In South Africa, numerous surveys have shown
that the majority of people interviewed are aware of
HIV, know its sexual transmission route and the
protective benefits of using condoms (Johnson &
Budlender, 2002; Kelly & Parker, 2000; Pettifor
et al., 2005b; Shisana & Simbayi, 2002). This
knowledge has not, however, translated into a
marked reduction in new HIV infections; on the
contrary national antenatal HIV prevalence has
risen in South Africa from less than 1% in 1990
to 30% within 5 years (Department of Health,
2005). The aim of this survey was to assess HIV
risk perception and risk behaviour in a specific
context characterised by high HIV prevalence and
exposure to treatment interventions, and to explore
at a community level any association between the
uptake of preventive interventions and the aware-
ness of ART.
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Khayelitsha is a township on the outskirts of Cape
Town, with a population of approximately 400,000
(Municipal Demarcation Board, 2007). The HIV
seroprevalence in the two public-sector antenatal
clinics in this district was 15% in 1999 and 33% in
2004 (Department of Health, 2005). Unemployment
is high at 43%. Most residents rely on health services
delivered by the state. In 1999, the first district-wide
public-sector programme in South Africa to prevent
the transmission of HIV from mother-to-child
(PMTCT) was initiated in Khayelitsha (Abdullah,
Young, Bitalo, Coetzee, & Myers, 2001). Dedicated
clinics for adults and children with HIV were
established in April 2000. In April 2001, the first
patients were started on ART. By the end of the
survey (March 2004), more than 1500 people were on
ART in Khayelitsha, representing at that time one of
the areas with the highest ART coverage. Other
preventive interventions such as VCT, condom dis-
tribution, treatment of sexually transmitted infections
and peer education have generally been available,
although coverage of these interventions has never
been systematically assessed.
Methods
Study design and sampling
The survey was conducted from September 2003 to
March 2004 using a two-stage cluster design. The
primary sampling units were enumerator areas
(EA’s) as defined for the national census, each
consisting of around 200 households. Eighty out of
a possible 622 clusters were selected on a probability
proportional to size basis. Within each EA, 10
households were randomly sampled. In each house-
hold, one randomly selected man and woman aged
between 14 and 49 years of age was interviewed. If
eligible participants were not at home at the first
visit, up to two repeat visits were made. The sample
size was calculated based on previous surveys in
Khayelitsha, which estimated condom use during
last sexual intercourse at around 50% (Parker,
Oyosi, Kelly, & Fox, 2002). Anticipating a design
effect of 2, it was calculated that a sample of 800
men and 800 women between 14 and 49 years old
would be required in order to provide a 95%
confidence interval (CI) spanning 3% either side of
this parameter for men and women separately.
Measurement
The questionnaire was developed based on prior
qualitative work, the UNAIDS Best Practice Collec-
tion on Behaviour Monitoring and the questionnaire
of a multi-centre study (Lagarde et al., 2001a),
adapted and translated into isiXhosa and piloted in
the community. The questionnaire is available on
request.
Data management and statistical analysis
All the data were double entered and validated.
Weighted proportions and means with 95%CI for
patient characteristics, HIV/AIDS knowledge and
sexual behaviour were estimated for men and women
separately. Each cluster was weighted equally and CIs
were calculated with cluster as primary sampling unit.
The associations between possible predictors and
condom use or VCT were assessed using simple and
multiple logistic regression models, adjusted for
correlated outcomes at the cluster level using general-
ized estimating equations (GEE) (Hardin & Hilbe,
2003). The relationship between age and condom use
or VCT was modelled using a piecewise linear effect.
Ethical approval for the study was obtained from
the ethical committees of the University of Cape
Town, South Africa and the Institute of Tropical
Medicine in Antwerp, Belgium.
Results
Community characteristics
A total of 1576 people were interviewed, of whom 879
(55%) were women (Table 1). The response rate was
84% for men and 92% for women. The mean age of
respondents was 28.3 years in men and 28.7 in
women. A total of 1127 households were visited,
with a mean of 3.0 adults and 1.1 children under 14
years. Two-thirds were informal structures. Although
only 5% of respondents were born in Khayelitsha,
more than half had been residing in Khayelitsha for
10 years or longer.
The literacy rate (defined as being able to read a
newspaper in isiXhosa) exceeded 90% and was
higher for women (98%) than for men (90%).
Overall, 28% of men and 29% of women had
obtained a school leaving certificate. Women were
more likely to report being unemployed (45% versus
28%) and of those women who had some employ-
ment, they were less likely than men to be in full-
time employment (17/34% compared to 33/51%).
This is corroborated by a higher proportion of
women relying on others for income. More women
however were able to access social grants as a source
of income (16% versus 2%).
In response to a question on circumcision, 75% of
all male respondents reported having been circum-
cised; the median age of circumcision was 21 years.
772 A. Boulle et al.
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Risk factors for HIV
In all 93% of men and 94% of women had ever been
sexually active (Table 2), with an average age of
sexual debut of 15.3 and 16.5 years. The total number
of lifetime sexual partners reported was most fre-
quently 510 for men and between 24 for women. In
every age group men reported more lifetime sexual
partners than women.
Men reported that their current partner was on
average 4.4 years younger than them, accentuated
when looking at men above 40 who reported partners
seven years younger on average, whilst women of all
ages reported partners who were 5.1 years older on
average.
Of the 83% of men and 82% of women who
reported a current sexual relationship at the time of
the interview, 29% and 8% stated they had been
sexually involved with someone outside of their
regular relationship in the previous 12 months. Of
these, men were more likely than women to have more
than one additional partner.
Table 1. Sociodemographic characteristics and relationships of 1449-year-old men and women in Khayelitsha (South Africa),
20032004.
Men (n697) Women (n879)
Estimate$ 95%CI$ Estimate$ 95%CI$
Age (mean) 28.3 (27.529.1) 28.7 (28.129.4)
Housing type (% living in brick house) 32.6 (25.240.9) 34.0 (26.742.2)
Schooling (%)
No schooling 2.4 (1.53.9) 1.0 (0.51.9)
Primary school only 20.8 (17.225.0) 15.5 (12.918.6)
Secondary school below grade 10 23.5 (20.426.9) 20.1 (17.423.2)
Grade 10 25.6 (22.628.9) 34.3 (31.137.7)
Matric (school leaving) 26.0 (22.429.9) 25.1 (21.928.5)
Tertiary 1.6 (1.02.7) 4.0 (2.65.9)
Literacy (literate) 90.4 (87.692.6) 97.7 (96.398.6)
Place of birth (%)
Khayelitsha 5.3 (3.87.5) 4.8 (3.56.6)
Cape Town 12.3 (9.416.1) 14.7 (11.518.5)
Western Cape 4.8 (3.37.0) 3.1 (2.04.8)
Eastern Cape 77.3 (72.281.8) 77.4 (73.081.3)
Other 0.2 (0.01.3) 0
Time lived in Khayelitsha (%)
Less than 1 year 7.3 (5.69.3) 5.6 (4.37.3)
15 years 18.9 (15.922.3) 18.9 (16.022.1)
510 years 22.3 (19.225.9) 25.0 (22.128.1)
More than 10 years 51.5 (47.755.4) 50.4 (47.053.9)
Employment status (%)
Full-time employed 33.3 (29.437.4) 17.1 (14.320.2)
Irregular employment 13.5 (11.216.3) 9.1 (7.311.4)
Self-employed or informal sector 3.9 (2.65.7) 7.9 (6.010.3)
Unemployed and job-seeking 27.8 (24.231.7) 44.9 (41.148.6)
Student 20.9 (17.824.2) 18.1 (15.521.1)
Other 0.6 (0.31.4) 3.0 (2.0 4.3)
Income source (%)
Family and friends 46.7 (42.551.0) 63.8 (60.567.0)
Employment 51.8 (47.456.2) 30.8 (27.434.5)
Grant 2.3 (1.43.7) 15.5 (13.418.0)
Other or none 2.8 (1.84.4) 5.7 (4.27.6)
Circumcised (%) 74.9 (71.178.4)
$Weighted mean or proportion adjusted for cluster as primary sampling unit. CI: Confidence interval.
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Knowledge about and exposure to HIV
The majority of respondents cited sexual and blood
transmission as the modes of transmission for HIV
(Table 3). Almost half of women identified vertical
perinatal transmission. The majority of respondents
spontaneously identified condoms as a means of
preventing HIV infection.
Over half the respondents knew someone with
HIV (54% of men and 63% of women), with women
more likely to report knowledge of a family member
infected than men (19% versus 10%) and similarly
more likely to report having cared for someone with
HIV. Close to three-quarters knew someone who had
died due to HIV (73% and 76%).
Weight loss (79% & 74%), diarrhoea (29% &
31%), immobility (29% & 21%), hair loss (44% &
30%) and lesions on the lips (36% & 20%) were the
symptoms and signs respondents most commonly
identified with HIV. Twenty-two percent of men and
14% of women felt one could tell if someone had HIV
by looking at them.
Condom use
When asked whether a condom was used the last time
they had sex with any partner, 41% of men and 33%
of women responded that they had (Table 4a). This
was highest in the youngest age group with 68% of
boys and 56% of girls reporting they used a condom
at last intercourse.
Protection against HIV and other infections were
the main reasons given by respondents for using
condoms. There were large gender differences how-
ever in the reasons given for not using condoms: 37%
of men felt they did not need to use condoms since
‘‘their partner is faithful’’ (compared to 23% of
women), whereas 27% of women reported not using
condoms as their partner refused (compared to 3% of
men), rising to 72% when limited to those women
Table 2. Sexual risk factors for HIV/AIDS of 1449-year-old men and women in Khayelitsha (South Africa), 20032004.
Men (n697) Women (n879)
Estimate$ 95%CI$ Estimate$ 95%CI$
Sexually active (%) 92.6 (90.494.4) 94.0 (92.495.2)
Age at sexual debut (mean) 15.3 (14.915.7) 16.5 (16.216.8)
Relationships (%)
Not in relationship 17.3 (14.720.1) 18.2 (15.720.9)
In relationship, but partner not living in Khayelitsha 13.5 (11.016.4) 14.0 (11.816.6)
In relationship, with partner in Khayelitsha 37.9 (33.942.0) 29.8 (27.132.7)
Living together with partner 31.4 (27.535.5) 38.0 (34.441.8)
Age difference with partner% (mean) 4.4 (4.14.9) 5.1 (5.5 4.7)
Used a condom last time with partner% (%) 43.7 (39.048.4) 34.2 (30.138.5)
Generally use condom with partner% (%)
Never 46.2 (41.351.2) 51.5 (47.355.6)
Sometimes 22.4 (18.227.2) 22.5 (19.326.0)
Always 31.4 (27.136.1) 26.1 (22.330.2)
Lifetime number of sexual partners (%)
None 7.8 (6.010.3) 6.3 (5.07.9)
1 3.4 (2.15.5) 14.7 (12.017.7)
24 26.9 (23.530.6) 58.4 (55.361.5)
59 28.5 (25.132.2) 16.4 (14.019.0)
1019 20.2 (17.123.7) 3.9 (2.85.4)
20 or more 13.2 (10.616.3) 0.3 (0.11.0)
Number of sex partners apart from regular partner during the last 12 months% (%)
None 71.1 (67.274.8) 91.7 (89.693.3)
1 16.1 (13.219.4) 7.5 (6.09.3)
24 10.9 (8.813.4) 0.8 (0.32.1)
59 1.6 (0.83.1) 0
10 or more 0.3 (0.11.2) 0
$Weighted mean or proportion adjusted for cluster as primary sampling unit; CI: Confidence interval.
%For those with regular sexual partner.
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who had wanted to use a condom in their most recent
sexual encounter but did not. Less than one in ten
respondents (7% of men and 10% of women)
reported buying condoms.
Models to explore associations with condom use
confirmed that condom use was highest in the
youngest age groups and decreased with increasing
age until age 35 in men and 25 in women (Table 4b).
Condom use was higher for respondents with at least
some secondary school education (OR: 1.3 and 1.9 in
men and women respectively). The lowest condom
use was seen in couples living together and highest in
short-term relationships. For men, condom use was
higher among those who knew how HIV is trans-
mitted (OR: 1.8), who knew that condom use and
abstinence prevent HIV infection (OR: 10.3 and 1.5)
and among those who discuss HIV/AIDS with
friends (OR: 1.7). For women, condom use was
negatively associated with living in a one-roomed
house (OR: 0.6) but higher in those who knew
someone who had died of AIDS (OR: 1.7), in those
who discussed HIV/AIDS with others (OR: 1.6) and
in those with specific knowledge of ART and the need
for treatment to be taken life-long (OR: 2.1).
Voluntary counselling and testing
Over three-quarters (78%) of men and almost all
(97%) women said they knew where they could be
tested for HIV and 28% of men and 53% of women
reported having been tested (Table 5a). When re-
spondents who had tested were asked whether they
would feel comfortable disclosing their HIV status to
the interviewer, the minority were uncomfortable
Table 3. Knowledge about HIV/AIDS transmission and prevention in 1449 year-old men and women in Khayelitsha, 2003
2004.
Men (n697) Women (n879)
%$ 95%CI$ %$ 95%CI$
Knows someone with HIV 54.0 (49.558.5) 62.7 (59.166.2)
Knows of infected family members 9.7 (7.612.1) 18.5 (15.921.4)
Knows of infected friends/colleagues 14.7 (11.818.3) 27.6 (24.331.1)
Cared for someone with HIV 6.0 (4.18.6) 15.0 (12.617.9)
Knows someone who died from HIV 72.7 (68.876.4) 76.0 (72.878.9)
Knows of a family member who died from HIV 12.4 (9.915.4) 22.9 (20.325.6)
Reported modes of contracting HIV%
Unprotected sex 95.3 (93.596.7) 94.7 (93.096.0)
Blood contact 81.4 (78.284.3) 84.4 (81.786.9)
MTCT 11.1 (8.614.1) 49.5 (44.954.0)
Dirty needles 23.5 (20.027.4) 60.2 (54.965.1)
Razorblades 22.4 (19.525.6) 52.7 (47.657.8)
Toothbrush 15.5 (12.818.6) 49.0 (44.353.6)
Punishment 0.6 (0.31.5) 25.5 (21.629.7)
Foreigners 5.7 (4.27.8) 32.6 (28.736.9)
Reported ways of preventing HIV%
Condoms 90.1 (87.292.5) 97.3 (95.998.1)
Abstinence 35.0 (31.638.6) 38.2 (34.642.0)
Being faithful 39.2 (35.443.3) 23.2 (20.326.3)
PMTCT 3.3 (2.0 5.3) 18.9 (16.122.0)
Behaving properly 14.0 (10.917.9) 21.0 (17.724.7)
Believes one can visually tell if someone is HIV-infected 21.9 (18.625.6) 14.4 (12.017.2)
Reported symptoms/signs of HIV/AIDS%
Weight loss 79.2 (75.882.2) 73.6 (69.577.3)
Diarrhoea 28.6 (24.932.7) 31.3 (28.134.7)
Inability to walk 29.0 (25.932.4) 21.1 (18.524.0)
Hair loss 44.2 (39.648.9) 30.4 (27.433.7)
Red lips 36.2 (32.240.4) 20.3 (17.423.5)
$ Weighted proportion adjusted for cluster as primary sampling unit; CI: Confidence interval.
% All answers occurring in at least approximately 20% of respondents for either gender.
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disclosing (4% of men and 1% of women). Of note,
only 1% of men and 6% of women who had tested
reported testing HIV-positive.
Models restricted to sexually active individuals
demonstrated a number of associations with having
tested for HIV (Table 5b). The strongest associa-
tions in men were a partner (OR: 9.6) or other
acquaintance (OR: 3.3) having tested for HIV,
increasing age until 30 (OR: 1.2/year), being full-
time employed (all other categories negatively asso-
ciated), being in a relationship but not living with
their partner, having a partner less than five years
younger (OR0.52 if greater) and knowing that
condoms prevent HIV infection (OR: 2.3). In
women, increasing age above 30 was negatively
associated with VCT (OR: 0.9/yr), whilst not work-
ing or job-seeking (OR: 3.8), being born somewhere
other than the Eastern Cape, having older partners
(OR: 1.6), openness about HIV (OR: 1.9), having
cared for someone with HIV (OR: 2.1), a partner
having tested (OR: 2.5) and knowing that condoms
prevent HIV (OR: 2.6) were positively associated
with VCT. In addition, knowledge about PMTCT
(OR: 4.2) and knowing people on ART (OR: 2.6)
were strongly associated with having tested.
Knowledge of prevention and treatment interventions
Overall, 8% of men and 7% of women believed that
HIV could be cured (Table 5a). More women than
men had heard of ART (43 versus 27%).
For all ages combined, radio was the most
common sources of information on ART, followed
by television. Four respondents were themselves on
ART, whilst 23% of men and 36% of women knew of
the Treatment Action Campaign, the most prominent
organisation in the area advocating for treatment.
Discussion
Khayelitsha is characterised by extremely high levels
of HIV sero-prevalence mirroring that in South Africa
more generally. Living in Khayelitsha reflects many of
the challenges faced by the urban poor, who are
generally considered to be at higher risk of HIV
infection for a myriad of reasons. Khayelitsha is a
community that has been at the forefront of activism
Table 4a. Condom use in 1449 year-old, sexually active men and women in Khayelitsha (South Africa), 20032004.
Men (n648) Women (n823)
%$ 95%CI$ %$ 95%CI$
Condom use in any last sexual contact 40.7 (36.445.1) 32.6 (28.936.5)
In 1419 year-old respondents 67.6 (53.479.1) 56.7 (44.867.9)
In 2029 year-old respondents 51.6 (45.158.1) 35.7 (29.942.0)
In 3039 year-old respondents 25.9 (19.932.9) 27.8 (22.034.4)
In 4049 year-old respondents 21.0 (14.030.5) 20.6 (14.628.2)
Reason for condom use%
To protect myself against HIV 49.3 (45.153.5) 32.8 (29.736.0)
To protect my partner against HIV 21.1 (18.024.6) 9.1 (7.111.7)
To protect against STI’s 35.7 (32.039.7) 32.3 (28.836.0)
To prevent pregnancy 20.3 (17.323.5) 22.2 (18.826.0)
Reason for not using condoms%
Don’t enjoy sex with them 13.6 (11.316.2) 1.0 (0.5 1.9)
Partner is faithful 37.2 (32.941.8) 23.2 (19.627.2)
Partner refuses 2.5 (1.5 4.2) 27.2 (24.030.6)
Buys condoms 7.3 (5.110.4) 9.8 (7.213.3)
Place for getting condoms for free%
Public sector clinic 52.5 (48.356.6) 46.2 (42.250.3)
Ever wanted to but did not use condoms 18.4 (15.022.3) 28.8 (25.532.4)
Reasons for not using condoms%,*
None available 15.0 (10.521.1) 7.7 (5.111.4)
Alcohol 18.3 (13.823.8) 0.8 (0.23.0)
Partner refused 14.8 (10.121.2) 72.1 (65.677.8)
$ Weighted proportion adjusted for cluster as primary sampling unit; CI: Confidence interval.
% All answers occurring in at least 10% of respondents for either gender.
* Responses to this question are based on 105 men and 224 women who answered the preceding question in the affirmative.
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around accessing antiretroviral treatment and is
looked to for evidence of the synergies between
treatment and prevention interventions. This survey
demonstrates that many of the best practice preven-
tion interventions do in fact have a high uptake in
Khayelitsha. There are relatively high levels of VCT
uptake, condoms use is consistent with or higher than
in other surveys (Pettifor et al., 2005b; Shisana &
Simbayi, 2002) and knowledge about HIV appears to
be good.
At the same time however, HIV prevalence has
continued to rise unabated, including in the youngest
age groups (Department of Health, 2005). A parti-
cular conglomeration of risk factors that are common
to the epidemic in the region continue in Khayelitsha,
including early sexual debut, missed opportunities for
condom usage, concurrent relationships, especially
amongst men where they are frequently multiple, age
differentials between male and female partners, and
the inability of women to negotiate condom usage
when they would otherwise choose to use condoms.
These estimates are not dissimilar to those described
in other South African surveys ( Parker et al., 2002;
Pettifor et al., 2005a; Pettifor et al., 2005b; Shisana &
Table 4b. Multiple logistic regression model for association with condom use during last sexual contact in 1449-year-old,
sexually active men and women in Khayelitsha (South Africa), 20032004.
Men
Factor Category OR$ 95%CI$ P-value$
Age Slope (OR/yr) forB35 years 0.96 (0.920.99) 0.025
Slope (OR/yr) for ] 35 years 1.04 (0.961.13) 0.310
Type of relationship Not in relationship 2.31 (1.204.46) B 0.001
In relationship, but partner not living in Khayelitsha 4.29 (2.298.07)
In relationship ofB1 yr, with partner in Khayelitsha 9.48 (4.6419.34)
In relationship of ] 1 yr, with partner in Khayelitsha 6.14 (3.4111.04)
Living together with partner Reference category
Education Secondary school or better 1.33 (0.812.18) 0.260
Knowledge route of transmission
Quotes 2 correct items 1.76 (1.132.74) 0.012
Knows that condoms prevent HIV transmission
Yes 10.28 (3.4530.63) B 0.001
Knows that abstinence prevents HIV transmission
Yes 1.50 (1.002.24) 0.048
Talks about HIV/AIDS
With friends 1.68 (1.032.76) 0.038
Women
Age Slope (OR/yr) forB25 years 0.89 (0.830.96) 0.005
Slope (OR/yr) for ] 25 years 1.00 (0.971.03) 0.835
Type of relationship Not in relationship 2.54 (1.474.37) B 0.001
In relationship, but partner not living in Khayelitsha 3.82 (2.276.43)
In relationship ofB1 yr, with partner in Khayelitsha 7.19 (3.8313.52)
In relationship of ] 1 yr, with partner in Khayelitsha 2.77 (1.784.32)
Living together with partner Reference category
Education Secondary school or better 1.93 (1.203.12) 0.007
Housing type One room house 0.55 (0.320.94) 0.029
Knows somebody who died of AIDS
Yes 1.67 (1.082.59) 0.022
Talks about HIV/AIDS
With friends, family or partner 1.60 (0.942.74) 0.086%
Knowledge of ART Knows ART needs to be taken for ever 2.09 (1.243.53) 0.042
Knows ART but not that it needs to be taken for ever 1.17 (0.791.74)
Has not heard of ART Reference category
$ Adjusted odds-ratio’s (OR), 95% confidence interval (CI) and p-values from multiple logistic regression model.
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Simbayi, 2002; South African Department of Health,
2001).
Given the importance of consistency in condom
use (Ahmed et al., 2001; Lagarde et al., 2001b), it is
notable that nearly 20% of men and 30% of women
would like to have used a condom the last time they
had sex but did not, with lack of availability
remaining an important contributing cause
The age differential between male and female
partners is particularly marked in Khayelisha, in
Table 5a. Uptake of VCT and knowledge of interventions in 1449-year-old men and women in Khayelitsha (South Africa),
20032004.
Men (n697) Women (n879)
%$ 95%CI$ %$ 95%CI$
Know where one can be tested for HIV 77.9 (74.481.1) 96.5 (95.197.5)
Ever tested for HIV 28.0 (25.131.1) 53.3 (49.157.5)
In 1419 year-old respondents 5.7 (2.811.5) 24.1 (17.332.6)
In 2029 year-old respondents 28.9 (23.734.7) 61.9 (55.667.7)
In 3039 year-old respondents 42.3 (34.550.5) 62.5 (56.068.5)
In 4049 year-old respondents 27.8 (19.138.7) 41.5 (32.850.7)
HIV status%
Preferred not to disclose 4.1 (2.08.1) 0.8 (0.3 2.3)
HIV-positive 1.1 (0.34.4) 6.1 (4.38.5)
HIV-negative 94.8 (90.597.2) 93.1 (90.695.1)
Reason for testing%
Told by health staff 7.9 (4.214.6) 11.4 (8.515.2)
MTCT 2.3 (0.96.0) 44.9 (40.149.7)
Was sick 25.4 (19.532.4) 18.2 (14.422.7)
Wanted to know status 51.2 (43.059.3) 39.3 (34.844.0)
Reason for not testing¥
I am afraid of the result 28.5 (24.233.3) 49.1 (43.754.4)
I do not feel at risk 31.9 (27.037.3) 27.1 (22.831.9)
I am not sexually active 14.3 (11.417.7) 13.4 (10.617.0)
I do not know where to test 18.7 (15.322.6) 3.1 (1.75.5)
Knows someone who had tested 47.2 (43.351.1) 48.9 (45.252.7)
Talks about HIV with friends 82.3 (79.484.8) 74.3 (71.177.4)
Talks about HIV with partner 75.1 (71.778.3) 77.0 (73.979.7)
Talks about HIV with other relatives 55.9 (51.660.1) 52.1 (48.855.4)
Heard of the Treatment Action Campaign 22.8 (19.726.2) 36.5 (33.239.9)
Believes HIV can be cured 8.1 (5.911.2) 6.7 (5.0 8.9)
Knows that TB can be cured 97.5 (95.898.5) 97.2 (95.798.2)
Heard of ART 26.9 (23.630.5) 43.3 (39.247.6)
Knows someone on ART’ 14.1 (9.221.1) 21.6 (17.226.9)
Knows where to get ART’ 68.9 (60.975.9) 73.4 (68.977.5)
Source of information on ART’
Newspaper 23.3 (17.829.9) 8.1 (5.611.5)
Radio 61.1 (52.069.4) 42.1 (36.947.5)
Church 0.6 (0.12.3) 0.4 (0.11.8)
Television 50.3 (42.758.0) 41.3 (35.647.1)
School 5.0 (2.78.9) 7.6 (5.211.0)
Treatment Action Campaign 4.8 (2.110.4) 5.6 (3.78.4)
Clinic 10.9 (6.916.8) 31.9 (26.837.4)
Other 8.2 (4.414.9) 13.6 (10.317.8)
$ Weighted proportion adjusted for cluster as primary sampling unit; CI: Confidence interval. ART: antiretroviral therapy; PMTCT:
Prevention of mother-to-child transmission of HIV.
% For those who tested.
¥ For those who did not test.
’ For those who have heard of ARVs.
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Table 5b. Multiple logistic regression model for association with VCT uptake in 1449-year-old, sexually active men and
women in Khayelitsha (South Africa), 20032004.
Men
Factor Category OR$ 95%CI$ P-value$
Age Slope (OR/yr) forB30 years 1.17 (1.091.26) B0.001
Slope (OR/yr) for ]30 years 0.97 (0.921.03) 0.318
Type of relationship Not in relationship 1.10 (0.722.68) 0.081
In relationship, but partner not living in Khayelitsha 1.39 (2.298.07)
In relationship of B1 yr, with partner in Khayelitsha 2.33 (1.104.94)
In relationship of ]1 yr, with partner in Khayelitsha 2.14 (1.124.08)
Living together with partner Reference category
Education Secondary school or better 1.20 (0.722.00) 0.497
Employment Status Retired, disabled, homemaker 0.24 (0.061.04)
Unemployed and job-seeking 0.82 (0.491.40)
Irregular, self or informal employed 0.49 (0.290.84) 0.040
Student 0.54 (0.231.27)
Full-time employed Reference category
Age difference with partner
Female partner5 yrs younger 0.52 (0.320.83) 0.006
Knows someone who has tested
Yes, partner 9.57 (5.2117.57) B 0.001
Yes, somebody other than partner 3.31 (2.135.14)
Knows nobody who has tested Reference category
Knows that condoms prevent HIV transmission
Yes 2.26 (1.124.55) 0.022
Women
Age Slope (OR/yr) forB30 years 1.03 (0.981.09) 0.188
Slope (OR/yr) for ]30 years 0.91 (0.880.95) B 0.001
Type of relationship Not in relationship 0.94 (0.561.57) 0.189
In relationship, but partner not living in Khayelitsha 0.56 (0.330.96)
In relationship ofB1 yr, with partner in Khayelitsha 0.49 (0.191.31)
In relationship of ] 1 yr, with partner in Khayelitsha 0.71 (0.451.12)
Living together with partner Reference category
Education Secondary school or better 1.24 (0.781.98) 0.372
Employment status At home, retired or disabled 3.80 (1.3810.46) B 0.001
Unemployed and job seeking 1.72 (1.112.65)
Irregular, self or informal 1.12 (0.631.98)
Student 0.60 (0.321.14)
Full time employed Reference category
Place of birth Born in Eastern-Cape 0.61 (0.400.94) 0.024
Age difference with partner
Male partner5 yrs older 1.60 (1.122.28) 0.010
Has knowledge of ART Knows somebody on ART 2.59 (1.364.94) 0.020
Knows of ART, but no one on ART 1.30 (0.921.85)
Has not heard of ART Reference category
Knows someone who has tested
Yes, partner 2.52 (1.284.99) 0.008
Yes, other than partner 0.86 (0.601.23)
Not knowing anyone who has tested Reference category
Has knowledge of PMTCT
Yes 4.16 (2.626.61) B 0.001
Knows that condoms prevent HIV transmission
Yes 2.58 (1.125.93) 0.026
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keeping with a number of studies in Southern Africa
in which older male partners are postulated to place
young women at greater risk of HIV acquisition
(Glynn et al., 2001; Gregson et al., 2002; Laga,
Schwartlander, Pisani, Sow, & Carael, 2001).
Given recent evidence on the potential role of
circumcision in contributing to HIV prevention
(Auvert, Taljaard, Lagarde, Sobngwi-Tambekou,
Sitta, & Puren, 2005), the potential impact on the
epidemic of an intervention around circumcision in
this community would need to be considered in the
light of the extremely high proportion of men who are
for traditional reasons already circumcised in early
adulthood, as well as the current age at circumcision.
In understanding the forces shaping risk beha-
viour, the importance of distal contextual factors in
addition to personal factors is increasingly stressed
(Eaton, Flisher, & Aaro, 2003; Mathews, 2005). In
this study, an important negative finding was a lack
of association with having undergone VCT and
condom usage in the last sexual encounter, whereas
trial evidence suggests an association between prior
VCT and risk behaviour (Allen et al., 2003; Hogan &
Salomon, 2005). In contrast, responses suggesting
openness around HIV, knowledge of antiretroviral
interventions and exposure to individuals on antire-
troviral treatment were variously associated with
condom usage and testing. The implausibly low
proportions of patients who admit in the survey to
being HIV-infected in spite of apparent openness,
reflects however ongoing stigma associated with the
diagnosis.
There are two broad conclusions from this
study  firstly, modest increases in coverage of
current best-practice prevention interventions are
limited in the extent to which they can impact on a
mature generalised epidemic as is found in Khayelit-
sha. In the same way as a constant expansion of the
clinical service platform is required in order to meet
treatment needs and approach universal access, so
too is a constant, aggressive and sustained expansion
in the promotion of prevention interventions required
in order to attain even higher levels of coverage.
Secondly, the relationship between treatment and
prevention services is impossible to unravel in the
constantly changing context of a maturing HIV
epidemic. Due to the global commitment to treatment
access, it is fortunately no longer necessary to justify
treatment interventions on the putative basis of their
impact on prevention. Furthermore, discussions on
the synergies between treatment and prevention often
focus on personal and proximal issues. The high
reliance on broadcast media as a source of informa-
tion in this survey point to the importance of the
distal context, where South Africa has lagged behind
many other countries in the region in terms of the
visibility, political commitment and priority afforded
to both treatment and preventive interventions for
HIV in the national discourse. It is at this level
perhaps that the greatest synergies might exist
between treatment and preventive paradigms.
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Objective To describe province-wide outcomes and temporal trends of the Western Cape Province antiretroviral treatment (ART) 
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located predominantly in primary-care facilities. Data on patients starting ART were prospectively captured into facility-based 
registers, from which monthly cross-sectional activity and quarterly cohort reports were aggregated. Retention in care, mortality, loss 
to follow-up and laboratory outcomes were calculated at 6-monthly durations on ART.
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in part by an increase in loss to follow-up (reaching 4.7% at 6 months in 2005). Over 85% of adults tested had viral loads below 400 
copies/ml at 6-monthly durations until 4 years on ART.
Conclusion The location of care in primary-care sites in this programme was associated with good retention in care, while the 
scaling-up of ART provision was associated with reduced early mortality.
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Introduction
The national antiretroviral treatment 
(ART) programme in South Africa was 
launched in April 2004.1 However, for 
some years prior to this, demonstration 
projects had provided ART to HIV-
infected individuals with advanced 
disease through government health 
services. Several projects were located in 
the Western Cape Province which, as a 
result, is able to report on outcomes up 
to 4 years after initiation of therapy. 
The first such project began providing 
ART in Khayelitsha in May 2001,2,3 
followed by a project in Gugulethu in 
September 2002.4–6
Since inception, the clinical guide-
lines and approaches to monitoring 
used in the Western Cape Province have 
been in line with those recommended 
by WHO.7–9 The treatment setting is 
reflective of public sector health services 
in South Africa. A description of out-
comes 5 years into this provincial pro-
gramme, and after significant scaling-
up of care, has relevance to what can be 
anticipated in South Africa and other 
similar settings in the region.
This paper demonstrates that ro-
bust and useful information can be gen-
erated using a basics-first, paper-based 
monitoring system, as recommended 
by WHO.10 There are some sites in the 
province that collect clinical data elec-
tronically and enhance these data for 
cohort surveillance and research. These 
are designated as sentinel sites and ad-
dress particular clinical and epidemio-
logical questions. This takes pressure 
off the remaining sites from having to 
institute complex monitoring systems 
and ensures that in the majority of sites 
only the information essential for man-
agement and programme assessment is 
collected.
The aim of this paper is to describe 
the key clinical outcomes in the West-
ern Cape provincial ART programme, 
in patients on therapy for up to 4 years, 
and the evolution of the programme 
over a 5-year period. Secondary aims 
are to demonstrate the field utility of 
the WHO monitoring guidelines and 
the feasibility of scaling-up services 
through primary-care sites.
Programme description
The first project to routinely offer ART 
in the public sector and on a district-
wide basis in South Africa was started 
in 2001 as a partnership between the 
provincial government and Médecins 
Sans Frontières in the Cape Town 
township of Khayelitsha. At that time, 
several local clinicians had already been 
involved in ART provision through 
clinical studies and private funding and 
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were able to support this and subse-
quent initiatives. These early sites can 
be considered as “innovator sites” in 
as far as they were able to grapple 
with many of the logistics of setting up 
services in anticipation of a more rapid 
scaling-up of ART services. By the time 
the national programme was launched 
in South Africa in April 2004, there 
were 16 discrete sites offering ART 
in the province, eight of which were 
in primary care. At this time there 
were 2327 patients receiving ART. By 
the end of March 2006, there were 
16 234 patients receiving ART (87% 
adults) across 43 sites, the majority 
being treated in primary-care settings 
(67% in clinics and community health 
centres, and 13% in district hospi-
tals). Enrolment increased steadily 
over this time to reach 1000 patients 
per month, with seasonal decreases 
in enrolment each December (Fig. 1 
and Fig. 2). Care was first offered as 
part of the primary-care HIV inter-
vention for children in 2002, with 
follow-up for children in this analysis 
extending to 3 years. Children were 
defined as patients starting ART under 
the age of 14 years.
Patients were considered eligible 
for ART if they had a stage IV illness 
(excluding extrapulmonary tuberculo-
sis) or a CD4 count less than 200 cells/
μl. The adult regimens used throughout 
comprised two nucleotide reverse tran-
scriptase inhibitors (NRTIs) and one 
non-nucleotide reverse transcriptase 
inhibitor (NNRTI). Initially, the NRTI 
backbone in Khayelitsha comprised 
zidovudine and lamivudine, but was 
later changed to stavudine and lami-
vudine in line with the national pro-
gramme. Paediatric regimens varied, 
with NNRTIs and protease inhibitors 
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being variously used with the NRTI 
backbone.
Six-monthly CD4 counts and 
viral-load testing were provided in 
the programme, together with safety 
monitoring according to the specific 
regimens. The protocol for changing to 
second-line therapy was two consecu-
tive viral loads above 5000 copies/ml.7 
All laboratory tests were conducted 
by the National Health Laboratory 
Services. CD4 counts were performed 
using the panLeucogating method.11 
Viral loads were conducted using the 
NucliSens HIV-1 QT® assay, and later 
NucliSens EasyQ® HIV-1 assay (bio-
Mérieux, Boxtel, the Netherlands) for 
which the upper limit of detection is 
just under 400 copies/ml, hence the 
use of 400 copies/ml as the defini-
tion of suppression in all registers and 
analyses.
Data collection and analysis
The routine monitoring system
Data analysed were collected through 
the routine monitoring system. This 
system is one component of a frame-
work for the monitoring of the ART 
programme in the province (Fig. 3). 
Other components include observa-
tional cohort studies in sentinel sites, 
special studies to address priority clini-
Fig. 3. A tiered routine monitoring system for ART
ART, antiretroviral therapy.
Sentinel surveillance
Clinical and operational research
based on validated individual records
Special studies
ad hoc
Routine aggregated reporting – all facilities
Quarterly cohort report – treatment-naive patients (outcomes)
Clinical record-keeping – all patients (including adverse drug-event reporting)
Routine monthly reports (coverage and resource planning)





cal research questions, and a passive-
stimulated pharmacovigilance reporting 
system.
Patients are entered into a register 
in the order in which they start ART. 
Monthly reporting is universal across 
the sites and comprises cross-sectional 
patient and enrolment totals (Fig. 1 
and Fig. 2), the essential information 
required by managers to keep track of 
resource allocation and progress against 
targets. Quarterly cohort reports are 
also universal and are provided a quar-
ter in arrears to allow sites to complete 
the ascertainment of outcomes before 
reporting. These reports are aggre-
gated by starting quarter, as well as by 
6-monthly durations on ART, allowing 
for cohort outcomes to be reported. 
The metrics reported on quarterly in-
clude regimen (first- or second-line), 
CD4 count, viral load and outcome (i.e. 
in care, transferred out, lost to follow-
up, died).
When aggregating from the regis-
ters, the measure of advanced immune 
suppression at baseline is determined 
by the proportion of adults with a 
baseline CD4 cell count of less than 
50 cells/μl and in children a CD4 
percentage of less than 15% of total 
lymphocytes. Immunological response 
during follow-up is determined by the 
proportion of patients tested with CD4 
cell counts above 200 cells/μl or greater 
(20% in children) and virological re-
sponse by the proportion of patients 
tested with viral loads below 400 
copies/ml. All cohort analyses are lim-
ited to treatment-naive patients.
Data analysis
The monthly data are presented as 
cross-sectional monthly totals, whilst 
the quarterly data are presented as 
combined annual enrolment cohorts 
followed up until study closure. The 
monthly data cover April 2004 to March 
2006, whilst the cohort data include 
patients enrolled between May 2001 
and December 2005, followed until 
March 2006. Owing to the aggregate 
nature of the data, all data are presented 
as proportions with 95% binomial 
confidence intervals. The definition of 
“remaining in care” is patients who had 
had at least one visit in the preceding 
90 days. Correspondingly, the defini-
tion of “loss to follow-up” is patients 
who had not had a contact with the 
health services for 90 days or more. 
The small number of patients who 
transferred their care to other sites are 
excluded in both the numerator and 
the denominator in the calculation of 
the proportions remaining in care, died 
and lost to follow-up. These measures 
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are limited to those patients followed 
up for at least the full duration under 
analysis. In addition, the proportion 
of patients remaining in care is further 
described as Kaplan–Meier estimates 
based on weighted survival data de-
rived from the count data. All analyses 
were performed using Stata statistical 
software version 9.0 (StataCorp. LP, 
College Station, TX, United States of 
America).
Results
Overall, 12 587 adults and 1709 chil-
dren were included in this cohort re-
port, totalling 14 296 treatment-naive 
patients. This is a near-complete repre-
sentation of all public-sector patients 
started on ART in the Western Cape 
Province by the end of 2005. Follow-
up for the oldest quarterly cohorts ex-
tends to 4 years on treatment. A further 
Table 1. Estimates of retention in care for treatment-naive adults
Duration on ART 
(months)
0 6 12 18 24 30 36 42 48
Total adults 
starting ART
12 587 8 341 4 726 2 167 852 561 328 189 80
Started before 30 Jun  
2005
31 Dec  
2004
30 Jun  
2004
31 Dec  
2003
30 Jun  
2003
31 Dec  
2002
30 Jun  
2002





545 (6.7) 397 (8.8) 239 (11.6) 131 (15.8) 96 (17.6) 60 (18.9) 36 (19.7) 18 (23.1)
Lost to follow-up 
since start
b,c













































a  Deaths since start = deaths / (total - transfers out).
b  Values in parentheses are percentages.
c  Lost to follow-up since start = losses to follow-up / (total - transfers out).
d  Transfers out since start = transfers out / total.
e  Remaining in care – absolute = (total - losses to follow-up - deaths - transfers out) / (total - transfers out).
f  Values in parentheses are exact binomial confidence intervals.
g  Weighted Kaplan–Meier estimate.
h  Values in parentheses are Greenwood point-wise confidence intervals.
2.4% of patients were treatment expe-
rienced before starting ART, and were 
not included in this analysis.
The percentage of men starting 
ART has remained around 30% over 
the 5 years of enrolment in the prov-
ince, with a very slight increase over 
time. The gender breakdown of chil-
dren is not routinely recorded but 
reviews of paediatric sentinel site data 
reveal that the gender breakdown of 
children starting ART is roughly even. 
Overall, 22.7% of adults began ART 
with a CD4 count below 50 cells/μl 
while 45% of children started ART 
with a CD4 count below 15% of total 
lymphocytes.
After 4 years on ART, 76% of 
adults remained in care (Fig. 4 and 
Table 1). For each duration on ART, 
this absolute estimate was based only 
on the data for those patients who 
started that number of months previ-
ously. Using the weighted survival data, 
the Kaplan–Meier estimate of reten-
tion in care was 72.0% at 4 years on 
ART with a narrower confidence in-
terval (95% confidence interval, CI: 
68.0–75.6). A similar analysis of pae-
diatric outcomes (Fig. 5 and Table 2) 
revealed 81.5% (95% CI: 75.7–86.1) of 
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Table 2. Estimates of retention in care for treatment-naive children
Duation on ART 
(months)
0 6 12 18 24 30 36
Total children 
starting ART
1 709 1 216 770 371 72 51 35
Started before 30 Jun 2005 31 Dec 2004 30 Jun 2004 31 Dec 2003 30 Jun 2003 31 Dec 2002
Deaths since start
a,b 84 (7.4) 68 (9.8) 32 (9.3) 4 (5.7) 4 (8.2) 4 (11.8)
Lost to follow-up 
since start
b,c
22 (1.9) 23 (3.3) 19 (5.5) 4 (5.7) 3 (6.1) 2 (5.9)
Transfers out since 
start
b,d
84 (6.9) 77 (10.0) 27 (7.3) 2 (2.8) 2 (3.9) 1 (2.9)































a  Deaths since start = deaths / (total - transfers out).
b  Values in parentheses are percentages.
c  Lost to follow-up since start = losses to follow-up / (total - transfers out).
d  Transfers out since start = transfers out / total.
e  Remaining in care = (total - losses to follow-up - deaths - transfers out) / (total - transfers out).
f  Values in parentheses are exact binomial confidence intervals.
g  Weighted Kaplan–Meier estimate.
h  Values in parentheses are Greenwood point-wise confidence intervals.







































children remained in care after 3 years. If 
looking only at those children who had 
been in care for the entire 3 years, the 
estimate is comparable (82.4%). In both 
adults and children starting ART, mor-
tality was highest in the first 6 months 
on therapy.
The first laboratory metric re-
ported on is the proportion of tests 
that are done when they should be 
done. This is a proxy for quality of care. 
Results were received in the cohort 
system for four out of five patients 
who should have received these tests 
(Table 3). There is currently a slight 
drop-off in the test completion propor-
tion as the duration on ART increases.
Looking at adult laboratory out-
comes, of those tested, 90.6% of adults 
achieved virological suppression by 
6 months on ART (Table 3). Although 
the proportion of patients on second-line 
regimens increases with duration on ART, 
and the data system does not distinguish 
which viral loads are done in patients on 
first-line versus those on second-line, for 
all patients combined this percentage re-
mained at 85% or above until 4 years on 
ART. At 2 years on ART, 3.7% of adults 
were on second-line, rising to 17.9% at 
4 years on ART. Combining all adult 
patients together, irrespective of the 
duration on ART, 1.3% of patients were 
reported to be on second-line regimens at 
the end of 2005. At the end of the first 
year on treatment, 74.7% of adult pa-
tients had attained a CD4 count above 
200 cells/μl or greater, rising to 86.0% 
at 2 years on ART and 95.3% at 4 years 
on ART.
The proportion of children achiev-
ing virological suppression ranged be-
tween 70% and 80% during the 3 years’ 
duration of follow-up (Table 3), while 
7.4% had been changed to second-line 
by 3 years on ART. By 2 years on ART, 
85.7% of children had achieved a CD4 
greater than 20% of lymphocytes.
As the rate of enrolment increased 
in the province (Fig. 1 and Fig. 2), the 
severity of illness in patients starting 
ART decreased, evidenced by the lower 
proportion with CD4 cell counts be-
low 50 cells/μl at ART initiation. In 
2001 and 2002, half the adult patients 
starting ART had a CD4 count below 
50 cells/μl, whereas this fell to 21.5% 
in 2005. This, coupled with the expan-
sion of the programme into different 
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Table 3. Laboratory outcomes in treatment-naive adults and children on ART
Duration on ART 
(months)
6 12 18 24 30 36 42 48
Adults in care and 
on ART
7 100 3 738 1 640 651 414 237 139 56
On second-line (%) 0.5 1.8 3.3 3.7 4.8 9.7 10.8 17.9
Viral loads done 5 979 3 330 1 401 573 343 171 93 44
Completion (%) 84.2 89.1 85.4 88.0 82.9 72.2 66.9 78.6
< 400 copies/ml (%) 90.6 89.0 88.1 88.3 88.0 86.0 84.9 90.9
95% CI 89.8–91.3 87.9–90.0 86.3–89.7 85.4–90.8 84.1–91.3 79.8–90.8 76.0–91.5 78.3–97.5
CD4 counts done 5 972 3 335 1 380 564 331 168 95 43
Completion (%) 84.1 89.2 84.1 86.6 80.0 70.9 68.3 76.8
≥ 200 cells/μl (%) 62.2 74.7 82.0 86.0 90.9 88.1 88.4 95.3
95% CI 60.9–63.4 73.2–76.2 79.9–84.0 82.9–88.8 87.3–93.8 82.2–92.6 80.2–94.1 84.2–99.4
Children in care and 
on ART
1 019 597 293 62 41 27 – –
On second-line (%) 0.1 0.7 2.0 4.8 4.9 7.4 – –
Viral loads done 822 531 245 53 28 20 – –
Completion (%) 80.7 88.9 83.6 85.5 68.3 74.1 – –
< 400 copies/ml (%) 72.7 72.3 74.7 77.4 78.6 75.0 – –
95% CI 69.6–75.8 68.3–76.1 68.8–80.0 63.8–87.7 59.0–91.7 50.9–91.3 – –
CD4 counts done 807 499 219 35 17 6 – –
Completion (%) 79.2 83.6 74.7 56.5 41.5 22.2 – –
> 20% lymphocytes (%) 57.5 71.5 74.9 85.7 88.2 83.3 – –
95% CI 54.0–60.9 67.4–75.5 68.6–80.5 69.7–95.2 63.6–98.5 35.9–99.6 – –
ART, antiretroviral therapy; CI, confidence interval.
communities, has seen mortality dur-
ing the first 6 months on ART almost 
halved from 12.7% to 6.6% (Fig. 6 and 
Table 4). At the same time there has 
been an increase in the proportion of 
patients lost to follow-up. For patients 
starting ART in 2005, 4.7% had been 
lost to follow-up 6 months after start-
ing ART.
Discussion
This analysis, based on routine data 
from a paper-based monitoring sys-
tem, has demonstrated good cohort 
retention at 4 and 3 years in adults and 
children respectively, combined with 
favourable immunological and viro-
logical responses to therapy.  As fewer 
patients have over time started ART 
with very low CD4 counts, so too has 
the mortality in the first 6 months of 
treatment declined.
The antiretroviral services in the 
Western Cape Province are represen-
tative of the national programme in 
South Africa, with the prior experience 
of innovator sites providing the oppor-
tunity to anticipate clinical outcomes 
and challenges that will be faced in the 
national programme.
The accumulated experience of 
these sites enabled the province to rap-
idly scale-up treatment in terms of both 
sites and patients around the time that 
the national programme became a real-
ity. It is estimated that, in the final year 
under review in this paper, half of those 
newly in need of antiretroviral therapy 
were able to access it in the province. 
The falling proportion of adult patients 
with extremely low CD4 counts at 
enrolment reflects the impact of this 
scaling-up of ART provision.
The concurrent halving in early 
mortality at 6 months on ART, which 
accompanied the improved immuno-
logical status of adults starting ART, 
suggests that the high early mortality 
that is characteristic of programmes in 
the region is in part mediated by the 
extreme disease advancement at enrol-
ment. This concurs with studies that 
have been able to stratify outcomes 
based on CD4 count categories.2,5,12,13 
Measures of the baseline CD4 count 
on enrolment may prove to be an ex-
tremely useful barometer of the extent 
to which programmes have caught up 
with the backlog in treatment in in-
stances where the need for ART cannot 
be easily assessed.
A key limitation of this analysis, 
and all analyses of aggregate data, is 
the inability to stratify outcomes by 
individual baseline measures of disease 
severity. It is not possible from this 
analysis to determine if the decline 
over time in early mortality is fully 
mediated by measured improvements 
in the baseline clinical status of patients 
starting therapy.
Increasingly, patients lost to 
follow-up are outnumbering patients 
who are known to have died in devel-
oping country cohorts.14 For this reason 
we believe that retention in care is the 
most useful metric for reporting on 
programme effectiveness. Retention 
in care in this analysis at 3 and 4 years 
on ART demonstrates unequivocally 
the huge survival benefit conferred by 
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Fig. 6. Temporal trends in baseline CD4 count survival and loss to follow-up at 6 
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the intervention. Most of the current 
simulation models that anticipate 
either patient numbers or the costs 
associated with ART have assumed a 
median of between 6 and 7 years 
survival on ART.15 The current data at 
4 years, where 7 out of 10 adult patients 
are still in care, suggest that these esti-
mates are not overoptimistic, especially 
since many of the patients lost to care 
may well subsequently return to care, 
given the very tight definition of loss 
to follow-up.
Using 90 days without a clinical 
visit as the definition of loss to follow-
up enables programmes to rapidly 
identify changes in this parameter and 
respond appropriately. It also fits in 
very well with the quarterly cohort 
reporting ensuring that, when report-
ing one quarter in arrears, all outcomes 
can be fully ascertained. On the other 
hand, many analyses have used longer 
durations (up to 1 year) without con-
tact with the services to define loss to 
follow-up.13
Notwithstanding the definition 
used, a higher proportion of patients 
were lost to follow-up in the first 
6 months on ART in 2005 compared 
to previously. It is probable that clinic 
patient loads exceeding manageable 
numbers in some clinics are affecting 
this. It is clear that retaining patients 
in constant care will become increas-
ingly difficult as the service continues 
to expand, highlighting the importance 
of adherence promotion extending be-
yond the health services to the national 
and local media, political, social and 
religious platforms, as well as through 
community interventions. Decentral-
ization of care to more facilities, and 
the appropriate resourcing of services, 
are key to ensuring that services at indi-
vidual facilities remain of a manageable 
size and are able to appropriately retain 
patients in care.
Even though most services retained 
some capacity to actively follow up 
patients lost to care during the period 
under review, it is probable that there 
remains residual under-ascertainment 
of mortality in the latter years as loss 
to follow-up increased.16 It is further 
unknown to what extent in future the 
increased loss to follow-up will result 
in intermittent care and consequently 
increased virological resistance due to 
repeated treatment interruptions (which 
are known to be strongly associated with 
resistance).17
The slower increase over time in 
the numbers of children on ART com-
pared to adults is entirely anticipated 
and does not imply that children are 
being underprovided for. Whereas the 
number of adults newly needing ART 
increases year on year, the number 
Table 4. Temporal trends in baseline CD4 count survival and loss to follow-up at 6 months in adults starting ART
Number of adults
a 80 248 524 3981 3508
Year started on ART 2001 2002 2003 2004 2005
CD4 < 50 cells/μlb,c 51.3 (39.8–62.6) 50.4 (44.0–56.8) 36.8 (32.7–41.1) 24.4 (23.1–25.8) 21.5 (18.8–20.6)
Mortality
c,d 12.7 (6.2–21.8) 11.7 (8.0–16.4) 9.6 (7.2–12.4) 6.0 (5.1–6.6) 6.6 (5.6–7.3)
Loss to follow-up
c,e 0.0 (0.0–4.5) 0.4 (0.0–2.2) 1.7 (0.8–3.2) 4.4 (3.7–4.9) 4.7 (3.9–5.3)
ART, antiretroviral therapy; CI, confidence interval.
a  Number starting in year and reaching 6 months of follow-up.
b  Proportion in starting cohort with CD4 counts < 50 cells/μl.
c  Values in parentheses are exact binomial confidence intervals.
d  Mortality = deaths by 6 months / (total in cohort - transfers out by 6-months).
e  Loss to follow-up = losses to follow-up by 6 months / (total in cohort - transfers out by 6 months).
of children is decreasing due to suc-
cessful implementation of a preven-
tion of mother-to-child transmission 
programme.18,19
The virological outcomes are en-
couraging and suggest that at a popu-
lation level the rates of viral rebound 
have not been alarming and are not 
undermining overall programme suc-
cess. Nevertheless, with up to one in 
five patients requiring second-line 
therapy by 5 years on ART, it is clear 
that the higher cost of second-line 
drugs will impact on total programme 
costs as programmes mature.20
There have been many lessons 
learned in implementing the WHO 
monitoring approach. This system, 
based on registers and regular cohort 
analyses, shares many attributes with 
systems that have been in use for many 
years for monitoring tuberculosis pro-
grammes. Worth noting is the value of 
differentiating sentinel from routine 
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Résumé
Traitement antirétroviral et mortalité précoce en Afrique du Sud 
sites,21 liberating the majority of sites 
from onerous data-collection pro-
cedures that are designed for clinical 
research rather than for supporting rou-
tine care. It has been our experience 
that, with viral loads being available, 
managers have paid little attention 
to CD4 count outcomes in assessing 
programme performance. We have also 
found that presenting the completion 
proportions for laboratory outcomes is 
an invaluable metric over and above the 
outcomes themselves in the subset of 
patients for whom results are available. 
Finally, one of the major challenges 
emerging as models of care evolve is 
the large number of patients moving 
between facilities, who, once trans-
ferred out, are censored in the cohort 
analyses.
The ability to report on cohort 
outcomes without electronic systems 
underscores the value of implement-
ing a basics-first approach to routine 
monitoring. This does not mean that 
there is no role for the progressive and 
measured development of electronic 
systems 22 but rather that the basic 
building blocks that are required for a 
paper-based system are the same mea-
sures that will make electronic systems 
a success.23
Perhaps the most important les-
son from the first 5 years of this pro-
gramme is that implementing an ART 
programme in primary-care facilities 
from the outset is feasible and can 
achieve excellent clinical results. It is 
probable that the location of care in 
community clinics is one of the key 
factors contributing to the retention of 
patients in care.24
Looking to the future, if the West-
ern Cape Province is to come close to 
the stated target of treating 80% of 
patients newly in need of therapy each 
year over the coming years, the annual 
number of patients enrolling in care 
will need to double while the total 
number of patients in care quadruples 
over a 5-year period. This will require 
even further task-shifting and expan-
sion of the service platform, given that 
enrolment is already threatened by 
capacity constraints in the existing service 
platform.25
In conclusion, this paper has dem-
onstrated excellent clinical outcomes 
5 years after the Western Cape Province 
began offering ART in the public sec-
tor, validating the decision to make this 
a primary-care intervention from the 
outset. The WHO monitoring system 
has enabled the province to keep track 
of the intervention and of the per-
formance of individual sites, while 
allowing space for more complex and 
durable solutions to be developed for 
the larger sites.  
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Objectif Décrire les résultats à l’échelle provinciale et les 
tendances dans le temps du programme de traitement 
antirétroviral (ART) de la province du Cap-Occidental, 5 ans après 
son lancement et démontrer l’utilité du système de surveillance 
de l’OMS pour ce traitement.
Méthodes Le programme de traitement a débuté en 2001 au 
niveau de sites « novateurs ». Un rapide passage à l’échelle 
supérieure de la délivrance du traitement a commencé début 
2004, à partir essentiellement d’établissement de soins de 
santé primaire. Des données relatives aux patients entamant 
un traitement ART ont été recueillies de manière prospective 
dans les registres des établissements de soins, ce qui a permis 
de constituer des rapports mensuels d’activité et des rapports 
trimestriels de cohorte. Les taux de rétention sous traitement 
et de mortalité, ainsi que les nombres de perdus pour le suivi 
et les résultats de laboratoire ont été calculés tous les 6 mois 
sous ART.
Résultats Fin mars 2006, 16 234 patients étaient sous 
traitement. L’analyse de cohorte a porté sur 12 587 adultes et 
1709 enfants. Les femmes représentaient 70 % des adultes 
inclus dans l’étude. Après 4 et 3 ans sous traitement ART, 
respectivement 72,0 % des adultes (intervalle de confiance à 
95 % : 68,0-75,6) et 81,5 % des enfants (IC à 95 % : 75,7-86,1) 
étaient encore sous traitement. Le pourcentage des adultes 
débutant le traitement ART avec une numération des CD4 
inférieure à 50 cellules/μl est tombé de 51,3 % en 2001 à 
21,5 % en 2005, tandis que la mortalité à 6 mois passait de 
12,7 % à 6,6 %, baisse en partie compensée par l’augmentation 
du nombre de perdus pour le suivi (atteignant 4,7 % à 6 mois 
en 2005). Plus de 85 % des adultes dépistés présentaient une 
charge virale inférieure à 400 copies/ml tous les 6 mois jusqu’à 
4 ans sous ART.
Conclusion La dispensation par ce programme des soins dans 
des sites de soins de santé primaire était associée à un taux de 
rétention satisfaisant, tandis que l’élargissement du programme 
était associé à une réduction de la mortalité précoce.
Resumen
Tratamiento antirretroviral y mortalidad temprana en Sudáfrica 
Objetivo Describir los resultados y las tendencias temporales a 
escala provincial del programa de tratamiento antirretroviral (TAR) 
de la Provincia de El Cabo Occidental a los 5 años de su puesta 
en marcha y demostrar la utilidad del sistema de vigilancia de la 
OMS para el TAR.
Métodos El programa de tratamiento dio comienzo en 2001 a 
partir de establecimientos innovadores. La rápida expansión del 
suministro de TAR comenzó a principios de 2004 y se centró 
predominantemente en los servicios de atención primaria. Los datos 
sobre los pacientes que comenzaron el TAR se reunieron de forma 
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ملخص
املعالجة مبضادات الفريوسات القەقرية والوفيات املبكرة يف جنوب أفريقيا 
لربنامج  الزمنية  املقاطعة، واالتجاەات  النتائج عىل مستوى  توضيح  الەدف: 
املعالجة باألدوية املضادة للفريوسات القەقرية يف مقاطعة الرأس الغريب بعد 
ميض خمس سنوات من إدخال الربنامج، وإبراز جدوى نظام املنظمة الخاص 
برصد املعالجة مبضادات الفريوسات القەقرية.
مستحدثة.  مواقع  خالل  من   2001 عام  يف  املعالجة  برنامج  بدأ  الطريقة: 
كام بدأ ترسيع وترية االرتقاء بتقديم املعالجة مبضادات الفريوسات القەقرية 
األولية بشكل أسايس. وتم تسجيل  الرعاية  2004، يف مرافق  يف مطلع عام 
املؤرشات الخاصة باملرىض الذين بدءوا يف تلقي املعالجة مبضادات الفريوسات 
ربع  األترابية  التقارير  تجميع  املرافق، مام ساعد عىل  القەقرية يف سجالت 
تحت  املرىض  استبقاء  معدالت  احتساب  وتم  الشەري.  والنشاط  السنوية، 
الرعاية، والوفيات، والفقدان أو الترسب من املتابعة، والنتائج املختربية كل 
ستة أشەر من املعالجة مبضادات الفريوسات القەقرية.
الرعاية  تحت  املرىض  عدد  أن  وجد   ،2006 آذار/مارس  بنەاية  املوجودات: 
بالغاً، و1709   12 587 األترايب  التحليل  234 16 مريضاً. فقد تضمن  يبلغ 
من األطفال، بينام مثلت النساء 70% من البالغني املدرجني بالتحليل. وبعد 
يتلقون  من  بني  الرعاية  تلقي  يف  االستمرار  نسبة  كانت  سنوات  أربع  ميض 
ثقة  (بفاصل   %72.0 البالغني  من  القەقرية  الفريوسات  مبضادات  املعالجة 
95%، إذ تراوح معدل األرجحية بني 68.0 و75.6)، وبعد 3 سنوات كانت 
املعالجة  يتلقون  الذين  لألطفال  بالنسبة  الرعاية  تحت  االستمرار  نسبة 
مبضادات الفريوسات القەقرية 81.5% (بفاصل ثقـة 95%، إذ تراوح معدل 
األرجحية بني 75.7 و86.1). فنسبة البالغني الذين بدأوا املعالجة مبضادات 
الفريوسات القەقرية وكان عدد CD4 لديەم أقل من 50 خلية لكل مكرولرت، 
حني  يف   ،2005 عام  يف   %21.5 إىل   2001 عام  يف   %51.3 من  انخفضت 
انخفضت الوفيات خالل 6 شەور من 12.7% إىل 6.6%. ولكن ەذە النتيجة 
إىل  (لتصل  املتابعة  من  وترسبوا  فقدوا  من  عدد  زيادة  مع  جزئياً  تكافأت 
4.7% يف خالل 6 شەور من عام 2005). فأكرث من 85% من البالغني الذين 
تم اختبارەم كان عبء الفريوس لديەم أقل من 400 نسخة لكل ميل لرت عىل 
مدى 6 شەور من املعالجة مبضادات الفريوسات وحتى مرور أربع سنوات من 
استمرار املعالجة مبضادات الفريوسات القەقرية.
االستنتاج: إن وضع الرعاية يف مواقع الرعاية األولية يف ەذا الربنامج يصاحبە 
االرتقاء  فإن  نفسە  الوقت  ويف  الرعاية،  يف  املرىض  الستبقاء  جيدة  معدالت 
تقلص  يصاحبە  القەقرية  الفريوسات  مبضادات  الدوائية  املعالجة  بتقديم 
الوفيات املبكرة.
prospectiva en los registros de los centros, a partir de los cuales 
se elaboraron informes mensuales transversales de actividad e 
informes trimestrales de cohortes. La retención en el sistema de 
atención, la mortalidad, las pérdidas para el seguimiento y las 
variables de laboratorio se calcularon considerando los periodos 
de 6 meses de TAR.
Resultados Al final de marzo de 2006 se estaba tratando a 
16 234 pacientes. El análisis de cohortes abarcó a 12 587 
adultos y 1709 niños. Las mujeres representaban el 70% de 
todos los adultos estudiados. Al cabo de 4 y 3 años de TAR, 
respectivamente, el 72,0% de los adultos (intervalo de confianza 
del 95%, IC95%: 68,0–75,6) y el 81,5% (IC95%: 75,7–86,1) 
de los niños seguían atendidos. El porcentaje de adultos que 
comenzaron el TAR con recuentos de CD4 inferiores a 50 células/
μl cayó del 51,3% en 2001 al 21,5% en 2005, mientras que la 
mortalidad a 6 meses cayó del 12,7% al 6,6%, compensada en 
parte por un aumento de las pérdidas para el seguimiento (que 
alcanzó el 4,7% a los 6 meses en 2005). Más del 85% de los 
adultos analizados presentaron cargas virales inferiores a 400 
copias/ml a intervalos de 6 meses durante los 4 años de TAR.
Conclusión La ubicación de la asistencia en los centros de 
atención primaria en este programa se asoció a una buena 
retención de los pacientes, mientras que la expansión del TAR se 
asoció a una disminución de la mortalidad temprana.
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This thesis has resulted in a series of five linked papers which all contribute to 
addressing the original aims of the thesis.  The synopsis below reflects on how the 
papers have contributed to addressing these, in the light of the rapid accumulation of 
data and analyses on ART outcomes in the region.  In order not to repeat the 
discussion points raised in each article, the synopsis attempts to draw out themes 
from the integrated body of work, and updates discussion points where additional 
data have become available subsequent to the publication of the papers included in 
the thesis. The synopsis also introduces data from other studies where there are gaps 
in the included papers. 
The effectiveness of ART in Khayelitsha and the Western Cape 
Province at averting mortality 
 
The over-riding concern emerging related to evaluating ART outcomes in Southern 
Africa is that the poor ascertainment of mortality in scale-up settings may be masking 
poor effectiveness.  The findings from this thesis that utilise linkages to the death 
registry demonstrate that after substantial scaling up of care, four out of five patients 
are alive at five years, in spite of increasing loss to follow-up.250  Compared to the 
anticipated natural history without ART, the benefits are profound.251-253 Data from 
the Entebbe cohort in Uganda from the pre-ART era, estimate that 8% of patients 
with an initial median CD4 count of 75 cells/µL were still alive after five years.253 
The impact on mortality estimates of correcting for deaths in those lost to follow-up 
This thesis found high cumulative proportions of patients lost to follow-up in 
Khayelitsha (23.4% at five years).  One third of those lost to follow-up had died 
when traced through death registry linkage.  The increase in the cumulative mortality 
estimate at five years is however relatively modest with and without the adjustment 
for deaths in those lost to follow-up (20.9% vs. 15.5%).  There are two explanations 
for this, not fully considered in the discussion of the paper.  Firstly, the rapidly 
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increasing enrolment year-on-year, evidenced both in Khayelithsa and the Western 
Cape, result in the cohorts being skewed towards patients followed for shorter 
durations on ART, with consequently lower overall proportions lost to follow-up 
than the distal cumulative estimates.  The second explanation is that the probability 
of having died in patients lost to follow-up is related to the duration of follow-up 
when lost, with patients in care for longer when lost less likely to have died. Prior to 
the availability of death-registry linked data, studies tracing patients lost to care have 
not been able to systematically describe this changing probability by duration of ART 
or calendar period.97 131-134 Attempts to use once-off tracing studies to adjust mortality 
estimates are likely to be highly dependent on the characteristics and calendar period 
of the utilised tracing study. 
The corrected mortality in Khayelitsha compared to other data from Africa and globally 
As reviewed earlier, there are two African studies that have formally reported five 
year outcomes. For patients starting ART more than five years ago in Botswana, 21% 
had died and 22% had been lost to follow-up by five years, compared to the 21% 
corrected mortality estimate in Khayelitsha.  As demonstrated in Khayelitsha and the 
Western Cape however, subsequent cohorts of adults starting ART in Botswana may 
have had improved survival compared to the first years of ART provision.  The 
Khayelitsha corrected survival at five years is also slightly higher than the estimate 
from the Senegalese government programme, prior to considering loss to follow-up 
in this cohort,104  but is still almost double the appropriate comparative estimates 
from a prognostic model from a collaboration of wealthier country cohorts (the ART 
Cohort Collaboration) presented in the literature review.  
 
Determinants of mortality in Khayelitsha and the Western Cape 
Comparative early mortality between settings and time periods 
The analyses included in this thesis have not directly included comparisons to 
outcomes from other settings, although data from the Western Cape have been a 
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in mortality between wealthy country and African cohorts, after adjustment for 
disease severity, provides a useful frame however for considering context-specific 
determinants of mortality.  The discussion below reflects on these differences based 
on both the data presented in this thesis and related studies.  
 
Some of the putative reasons for the differences in early mortality between settings 
were reviewed in the literature review.  In the discussion of the published declines in 
early mortality over time in the Western Cape,77 it was reflected that the aggregate 
data did not enable an analysis of whether or not the declines could be fully ascribed 
to changing disease severity at ART initiation.   
 
The measures of disease advancement available for adjustment of comparative 
analyses (whether compared between settings or between time periods in the same 
settings) may not be adequate to fully adjust for differences in patients characteristics. 
The first possibility is one of residual confounding – that there may be unmeasured 
characteristics that describe disease severity that are not fully captured by clinical 
stage and CD4 count. For example, the number of stage defining illnesses in patients 
with a given WHO clinical stage may be greater in one context or time period 
compared to another.  The mix of individual stage-defining illnesses may differ 
between settings in patients with the same clinical stage. There is also a possibility of 
misclassification bias, whereby the availability of specialist clinical care may result in a 
higher probability of stage-defining illnesses being diagnosed in some contexts 
compared to others. Finally, there is a possibility of selection bias, whereby patients 
with very low CD4 counts may represent average patients in one setting, and 
unusually robust patients in another, as evidenced by the comparative distribution of 
CD4 counts when initiating ART in Khayelitsha and Switzerland (Figure 3).254  
 
If these explanations held true, one might have expected the temporal trends in early 
survival in Khayelitsha, after adjustment for disease severity and correction for deaths 
in those lost to follow-up, to have demonstrated an improvement with calendar 
period.  We found, however, that whereas in crude terms survival improved with 
calendar period, there was no improvement with calendar period in early or late 
mortality after adjustment for CD4 count and AIDS at ART initiation.250  This 
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finding is difficult to interpret, as there have been dramatic changes in the scale of the 
service with calendar period, which could also have resulted in worsening care, or 
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Figure 3. Comparative baseline CD4 counts at ART initiation: Khayelitsha and Swiss 
HIV Cohort Study  
 
The other difference between settings that is often implicated in discussions on this 
differential early mortality, is the much higher prevalence at baseline and incidence 
during follow-up of tuberculosis in Southern Africa.  This thesis has presented data 
demonstrating that patients initiating ART with prevalent tuberculosis are not at a 
higher risk of mortality compared to those without prevalent tuberculosis after 
adjustment for disease severity.166  Although another study from Cape Town 
presented evidence of a higher mortality in those with tuberculosis, this was a crude 
comparison not accounting for the lower CD4 counts and more advanced clinical 
stage in those with tuberculosis.239  Tuberculosis is however often identified as the 
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In 10 out of 13 patients in whom tuberculosis was identified as the cause of death in 
a Ugandan study, treatment for tuberculosis was not commenced prior to ART 
initiation, five of whom were asymptomatic at the start of ART.238  There is 
increasing evidence as to the prevalence of undiagnosed tuberculosis at the start of 
ART in patients without symptoms suggestive of tuberculosis – in Khayelitsha 7% of 
patients starting ART who were asymptomatic after a systematic screen for 
symptoms of tuberculosis were found to have Mycobacterium tuberculosis confirmed on 
sputum culture.255  It is highly likely that new or unmasked tuberculosis in patients 
recently started on ART contribute substantially to mortality in the Western Cape and 
similar contexts. 
 
Finally it is possible that the availability and quality of clinical care differs between 
settings, resulting in mortality differences that are accentuated as patients are sicker 
and are more likely to require acute care and hospitalisation.  There is evidence that 
aside from HIV, the background mortality for adults of the same ages as those 
starting ART in South Africa is twice that in Switzerland.127  
Other domains of effectiveness in Khayelitsha and the Western 
Cape 
Virological response 
The viral load responses described in the Khayelitsha outcomes paper 250 are broadly 
similar to those in the larger Western Cape province-wide programme.77 Although 
biased by the exclusion of patients in whom viral loads were not measured, the 
consistent recording of more than 80% of patients with viral loads below 400 
copies/mL through the first few years of ART is re-assuring in terms of adherence 
being maintained in spite of the scaling up of care and increased patient volumes.  
Further reassurance, while not forming part of this thesis, comes from a comparison 
of time to virological suppression and rebound between two Western Cape cohorts 
and the Swiss HIV Cohort Study.127  In this comparison, which included data from 
Khayelitsha, there was no difference in either measure between settings.  Confirmed 
virological failure is discussed further below as part of regimen durability. 
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Immunological response 
The presentation of CD4 count response conditioned on viral load suppression was 
identified as a unique opportunity in South African cohorts, due to the availability of 
paired viral load and CD4 count measures, and was demonstrated in Khayelitsha to 
be consistent with the responses described in Europe and North America.250  A 
collaborative analysis in the ART-LINC collaboration in which viral load data were 
not available, showed a plateau in CD4 count recovery at 3 years in all strata of 
baseline CD4 count except for those patients initiating ART at a CD4 count of 
>=300 cells/µL.123  Some of this inference may be an artefact of the fractional 
polynomial functions fitted to the response in each stratum, in addition to the 
inability to exclude responses in patients who might have been failing virologically.  
Nevertheless, it would be valuable to further explore the CD4 count response 
conditioned on virological suppression in Khayelitsha in subgroups of patients, 
particularly those with extremely low CD4 counts (<25 cells/µL) on ART initiation. 
 
The observation in both the Khayelitsha and ART-LINC studies that CD4 count 
response was greater in women than in men has also been described in other 
settings.256 
Effect of ART on tuberculosis and other HIV-associated events 
This thesis did not seek to explore the effect of ART on morbidity or HIV-associated 
events, due in part to the poor availability (except in the case of tuberculosis) of data 
on individual clinical diagnoses during follow-up.  In addition to the studies from the 
same context on the reduction in tuberculosis on ART described earlier,75 119 232-233 
there has been a conference report on the reduction in tuberculosis on ART in 
Khayelitsha (Boulle, 2004),257 demonstrating that the incidence rate ratio of 
tuberculosis on ART compared to pre-ART was either 0.32 or 0.46 depending on the 
inclusion or exclusion of the first month after referral or after ART initiation.  This 
question is the subject of ongoing analyses on the Khayelitsha data, in which marginal 
structural models are being used to adjust for time-varying confounding by CD4 
count which predicts tuberculosis and is itself affected by prior ART. Only one study 
in adults and one in children have to date reported on the causal effect of ART on 
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studies reported smaller relative reductions in tuberculosis risk on ART than 
preceding studies. 
 
Although no analyses are presented on the effect of ART on other HIV-associated 
conditions in Khayelitsha, the Khayelitsha cohort was one of the early cohorts to 
confirm the effect of ART on quality of life.259 
Effect of ART on risk behaviour of those on ART and beyond those receiving ART 
One of the papers in this thesis was originally intended to explore the broader 
community impact of ART availability.260 Even though ART had been available 
earlier and more widely in Khayelitsha than in most other Southern African 
townships at the time of the survey, more than half the respondents had not heard of 
ART, and of those who had, only 14% of men and 22% of women knew someone on 
ART at the time.  Although many more people are likely to have heard of ART and 
to know someone on ART currently given the many fold increase in treatment since 
then in Khayelitsha, attempts to link ART availability to more openness about HIV 
and behavioural change are fraught with difficulty in cross-sectional studies. As 
argued in the paper, there is now sufficient agreement on the imperative for 
treatment for the purposes of averting mortality and morbidity, not to have to 
demonstrate an impact on prevention through behaviour modification either for 
those on ART or those not on ART. Looking at behaviour modification for patients 
on ART, there are few rigorous studies, and as yet evidence points towards positive 
rather than negative impacts on risk behaviour.261 Research in Cape Town has 
demonstrated high levels of risk behaviour amongst adults initiating ART,262 but also 
substantial declines in risk behaviour over the first year of ART.263 
Regimen durability and tolerability 
A number of the papers included in this thesis directly assess the tolerability and 
durability of the regimens used in the Khayelitsha and Western Cape ART 
programmes.126 166 250 While demonstrating the effectiveness of ART in terms of 
survival has been an important contribution validating the investment in providing 
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this intervention on such a large scale, the analyses addressing ART regimens have 
had a more direct impact on programme design. 
Tolerability of stavudine 
Early reports identified a high number of diagnoses of lactic acidosis in patients in 
South Africa initiating ART on stavudine-containing regimens.147 The cohort analysis 
from Khayelitsha and Gugulethu was one of the first to be able to quantify the risk of 
symptomatic hyperlactataemia or lactic acidosis (SHLA), and assess baseline 
associations with the development of this condition.126  In particular, the anecdotal 
concerns about overweight women being predisposed to this complication were 
documented and the excess risk quantified.  A study from a hospital-based cohort in 
Johannesburg reported soon after the Western Cape study,145 with the incidence of 
SHLA reported as 31 per 1000 patient years compared to 19 in the Western Cape 
study. The higher incidence in Johannesburg might have been the result of a younger 
cohort, with more person time at risk between 6 and 18 months on ART, the 
duration on ART when the majority of cases are diagnosed.152  A case control study 
in the Western Cape, which incorporated some of the incident cases from the cohort 
study, confirmed the association with higher weight and body mass index (BMI) in 
women (adjusted odds ratio of 19 comparing women initiating ART with a weight 
above 75kg compared to those below 60kg, compared to the adjusted hazard ratio of 
36 for the same comparison in the cohort study).264  The hospital cohort in 
Johannesburg did not report on associations with SHLA, but reported that 35% and 
20% of patients with lactic acidosis and symptomatic hyperlactataemia respectively 
had BMIs above 30.   
 
The Western Cape Province instituted a range of guideline changes to address the 
risk factors for SHLA, resulting in a dramatic decline in referred cases of SHLA, and 
related deaths.265  These changes included the scrapping of the d4T dose escalation in 
patients above 60kg, the preferential use of AZT in women with high BMIs, clinical 
training and the use of point-of-care lactate metres in primary care settings.  As 
discussed in the literature review, the WHO amended their guidelines similarly to 
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difference in virological suppression in patients above 60kg before and after the 
guideline amendment.267 
 
Aside from SHLA, compared to other first line antiretrovirals, the notable feature of 
treatment-limiting toxicities to stavudine is that they were demonstrated to continue 
to accumulate with time on ART, especially peripheral neuropathy and lipodystrophy. 
In the context of needing to minimise the requirements for clinical care in order to 
facilitate the scaling up of ART, the disadvantages of d4T with respect to toxicity may 
counterbalance the advantages in terms of cost, accessibility and co-formulation. 
Effectiveness of nevirapine with and without concurrent tuberculosis treatment 
Both the analysis of nevirapine effectiveness in patients starting ART while co-
infected with tuberculosis,166 as well as the overall analysis of associations with 
virological failure in the Khayelitsha cohort,250 identified that NVP use as choice of 
NNRTI was associated with inferior virological outcomes. As discussed in both 
papers and the literature review, these findings are not unique in observational 
settings,79 161 167 and do not conflict with clinical trial data.160   
 
The association described in this thesis between being on treatment for tuberculosis 
at the start of ART and inferior effectiveness of nevirapine-based ART is less 
supported by other studies.  Some studies reporting a lack of this association have 
however been underpowered to detect such an association.268-269 Results of ongoing 
clinical trials are awaited.  A trial in Thailand found equivalent proportions of 
tuberculosis co-infected patients remaining suppressed on NVP and EFV after 48 
weeks.270 Although a higher proportion of patients on NVP had NNRTI plasma 
concentrations (C12) below the recommended therapeutic minimum than those on 
EFV, there was no evidence of a difference in virological outcomes (n=71 per 
group). It is unclear how generalisable Thai studies on drug interactions are to 
Southern Africa. A trial of different once daily regimens in co-infected patients 
confirmed the findings of the Khayelitsha study, but differed from local practice in 
that NVP was dosed daily as opposed to twice daily.271  The strongest effect seen in 
the Khayelitsha study was on confirmed virological failure (two consecutive viral 
loads above 5000 copies/mL), whereas most other studies have looked at virological 
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response in the first year. It is possible that confirmed failure is more likely to be 
indicative of NNRTI resistance, and that associations with this are less prone to 
dilution by adherence and other issues.  One putative mechanism offered in 
discussion of the Khayelitsha findings was that the lead-in dose of NVP in patients 
who already have hepatic induction by rifampicin could be resulting in sub-
therapeutic NVP levels in the first two weeks of therapy.  A Thai study sought to 
compare standard NVP dosing to an increased dose of NVP both during the lead-in 
period (200mg bd) and subsequently (300mg bd). The higher dosed group had more 
favourable NVP levels, but also more hypersensitivity reactions.272 
 
In spite of these documented concerns regarding comparative NVP effectiveness, 
NVP-based ART was nevertheless highly effective in the presented analyses. The use 
of alternatives is also limited due to the costs of both EFV and boosted protease 
inhibitors, as well as the concerns regarding EFV use in women at risk of conception.  
Durability of current first-line regimens 
As reviewed in the literature review, the South African and Botswana national 
treatment programmes are unique in the region in providing for regular viral load 
monitoring. One of the contributions of this thesis has been to explore how these 
guidelines are being applied, as well as the time to meeting guideline definitions of 
virological failure, and the time to switching therapy in patients who meet this 
definition.  Both the Khayelitsha cohort and the Western Cape provincial programme 
have been able to report these outcomes at longer durations on ART than most 
similar programmes.  The proportion of patients failing therapy and starting second-
line therapy at five years is lower than many anticipated when cohorts such as 
Khayelitsha first started offering ART.  Combined however with the massive scaling 
up of ART, the modest proportions failing ART will still result in very large absolute 
numbers of patients requiring second-line therapy, with important consequences on 
programme costs.   
 
The delay between meeting guideline definitions and starting patients on second-line 
ART could compromise the limited benefits, described in the literature review, that 
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or recycled thymidine analogue NRTI’s.  These delays reflect the difficulties in tightly 
applying guidelines that are based on laboratory measures in the context of busy 
clinical settings where patient numbers are constantly expanding.  The laboratory, 
clerical and financial challenges to ensuring the completeness and ready availability of 
twice-yearly viral load tests have lead some scientists to suggest less frequent viral 
load monitoring in South Africa.273 
Implications for regimen choices and laboratory monitoring 
The studies in this thesis have raised concerns about the safety of d4T, the 
effectiveness of NVP, and have demonstrated the difficulties in tightly following the 
guidelines for switching patients on virological grounds.  Although this thesis did not 
seek to review health system issues related to the scaling up of ART, all of these 
findings support moving towards simplified guidelines that recommend the use of 
both d4T and NVP in fewer circumstances, and less frequent laboratory monitoring 
of ART.  A once daily regimen of TDF, 3TC and EFV is now the most commonly 
prescribed regimen in wealthier countries. If utilised more widely in Southern Africa, 
this regimen would minimise the risks associated with d4T and NVP, would spare 
more future treatment options, would ease supply chain management, and would 
assist in patient adherence due to the lower pill burden.  The less frequent laboratory 
monitoring would save costs, as well as the burden on both clerical staff and patients 
in being monitored twice annually. The averted viral load tests could allow the 
introduction of an early viral load test to assist in assessing adherence and allocating 
patients to less intensive follow-up if virologically suppressed. The findings from the 
studies included in this thesis constitute a small but important contribution to 
informing these discussions. 
Scalability of ART and generalisability of findings 
The paper included in this thesis on the Western Cape provincial outcomes, two 
years after the launch of the national programme, demonstrated how the early results 
from cohorts such as Khayelitsha were sustained when scaled up throughout the 
province.77 The Khayelitsha sub-district has undergone large year-on-year increases in 
patient enrolment itself, and it is reassuring that in the cohort, survival has not 
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deteriorated with calendar time after adjustment for other factors associated with 
survival.250 Not documented in detail in the thesis, Khayelitsha has, of all services in 
the province, undergone the most dramatic changes in the model of ART care 
provision.  Some years ago we reflected on the challenges to scaling up enrolment 
further in Khayelitsha without expanding the service platform.274  The service 
platform has indeed expanded to the smaller clinics run by the City of Cape Town, 
but enrolment in the existing provincially run community health centres has also 
increased dramatically in spite of unchanging physical and human resources.  The 
service changes alongside which outcomes have not deteriorated have included the 
fast-tracking of stable patients through afternoon clubs, more efficient medicine 
dispensing, wider spacing of appointments, and less intensive counselling and 
community follow-up.   
 
In most instances achieving increases in ART services as seen in the Western Cape 
has either compromised information systems to the extent that robust outcome 
reporting is no longer possible,275 or has required huge investments in information 
technology and associated human resources in order to be able to reflect the success 
of scaling-up therapy.101  The Western Cape study has demonstrated how de-linking 
research and sentinel surveillance from routine monitoring enables a more rational 
and simplified routine monitoring system to be implemented.  Although the paper-
based monitoring system in use is currently under immense pressure due to patient 
numbers and duration of follow-up in many facilities, complete cohort data are today 
still available on all 60,000 patients on ART in the province.  The trends described 
until mid-2006 (published in 2008) and included in this thesis have continued and in 
some cases (such as rising loss to follow-up and declining mortality) been 
accentuated.  Overall the programme has continued to scale better than initial 
expectations.   
 
Comparing the papers on Khayelitsha and the province, many of the outcomes from 
the province are similar to or better than those in Khayelitsha, demonstrating that 
outcomes have not been compromised with the wider availability of ART in the 
province.  For example virological suppression to below 400 copies/mL in adults at 
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province as a whole. This also helps establish the generalisability of the findings from 
Khayelitsha for other settings.  
 
The survey that was conducted in Khayelitsha and included in this thesis, clearly 
confirms that the referral area for the Khayelitsha cohort is representative of urban 
townships: only a third of respondents were in formal housing, and at least a quarter 
of men and almost half of women were unemployed. High school completion was 
low notwithstanding that the survey included some respondents who were still at 
school.  Risk factors for HIV acquisition such as multiple concurrent partnerships 
were in keeping with surveys in other South African townships.   
 
Although per capita expenditure on health is highest in the Western Cape compared 
to other Provinces in South Africa, Khayelitsha is one of the most underserved sub-
districts in the Western Cape, and it is probable that it is much more reflective of 
challenges in other urban settings in South Africa and possibly the region than is the 
case for the province as a whole. 
Limitations and gaps in the thesis 
Health system issues 
This thesis has sought to address the effectiveness and scalability of ART in the 
Western Cape Province, but has not covered health system aspects of ART provision 
in any detail.  Although the focus has been on clinical outcomes and clinical 
programme design, questions of feasibility and sustainability require a more detailed 
consideration of the health system capacity, financing, human resource requirements, 
and the evolution of the model of care for ART provision in the setting. 
 
There are however a number of publications based on the Khayelitsha project which 
are not formally part of this thesis, but which do address these issues in part.  In 
2006, a cost-effectiveness analysis was published which drew on effectiveness, quality 
of life and cost data drawn directly from the Khayelitsha project.276 At the time it was 
the only such study in which all these domains were based on primary data collected 
from the same patients. A subsequent analysis considered the delivery of ART within 
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a budget constraint.277 Also in 2006, the Khayelitsha project reflected on the future 
challenges facing ART provision.274  The move to less intensive adherence 
counselling was described, and the need for further task shifting and expansion of the 
service platform in order to meet future enrolment targets was highlighted.  The first 
paper in this thesis demonstrates that for the most part, these shifts did indeed occur, 
and makes reference to the less intensive patient preparation, whilst retaining an 
overall frame of a patient-centred approach to adherence promotion.250 A report on 
four different ART services in the Western Cape, including Khayelitsha, sought to 
explore the relationship between the model of care for ART service provision and 
patient outcomes, concluding that the human factors other than the model itself were 
the most important factors related to efficient and effective service provision.278 
Finally, the comparison between Switzerland and the Western Cape, referred to a 
number of times above, looked more broadly at the public health approach compared 
to the standard of care in wealthier countries.127 
Effect of ART on opportunistic infections and disease progression 
This thesis has examined mortality and laboratory outcomes, but has not addressed 
disease progression in terms of new HIV-associated conditions or AIDS-defining 
illnesses.  In part, deficiencies in the systematic recording of HIV-associated events 
hinder the ability to look at disease progression in this way. There are nevertheless 
some additional outcomes that are recorded accurately enough to explore, which have 
not been described in this thesis, most notably tuberculosis. 
 
Besides the effect of ART on HIV-associated conditions, the other gap in the scope 
of this thesis is the effect of HIV-associated conditions at ART initiation on other 
ART outcomes.  Although the presence of AIDS-defining illnesses has been included 
in multivariate models for associations with early and late mortality,250 the number 
and nature of specific conditions has not been included in models of associations 
with mortality.  In spite of the concern that the ascertainment and accurate recording 
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Conclusion and recommendations for future research 
This thesis has presented five papers which broadly describe the population, the 
outcomes and the associations with outcomes in the Khayelitsha and Western Cape 
ART programmes. 
 
The first contribution of this thesis has been to describe in detail the clinical 
effectiveness of ART, and how this changes over time. Both the Khayelitsha and 
Western Cape cohort analyses presented in this thesis provide benchmarks as to the 
real world effectiveness of ART in the region, and considerable reassurance that the 
anticipated benefits of ART have not to date been completely eroded by the health 
system weaknesses or contextual challenges. 
 
The second contribution has been to examine the clinical sequelae of the ART 
regimens in use in the region, describing both novel associations with toxicity and 
failure to achieve virological suppression, and event rates for common toxicities in a 
population representative of many contexts where ART is provided in the region. 
 
The coverage of ART in the Western Cape had by 2008 increased to 80% of new 
AIDS cases each year, and 70% of new patients meeting CD4-based eligibility 
criteria,279 and is continually increasing. Determining the population-level impact of 
this intervention is a research priority.  Routine mortality data from registered deaths, 
examined until 2007, demonstrated that for the three preceding years in the Western 
Cape, an increase in adult deaths had been averted compared to what would have 
been expected had coverage not increased.280  If the increased coverage estimate, 
coupled with the programme outcomes described in this thesis are robust, a 
discernible decline in registered adult deaths should be apparent in the next year or 
two. 
 
Maintaining both the Khayelitsha and Western Cape cohorts going forward is a 
considerable challenge.  Many of the contributions in this thesis relied on the accurate 
recording in the routine data system of clinical events. As is the case for most 
academic cohorts in the region, maintaining this level of ascertainment in the context 
of continued year-on-year increases in patient numbers in unlikely unless there is a 
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paradigm shift in the conceptualisation of ART research cohorts.  The size of cohorts 
will need to be limited in a way that remains representative, but also allows better 
clinical record keeping, and accurate data capture and data quality control.  This will 
require increased funding levels, and fewer and smaller cohorts.  In South Africa in 
particular, in addition, there will need to be a greater reliance on data linkage to death 
registries, laboratory databases, hospital information systems and other disease 
registries such as the electronic tuberculosis register, in order to assist with near-
complete ascertainment of events. These are all approaches which are being pursued 
in the Western Cape, and it is sincerely hoped that the analyses included in this thesis 
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